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Summary 
The introduction of highly active antiretroviral therapy has been a major breakthrough in HIV 
research but is not able to cure infected patients. A detailed understanding of HIV biology is 
mandatory to develop new treatment strategies.  
This thesis explored three aspects of Host-HIV interaction. First, we established a human-to-
small animal xenotransplantation model, which is based on the transplantation of CD34+ cord 
blood cells into newborn Rag2-/- Il2rg-/- mice, as a new tool to study HIV infection and 
pathogenesis in vivo. Notably, HIV research has been hampered due to the lack of assessable 
animal models. Upon CCR5-tropic or CXCR4-tropic HIV challenge, these mice develop 
long-term, high-titer, and lymphoid organ disseminated infection, closely resembling HIV 
infection in humans. This straight-forward to generate, cost-effective, ethically unproblematic, 
and easy to monitor new in vivo model should thus be valuable to study virus-induced 
pathology, as well as pharmacologic or genetic approaches aiming to prevent or treat HIV 
infection. In particular, these mice may help to investigate vaginal and rectal transmission or 
the role of chronic immune activation in HIV pathogenesis.  
Chronic immune activation is a major cause for progressive immunodeficiency in HIV 
infection. The underlying trigger, however, remains largely unknown. HIV single stranded 
RNA (ssRNA) reaches high copy numbers throughout the infection and has been shown to 
trigger Toll-like receptor (TLR) 7 leading to cellular activation. We used the synthetic 
compound R848 to explore the effects of sustained TLR7 triggering on the murine lymphoid 
system. We report immune activation and disruption of the lymphoid system reminiscent of 
HIV-associated pathology. This suggests that HIV ssRNA may directly contribute to chronic 
immune activation and dysfunction by signalling through TLR7. Hence, manipulating TLR7 
triggering or down-stream signalling may be therapeutically valuable to reduce chronic hyper-
immune activation and immune dysfunction. 
Third, we investigated whether HIV exploits signalling through the HIV receptor complex 
(i.e., CD4 and CCR5) to optimize conditions for viral replication. We generated human T-cell 
lines stably expressing different combinations of either wild-type or mutant CD4 and CCR5 
and used them to study both the overall influence of signalling through the receptor complex 
on HIV replication and the contribution of each receptor to such effects. In conclusion, our 
data suggest that signalling through CD4 has an inhibitory effect on early reverse 
transcription, whereas CCR5 signalling does not play a major role, and later steps of the HIV 
replication cycle are not modulated by CD4/CCR5 signalling.    
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Zusammenfassung 
Die Entwicklung von antiretroviralen Medikamenten war ein bedeutender Meilenstein im  
Kampf gegen HIV. Dennoch vermögen auch modernste Therapien Patienten nicht zu heilen. 
Deshalb sind neue Strategien notwendig. Dies verlangt ein vertieftes Verständnis der Biologie 
von HIV. 
Den Forschern fehlte bis anhin ein geeignetes Kleintiermodell. Im ersten Teil dieser Arbeit 
wurde ein vielversprechendes neues HIV Mausmodell etabliert. CD34+ blutbildende 
Vorläufer- und Stammzellen aus Nabelschnurblut wurden Rag2-/- Il2rg-/- Mäusen unmittelbar 
nach Geburt intrahepatisch verabreicht. Daraufhin liessen sich diese mit CCR5 und CXCR4-
tropen HIV Stämmen infizieren, entwickelten eine hohe Virämie in allen lymphatischen 
Organen und zeigten einen ähnlichen Infektionsverlauf wie im Menschen. Die 
pathobiologischen Prozesse von HIV sowie neue therapeutische oder genetische 
Behandlungsansätze können nun mit unserem Modell untersucht werden. Besonders für das 
Studium der vaginalen und rektalen Transmission oder der Bedeutung der chronischen 
Immunaktivierung sollte dieses Modell hinreichend geeignet sein. 
Immunaktivierung wird als eine der Hauptursachen der progressiven Immundefizienz im HIV 
Patienten verstanden. Der Auslöser ist aber nach wie vor unklar. Kürzlich wurde in vitro 
gezeigt, dass einzelsträngige HIV RNA (ssRNA) über die Stimulation von Toll-like Rezeptor 
(TLR) 7 direkt Immunaktivierung induziert. Wir zeigten nun in der Maus, dass die repetitive 
Stimulation von TLR7 mittels der synthetischen Droge R848 zu vergleichbarer 
Immunaktivierung und Absonderlichkeit des lymphatischen Systems führte, wie sie im HIV 
infizierten Patienten beobachtet wird. Wir schliessen daraus, dass die ständige Stimulation 
von TLR7 durch HIV ssRNA, welche während der ganzen Infektionsdauer in hoher Zahl 
vorhanden ist, eine direkte Ursache von Immunaktivierung und Immuno-adenopathie der HIV 
Infektion sein könnte. Ein therapeutischer Eingriff in die TLR7 Signaltransduktion zur 
Eindämmung der Immunaktivierung sollte getestet werden. 
HIV gelangt nach Bindung an den CD4/CCR5 Rezeptor-Komplex in die Wirtszelle. Wir 
generierten rekombinante T-Zelllinen, die verschiedene Kombinationen von natürlichem und 
mutiertem CD4/CCR5 exprimieren. Damit untersuchten wir im dritten Teil ob Signal-
transduktion über den Rezeptor Komplex die HIV Replikation positiv oder negativ 
beeinflusst. Unsere Daten legen nahe, dass die frühe reverse Transkription durch CD4 
Aktivation unterdrückt wird, wohingegen CCR5 Aktivation nur geringfügige Auswirkungen 
hat. Ebenso scheinen spätere Schritte des Replikationszyklus unbeeinflusst. 
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Introduction 
 
 
 
 
 
 
 
Chapter 1.1, 1.2, and 1.3 provide an introduction into HIV biology. Chapter 1.4 and 1.5 focus 
on recent progress in the area of HIV animal models, particularly mouse models transplanted 
with human lymphoid tissue. Chapter 1.6 describes recent advancement in the understanding 
of immune activation and HIV pathogenesis and chapter 1.7 discusses the impact of HIV 
receptor complex signalling on HIV replication. 
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1.1 HIV Infection – Global impact 
 
Since the beginning of the human immunodeficiency virus type-1 (HIV) pandemic, 25 years 
ago, HIV infected 65 million people and killed 25 million! Each year, more than 4 million 
people are newly infected worldwide. To date, the number of HIV-infected people is 
estimated at 40 million 1. In 2001, leaders from 189 UN Member States recognized that HIV 
infection was one of the most urgent issues of national and international development. They 
signed the “Declaration of Commitment on HIV/AIDS” to help reach the “Millennium 
Development Goal” of stopping and beginning to reverse the HIV epidemic by 2015 1.  
Since its introduction, antiretroviral therapy (ART) has resulted in marked decreases of 
morbidity and mortality of patients infected with HIV. However, ART has substantial 
limitations such as side effects and emergence of drug resistant virus strains. Most notably, 
the high cost of ART restricts its usage nearly exclusively to the 1st world. Thus, the HIV 
pandemic continues, presenting new medical problems and leading to almost 3 million deaths 
in 2005 1. Novel treatment strategies are urgently needed to reach the ambitious aims of the 
above mentioned declaration. Defining potential targets for intervention requires a detailed 
understanding of the HIV biology. This in turn necessitates appropriate in vitro and in vivo 
models.  
 
1.2 Genetic organization, structure, and replication cycle of HIV 
 
HIV is a member of the genus Lentiviridae and belongs to the family of the Retroviridae 
which are characterised by their unique replication cycle: genomic RNA containing viral 
particles are reverse transcribed upon entry into the host cell and, thereafter, integrated into 
the host genome. The integrated viral genome, the provirus, is replicated along with the host 
cell DNA and serves as a template for transcription of viral RNA, which subsequently is 
translated into proteins eventually resulting in the formation of progeny virions.  
The HIV genome is 9.7 kb in length and encodes the gag (group-specific antigen) pol 
(polymerase) and env (envelope) genes yielding the nucleocapsid core proteins, enzymes 
required for replication, and envelope proteins (Fig. 1). Gag, pol, and env are conserved in all 
retroviruses. HIV, in addition, encodes three early, mostly regulatory, and three late accessory 
proteins. The early proteins Tat (transactivator of transcription), Rev (regulator of virion gene 
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expression) and Nef (negative effector) play a major role in controlling gene expression. 
Notably, Tat is a powerful transactivator of gene expression, which acts by both inducing 
chromatin remodeling and by recruiting transcriptional complexes. Rev protein acts 
postranscriptionally and regulates the transition between the early and late phases of viral 
gene expression by allowing the transport of singly spliced and unspliced viral mRNA species 
from the nucleus to the cytoplasm. Although Nef was originally named "negative factor," it 
has a positive role in viral replication and pathogenesis. Multifunctional Nef helps the virus to 
maintain high viral loads and to overcome host immune defenses by interacting with host cell 
signal transduction proteins to provide for long term survival of infected T cells and by 
advancing endocytosis and degradation of CD4 and MHC proteins, which possibly impairs 
cytotoxic T-cell function.  
The accessory proteins Vif (viral infectivity factor), Vpr and Vpu (viral protein r, u) have 
multiple functions, i.e., RNA processing, virion assembly, and host gene expression 2. The 
long terminal repeats (LTR) on both sides of the genome are regulatory elements and do not 
code for any proteins. 
 
 
 
 
Fig. 1. Genetic organization of HIV. The three major genes gag, pol, and env (shown in black) encode 
polyprotein precursor proteins that are subsequently processed by viral or cellular proteases into mature proteins 
(indicated below). Gag is processed into capsid and matrix proteins. Pol is processed into protease, reverse 
transcriptase and integrase. Env is cleaved by cellular proteases into gp120 and gp41. In addition HIV encodes 
regulatory and accessory genes and LTRs, which contain various regulatory protein binding sites. Abbreviations 
are explained in the text. 
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A mature HIV virion is made of envelope, capsid, matrix, and enzyme proteins (Fig. 2). The 
viral envelope derives from the host cell and thus contains some host-cell membrane proteins 
and in particular the HIV envelope glycoprotein Env. Env consists of an outer protruding cap 
glycoprotein (gp) 120, and a transmembrane protein gp41, which are non-covalently linked to 
each other forming a heterodimer which is present on the virion surface as a trimer. The inner 
surface of the virus is made of the matrix protein p17 and a viral core or capsid, comprising 
the capsid protein p24. The major elements contained within the HIV capsid are two single 
strands of unspliced HIV genomic RNA, which are stabilised as a ribonucleoprotein complex 
with the nucleocapsid protein p7, and three enzyme proteins, reverse transcriptase, protease 
and integrase. 
 
 
 
 
Fig. 2. Structure of HIV. Abbreviations are explained in the text. 
 
The binding of the HIV Env protein mediates virus entry and initiates the viral replication 
cycle (Fig. 3). Gp120 binds to the cell-surface receptor CD4 causing a conformational change 
in the gp120 molecule resulting in the engagement of a second receptor, i.e., CCR5 or 
CXCR4. CCR5 and CXCR4 are also known as HIV co-receptors. They are seven-
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transmembrane receptors and belong to the family of chemokine receptors. A subsequent 
change in gp41 eventually leads to the fusion of the HIV envelope and the cell membrane, 
enabling the viral core to enter the cell. In the cytoplasm, HIV reverse transcriptase converts 
viral RNA into complementary DNA (cDNA) which is transported as preintegration complex 
to the nucleus. In the nucleus, the integrase covalently integrates the viral DNA into the host 
genome creating the provirus. The provirus either remains latent or produces progeny virus by 
synthesis of viral mRNAs, which are transported to the cytoplasm for translation. Newly 
made core proteins, enzymes, and genomic RNA assemble in the cytoplasm and form an 
immature viral particle. This particle buds of from the cell and acquires its envelope from the 
cell membrane. Released particles complete maturation and become infectious. 
 
 
 
Fig. 3. The HIV replication cycle in CD4+ T-lymphocytes. Steps in viral replication cycle are 1) binding to the 
cellular receptor complex, 2) fusion and uncoating, 3) reverse transcription, 4) nuclear import and integration 
into host genome, 5) transcription and translation, 6) assembly, budding and maturation.  
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1.3 HIV Infection and AIDS 
 
Hallmark of HIV infection is the progressive depletion of CD4+ T cells, also called T helper 
(TH) cells. The CD4+ T cells have a crucial role for an efficient immune defense. Thus, in 
advanced stage of HIV infection patients are at risk to suffer from opportunistic infections, 
neoplastic diseases, HIV-associated wasting and eventually death 3 . The advanced stage is 
best known under the acronym “acquired immunodeficiency syndrome” (AIDS). For 
instructive purposes, the prototype HIV infection can be divided into acute infection, chronic 
infection and the AIDS stage (Fig. 4): 1) the acute or primary infection is characterized by an 
initial burst of HIV viremia and sharp decline of CD4+ T-cells. 40-90% of individuals in the 
acute phase develop a flu-like disease. Within 3 months after transmission, the immune 
response is able to contrain partially HIV which is mirrored by a recovery of CD4+ T cells and 
a levelling of the HIV RNA in the range of 5x103 – 1x105 copy numbers per ml; 2) The 
chronic or asymptomatic phase follows which is also called clinical lateny. The virus 
replicates, CD4+ T-cell counts continue to drop while the patient is asymptomatic. This phase 
lasts approximately 10 years. There are, however, patients suffering from rapid progression 
with only 3 years of clinical latency while on the opposite, there are elite controllers with 
long-lasting host-endogenous control of HIV; 3) An individual is considered to have AIDS 
(according to the 1994 expanded World Health Organization AIDS case definition) if a test 
for HIV antibody gives a positive result, and 1 or more of the following conditions are 
present: 
- > 10% body weight loss or cachexia, with diarrhoea or fever, or both, intermittent or 
constant for at least 1 month, not known to be due to a condition unrelated to HIV 
infection.  
- cryptococcal meningitis  
- pulmonary or extra-pulmonary tuberculosis  
- Kaposi's sarcoma  
- neurological impairment that is sufficient to prevent independent daily activities, not 
known to be due to a condition unrelated to HIV infection (for example, trauma, or 
cerebrovascular accident).  
- candiasis of the oesophagus (which may be presumptively diagnosed based on the 
presence of oral candiasis accompanied by dysphagia.  
- clinically diagnosed life-threatening or recurrent episodes of pneumonia, with or 
without etiological confirmation  
- invasive cervical cancer  
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The acquired immunodeficiency syndrome (AIDS) usually occurs if CD4+ T-cell counts drop 
below 200 cells/mm3 blood. Below this level is a substantial risk of opportunistic infections. 
HIV-infected patients eventually die of opportunistic infections or of HIV-associated 
cachexia.  
 
 
Fig. 4. Prototype HIV infection. During the acute phase, HIV disseminates widely in the body often associated 
with a marked loss of CD4+ T-cells. Immune responses to HIV lead to decreased viremia. An asymptomatic 
phase of persistent viral replication, that can last from months to years, follows. When CD4+ T cell numbers 
decline below a critical level, cell-mediated immunity is lost leading to death. Adapted from 4. 
 
HIV isolates are classified based on their co-receptor use. R5 strains of HIV use CC-
chemokine receptor (CCR5) as their co-receptor and can therefore, enter macrophages, 
dendritic cells and T cells. X4 strains use CXCR4 as a co-receptor and can infect CD4+ T 
cells only 2. R5 isolates are responsible for viral transmission, predominate during the early 
stages of the disease, and are present throughout the whole infection period 5. Individuals 
homozygous for a 32–base pair deletion in the coding region of CCR5 are almost completely 
resistant to HIV infection 6. In late stage disease, X4 viruses emerge in approximately 50% of 
all patients. This emergence is associated with an acceleration of the CD4+ T-cell loss. 
However, it remains controversial whether the emergence of X4 strains is the cause or the 
consequence of the accelerated immunodeficiency.  
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1.4 Animal models in HIV research 
 
In vitro cell biology and virology have significantly advanced the understanding of HIV 
disease. Nevertheless, in vivo models are required to address complex questions such as 
immunopathogenesis and to test potential novel therapies as well as to examine drugs aiming 
to block HIV transmission. HIV research, however, has been hampered because of the lack of 
a small animal model that mirrors infection in humans. HIV is a human-specific virus and 
does not infect or cause disease in other species. Thus, mice or rats, the commonly used 
animals in biomedical research, are not susceptible to HIV 7-9. Optimally, an animal model for 
studying HIV disease would mirror the multifaceted pathogenesis in man, have a well-
characterized immune system, and be readily available at low cost. To this end, several animal 
models for HIV have been established and include monkeys infected either with HIV, simian 
immunodeficiency virus (SIV) or chimeric HIV-SIV, cats infected with feline 
immunodeficiency virus (FIV), immunocompromised mice transplanted with human 
lymphoid tissue as well as transgenic mice 10,11. In this chapter, I will discuss the animal 
models that are more frequently used and thus have added substantially to the progress in HIV 
research - i.e., non-human primates and rodents (especially immunocompromised mice 
transplanted with human tissue).  
 
1.4.1 Non-human primate models 
 
Chimpanzees and gibbon apes are susceptible to HIV. However, they do not develop HIV-
associated immunodeficiency and do not get sick 12,13. Importantly, these apes are extremely 
costly for experimentation. For those reasons, chimpanzees and gibbon are rather rarely used.  
African green monkeys, sooty mangabeys, rhesus macaques and baboons are exclusively  
susceptible to SIV 14. Based on their genetic, antigenic, and biologic properties, SIV is closely 
related to HIV 15. Naturally SIV infected African green monkeys and sooty mangabeys 
remain asymptomatic throughout their life and do not develop any disease despite high level 
viremia 16. 
In contrast to naturally SIV infected monkeys, experimental infection of non-natural host 
species such as macaques results in a disease pattern that is remarkably similar to human 
AIDS 17-19: macaques show diarrhoea, weight loss, hematologic abnormalities including 
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lymphopenia and thrombocytopenia, lymphadenopathy / lymphoid hyperplasia that progresses 
to lymphoid depletion, immunosuppression with marked reduction in CD4+ cells and in the 
CD4+/CD8+ cell ratio, and opportunistic infections. The majority of macaques infected with 
SIV die from an AIDS-like disease within one to three years of infection 15. Thus, the 
similarity of HIV and SIV pathogenesis, makes SIV infected macaques very attractive for 
biomedical research 10. In addition, the investigation of the mechanisms that account for the 
non-pathogenic course of infection in naturally SIV-infected monkeys provided important 
clues to the pathogenesis of immunodeficiency in HIV-infected humans 20.  
However, there are clear limitations for using the SIV monkey model: they are extremely 
costly with ~5,000 - 12,000 $ per macaque, limited availability, and ethical concerns. There is 
a particular concern and uncertainty about the acceptability of using non-human primates in 
medical research, primarily because of their evolutionary proximity to human beings. The 
report “Forschung an Primaten – eine ethische Bewertung” from the Federal Animal 
Experimentation committee evaluated the ethical position concerning monkey experiments in 
Switzerland and recommended  to authorize experiments with utmost reserve 21. Further and 
very crucial, and even though SIV is closely related to HIV, the results obtained with SIV in 
monkey models cannot be directly extrapolated to HIV: for example, the accessory protein 
Vpu does not have a homologous counterpart in SIV. Another example is the virus-specific 
difference in reverse transcriptase (RT): the non-nucleosid RT inhibitors which are used in 
daily clinical practice inhibit HIV RT but not SIV RT 22,23. SIV/HIV chimeric viruses (SHIV) 
have been developed to overcome some of these limitations and have been useful for in vivo 
testing of numerous vaccines that specifically target HIV proteins. Unfortunately, SHIV with 
genomic information mainly from HIV, which would reflect the biological properties of HIV 
more accurately, were poorly replicating in rhesus macaque cells 23,24. 
To summarize, HIV research in non-human primates remains restricted by biological as well 
as by ethical and financial constraints. 
 
1.4.2 Rodent models   
 
There are significant advantages in developing rodent models over primate models: i) wide 
availability and low costs, ii) ability to generate large cohort sizes, iii) relative ease of 
transgenic manipulation 25. HIV, however, does not efficiently replicate in wild-type mice or 
rats. In one publication, Langley et al. reported that HIV replicated in non-transgenic cotton 
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rats 26. HIV was passaged from animal to animal for three serial passages, but HIV replicated 
poorly in vivo, was only detectable as proviral DNA, and never exceeded one provirus per 1.8 
x 105 PBMCs. However, it appears that this rat model has not been used anymore since this 
initial report.  
The failure of viral replication in rodents is explained by the lack of appropriate receptors for 
HIV cell entry, inefficient provirus gene expression and viral assembly in murine cells 25, the 
block of HIV virus entry and impaired viral gene expression in rat cells 27, and the block of 
HIV virus entry in rabbit cells 28.  
 
1.4.2.1 Transgenic animals and viruses 
 
To overcome viral integration and replication blocks, investigators have made a huge effort to 
generate rodents transgenic for known critical host cellular factors. While in vitro rodent cells 
complemented with human trangenes were susceptible to HIV, transgenic rodents were still 
rather resistant to HIV. For example, Speck et al. overcame the entry block by transfecting 
rabbit cells with human CD4 and CCR5 in vitro and demonstrated that these cells allow viral 
entry and replication 29. Transgenesis of rabbits, however, is cumbersome. Thus, this model is 
buried in oblivion. Keppler et al. overcame the entry block in transgenic rats expressing 
human CD4 with either human CCR5 or CXCR4. These rats displayed a transient and very 
low-level plasma viremia upon HIV infection in the range of hundred copies of HIV RNA/ml 
30. Furthermore, HIV replication in these rats occurred only in macrophages and was 
completely absent in CD4+ T cells for unknown reasons 30. 
The situation is similar in mice: the block to HIV entry was overcome in CD4/CCR5 and 
CD4/CXCR4 transgenic animals. Follow-up studies, however, concurrently indicated that 
additional post-entry blocks to viral replication must exist. Reduced viral production in 
murine cells has been attributed to decreased activity of HIV regulatory genes such as tat 7 
and rev 31. Cyclin T is a species-specific cellular factor recently identified in human cells 
potentiating Tat activity when transfected into murine cells 32. Finally, a recent report 
uncovered an additional cellular block to virion assembly 33. All these blocks to viral 
replication must be conquered before the transgenic mouse models can be fully utilized. It is 
highly unlikely that transgenic mice expressing multiple human genes will represent the long-
awaited model. 
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Alternatively, investigators have adapted the host to express the full HIV genome or some 
viral genes. Hanna et al. created transgenic mice encoding the entire HIV genome in CD4+ T-
cells. These mice developed a severe AIDS-like disease leading to early death 34. Numerous 
subsequent studies created mice containing various HIV derived genes. This approach 
allowed close examination of individual HIV genes and mechanisms that contribute to HIV 
disease. Joliceur’s group, for example, showed that Nef is necessary and sufficient to induce 
pathogenesis 35. However, these models can not model the processes of infection such as viral 
spread and the emergence of viral variants. 
Similarly to the approach generating SHIV, murine leukaemia virus (MuLV)/HIV chimeric 
viruses have been developed to overcome some of the above mentioned limitations. Potash et 
al. replaced the coding region of the envelope protein gp120 in HIV with that of gp80 from 
ecotropic MuLV, a retrovirus that infects only rodents 36. Adult, immunocompetent mice were 
readily susceptible to infection and virus was detected in splenic lymphocytes, peritoneal 
macrophages, and the brain. This model has been valuable to study HIV therapy 37, vaccines 
38, and neuroinvasiveness 36. Unfortunately, these chimeric viruses have the same 
disadvantages as SHIVs – i.e., results obtained with (MuLV)/HIV cannot be directly 
extrapolated to HIV because of virus-specific differences.  
 
1.4.2.2 “Humanized” mouse models 
 
As outlined above, efforts to genetically engineer rodents to render them susceptible to HIV 
have largely failed. Even if infection in vitro was achieved by human transgene 
complementation, HIV replication in vivo was limited or absent. Thus, substitute 
xenochimeric mouse models have been developed by transplanting immunodeficient mice 
with pieces of human cells or tissues that normally serve as targets for HIV. More-recent 
advances have allowed reconstitution of apparently functional human lymphoid organs, which 
dramatically enhanced the utility of humanized mice in HIV research. 
 
1.4.2.3 The development of humanized mice 
 
The mice used for engraftment of human tissue must be strongly immunosuppressed 
otherwise the transplanted tissue will be rejected. The detailed history and state of the art in 
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this field has been extensively reviewed 39-42. Briefly, three major breakthroughs have 
occurred in the field of engrafting foreign tissue in mice which is based on the discovery of 
distinct mutations resulting in strong immunosuppression:  
First, the discovery of the Prkdcscid (protein kinase, DNA activated, catalytic polypeptide; 
severe combined immunodeficiency; abbreviated as SCID) mutation which leads to a 
complete absence of mature T and B cells allowed researchers to successfully transplant 
human cells and tissues into mice 43. However, these mice still had active natural killer (NK) 
cells, intact innate immunity and spontaneous rearrangement of T- and B-cell receptors over 
time leading to the generation of mature T and B cells. These limitations explain the rather 
low engraftment levels of transplanted lymphoid tissue. Preparative treatment or conditioning 
is mandatory prior to transplantation. Total body irradiation with sublethal doses of γ-
radiation is commonly employed. SCID mice, however, have an increased radiosensitivity; 
the defect in the mechanism for repairing DNA double-strand breaks also leads to a decreased 
recovery from general radiation damage 44. The Rag1 and Rag2 (recombination-activating 
gene 1 or 2) mutation prevent mature T- and B-cell development too, but do not cause 
leakiness or radiosensitivity 45. Nevertheless, these mice also showed very low engraftment 
levels of foreign lymphoid tissue; the NK cell activity was claimed to prevent a better 
engraftment.   
The second important event in the development of humanized mice was the generation of 
non-obese diabetic (NOD)-SCID mice. These mice have lower NK-cell activity and 
additional defects in innate immunity such as functionally less mature macrophage 
populations and reduced serum haemolytic complement activity, and supported 5-10 fold 
higher engraftment levels 46. Thus, NOD-SCID mice became the gold standard. The relatively 
short life span of only 8.5 months, because of a high incidence of thymic lymphomas, limited 
long-term experiments. Unfortunately, the majority of human T- and B-cell do not maturate in 
these mice. 
The third important step was the development of the Il2rg (interleukin-2 receptor γ-chain 
locus; also known as the common cytokine receptor γ-chain, γc, common to the IL-2, IL-4, 
IL-7, IL-9, IL-15, and IL-21 receptors) mutation which allowed much higher engraftment 
rates than in all previously models when crossed to NOD-SCID 47,48 or Rag2-/- mice 49. 
Cytokines that signal through γc play a pivotal role in lymphopoiesis 50. Notably, all Il2rg 
knockout strains completely lack mouse T, B, and NK cells, have normal life spans and show 
no obviously high rate of tumour development. Many Il2rg-/- strains were developed mainly 
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differing in the Il2rg mutation (truncated versus complete absence of IL-2R γ-chain) and 
strain background. Importantly, we and others found that strain background can severely 
affect engraftment: BALB/c but not C57BL/6 Rag2-/- Il2rg-/- can be successfully engrafted.  
As compared with previously available models, reconstitution of newborn mice represented a 
major improvement in the field of haematopoietic stem cell (HSC) transplantation 40,49,51. At 
the newborn age the expansion of the hemato-lymphoid system is maximal. Transplanting 
human HSC in newborn mice resulted in the generation of a thymus of human origin with 
intrathymic de novo human T-cell development 49. The route of injection may also affect 
engraftment efficiency by directing HSCs to a supportive niche.  Intravenous injection 
increased HSC engraftment as compared to conventional intraperitoneal (i.p.) injection 39. 
Intrahepatic injection, as the liver contributes to perinatal hematopoiesis, was even superior 49. 
Intra-bone-marrow and in utero injections aiming to place HSCs directly into a supportive 
microenvironment have also been performed 52,53. The optimal host strain, age and route of 
infection, however, are not yet known. A thorough direct comparative analysis of the various 
model systems would need to be done. 
Irrespective of the distinct approaches outlined above, the injection of HSCs into sublethally 
irradiated newborn NOD-SCID Il2rg-/- or BALB/c Rag2-/- Il2rg-/- mice resulted in formation 
and structuring of major hemato-lymphoid organs and successful differentiation of human 
cells into many lineages of haematopoietic cells including dendritic cells, natural-interferon 
producing cells, immunoglobulin producing B cells, T cells, and, to a lower extent, NK cells, 
myelo-monocytic cells, platelets, red blood cells, and hepatocytes 42,49,51,54,55. We would like 
to emphasize that T cells did not reproducibly develop in previous models. 
 
 
1.5 “Humanized” mouse models with HIV infection 
 
The above mentioned humanized mouse models gave rise to several HIV mouse models. 
Basically, although many variations exist, two major models have prevailed: 1) the classical 
SCID-hu and the hu-PBL-SCID models and 2) several more-recent models that rely on the 
transplantation of HSCs.  
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1.5.1 The SCID-hu model 
 
The SCID-hu model for studying HIV was developed in 1988 by Mike McCune’s group 56-58: 
human fetal thymus and liver obtained from fetuses of ~14-23 gestational weeks are 
surgically implanted under the kidney capsule  forming a conjoint organ referred to as thy/liv 
implant. The thy/liv implant resembles a normal human thymus displaying thymic 
architecture and an appropriate array of thymocytes subsets allowing thymopoiesis from 
haematopoietic precursor cells for up to one year 58. However, there is no or only limited 
egress of mature T cells from the thymus and no repopulation of human cells from the implant 
into other organs 59. Successful HIV infection is only achieved by injecting HIV directly into 
the implant. Thus, the resultant HIV infection and pathology is restricted to the implant. The 
levels of human T cells in peripheral blood (~0.7%) and in the spleen are insufficient for 
disseminated HIV infection. Furthermore, since thymocytes express CXCR4, but only a low 
level of CCR5, thymocytes are mainly permissive to CXCR4-tropic HIV strains 60. Notably, 
in man CCR5-tropic strains are the strains that are predominantly sexually transmitted and 
persist during early to late stage disease 5,61. Moreover, monitoring of HIV infection requires 
either repeated biopsies from the implant or that the animal has to be sacrificed. In particular, 
it must be noted that neither HIV viremia nor immune responses occur 9,62. 
Several modifications to increase the population of human cells were introduced including 
increasing the quantity of tissue implanted or transplanting additionally human fetal bone 
marrow 63 resulting in two major advantages: disseminated HIV infection and successful 
infection when inoculating HIV i.p..  
These dynamic systems have been very valuable to study HIV induced pathogenesis such as 
mechanisms of HIV-induced CD4+ T-cell depletion or the role of HIV accessory genes in vivo 
58. Notably, nef is critical for achieving high viral loads and depletion of CD4+ T cells 64. In 
contrast, vpu, vpr or vif demonstrated little impact on viral replication or cyopathicity 65. The 
SCID-hu models is also useful for the assessment of drug 64 and potentially gene therapeutic 
strategies 66. 
However, none of these modified models was able to mount a primary immune response. 
Recently a SCID-hu model has been described where fetal thymus, liver, bone marrow, lymph 
node and skin have been transplanted 67. In this modified SCID-hu model, primary immune 
responses have been observed. For practical reasons i.e., obtaining and transplanting all this 
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fetal tissue, this model will most likely not be generally available for medical research. In fact 
after its first description in 2000, no further reports have been published.  
To summarize, SCID-hu thy/liv mice permit the succesfull HIV infection of the implant. 
However, HIV pathology is mainly limited to the tissue implant, with naïve T-cells being 
preferentially susceptible to CXCR4-tropic strain infection. Furthermore, the availability of 
human fetal organs is very restricted in many countries depending on the legal regulations of 
abortions (e.g., abortions are not permitted after the 14th week of gestation in Switzerland).  
 
1.5.2 The hu-PBL-SCID model 
 
Human peripheral blood mononuclear cells (PBMC) are widely available; there are no ethical 
hurdles for getting it. Donald Mosier’s group reported the successfull transplantation of 
PBMC into SCID 18 years ago mice 68: after i.p. injection there is survival and expansion of 
human T cells, B cells, NK cells and monocytes. However, human cell numbers in the 
peripheral blood and other lymphoid organs are low. No human cells are found in the thymus. 
Successfull HIV infection was achieved with either cell-free or cell-associated HIV by i.p. 
injection. Some animal remained persistently infected for 16 weeks. HIV was detected in 
plasma, spleen, peritoneal lavage, PBMC, bone marrow and lymph nodes 10.  
PBMC were also transplanted into NOD-SCID mice as soon as they became available. In 
these mice higher levels of HIV replication were achieved due to more efficient grafting and 
proliferation of human T cells 69,70. Nonetheless, NOD-SCID mice lack potent human antigen 
presenting cells (APC) such as dendritic cells. The separate injection of human dendritic cells 
recently improved the model’s value for vaccine testing: partial protection from HIV 
infection, via both humoral and cellular immune responses, was conferred by injecting 
autologous dendritic cells transduced with replicative defective herpes simples virus 
amplicons that express HIV gp120 71.  
Massive and systemic HIV infection was reported as soon as NOD-SCID Il2rg-/- entered the 
field. For the first time, HIV viremia reaching as high as 106 copies/ml were achieved 72. This 
unprecedented susceptibility of the implanted human PBMCs stemmed from unnatural 
hyperactivation of the PBMCs.  
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However, there are major disadvantages when transplanting adult PBMC into mice: T cells 
show signs of major activation within hours and the memory T cells are selectively expanded. 
In addition, there is no continuous cell renewal because there is no repopulation of the 
thymus, the spleen or the bone marrow with CD34+ HSC. Very importantly, ~1 month after 
transplantation, PBMC expand as a consequence of a xenoreactive response and human T 
cells become anergic and are unable to respond to mitogens or to CD3 stimulation 73. Most of 
the transplanted mice show signs of graft-versus-host reaction. Thus, the time span to do 
experiments is very short. 
In summary, immunosuppressed mice transplanted with PBMC sustain HIV infection and 
replication in vivo. However, xenoreactivity and successive loss of human leukocytes limit 
infection to a relatively short time frame. Moreover infection is skewed toward HIV strains 
with the CCR5 co-receptor tropism - possibly driven by activation-induced CCR5 expression 
on human cells.  
 
1.5.3 CD34+ HSC transplanted mice – the hNOG and RAG-hu models 
 
Given the limitations of SCID-hu and hu-PBL-SCID mice and the fact that no primary 
immune responses were generated, these models did not fully match the demand for a small 
HIV animal model. Thus, a model that closely resembles a functional human adaptive 
immune system including the repopulation and structuring of primary and secondary 
lymphoid organs was required.  
At present, the two recipient mouse models fulfilling these criterions best seem to be: 
1) CD34+ HSC transplanted NOD-SCID Il2rg-/- mice, independently developed in the 
laboratories of Mamoru Ito 47 and Leonard Shultz 48 - hereafter referred to as hNOG 
mice, and 
2) CD34+ HSC transplanted BALB/c Rag2-/- Il2rg-/- mice independently developed in the 
laboratories of Markus Manz 49 and Hergen Spits 54 - hereafter referred to as RAG-hu 
mice (Table 1). 
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Abbreviation Common Strain Name Strain nomenclature Properties Refs 
hNOG NOD/LtSz-scid Il2rg-/- NOD.Cg-Prkdc
scid 
Il2rgtm1Wjl/SzJ 
- Long lifespan 
- Strong reduction in innate immunity 
- NK cells absent 
- High level of engraftment of human cells 
- Develop functional human immune system 
- Complete absence of Il2rg gene 
48,51 
hNOG NOD/Shi-scid Il2rg-/- NODShi.Cg-Prkdc
scid 
Il2rgtm1Sug/Jic 
- Similar to NOD/LtSz-scid Il2rg-/- except IL-2R γ-chain  
   is truncated, not absent, and still binds cytokines 
47,74 
Rag-hu Balb/c Rag2-/- Il2rg-/- C.Cg-Rag2
tm1Fwa 
Il2rgtm1Sug/Jic 
- Similar to hNOG mice except RAG-hu are radiation     
  resistant 
49 
Rag-hu H2d Rag2-/- Il2rg-/- Stock (H2
d)-Rag2tm1Fwa 
Il2rgtm1Krf/Brn 
- Similar to hNOG mice except RAG-hu are radiation  
  resistant 
54 
 
Table 1. Immunodeficient mice with mutations in the IL-2 receptor γ chain appear to be the best model for 
transplanting human cells and tissues. Adapted from 39. 
 
These mice, created by the injection of CD34+ HSC at the neonatal stage, achieve 
tremendously high levels of engraftment with successive formation of primary and secondary 
lymphoid organs, and some in vivo immune responses making them the favourite candidates 
for studying HIV pathogenesis. My thesis project entailed the thorough evaluation and 
establishment of RAG-hu mice as a mouse model for HIV infection (Section 2). In the mean 
time, several other groups also demonstrated that these models support productive HIV 
infection closely resembling HIV infection in man. Results will be discussed in section 5. 
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1.6 Immune activation in HIV pathogenesis 
 
The hallmark of HIV infection is the depletion of CD4+ T cells in peripheral blood, lymphoid 
organs, and mucosal tissues. The underlying mechanism(s) are not well understood despite 
almost 30 years of intensive research. Early studies mainly favored direct viral infection and 
subsequent cytopathic effects as the major cause of CD4+ T-cell loss 4, whereas contemporary 
studies mainly favour immunopathology and in particular immune activation by HIV as the 
underlying trigger of progressive immunodeficiency. In this chapter I will discuss the various 
views about the molecular mechanism(s) resulting in CD4+ T-cell loss with emphasis on 
immune activation.  
 
1.6.1 Direct viral cytopathogenicity (single-cell killing) 
 
In the eighties, CD4+ T-cell depletion was thought to be mainly due to direct cytopathic 
effects as a consequence of  disruption of the cell membrane as large amounts of virus bud 
from the surface 75 or as a consequence of intracellular accumulation of viral RNA 76 and  
unintegrated DNA 77 resulting eventually in host cell apoptosis. Killing of HIV-infected cells 
by HIV-specific cytotoxic CD8+ T lymphocytes may also contribute to CD4+ T-cell loss. 
However, this intuitive theory that HIV directly kills CD4+ T cells and that the slow 
progression to AIDS reflects a long, but eventually lost struggle of the immune system to 
replace killed cells in its effort to maintain T-cell homeostasis 78,79 is highly unlikely, because 
only a barely detectable number of cells (0.01-1%) are productively infected in chronic 
infection 80,81. The thymus would easily be able to cope with the number of productively 
infected cells lost. Thus, indirect mechanism(s) are most likely the main determinant for the 
progressive CD4+ T-cell loss.  
 
1.6.2 Indirect mechanisms - Bystander killing 
 
Uninfected cells may die in several innocent bystander scenarios, including formation of 
multinucleated giant cells (syncytia formation), immunopathology (immune-mediated 
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toxicity), autoimmune mechanisms, increased apoptosis, superantigen-mediated anergy, and 
precursor-cell damage:  
Multinucleated giant cells form when the cell membranes of infected cells expressing high 
levels of gp120 on their surfaces fuse with uninfected CD4+ T cells via conventional HIV 
receptor complex interactions. These multinucleated giant cells are likely associated with the 
cytopathic effects of HIV 82,83.  
Immunopathology is considered a major determinant of bystander killing. Uninfected cells 
may be killed when free gp120 binds to their cell surface, giving them the appearance of an 
infected cell and marking them for antibody-dependent cellular toxicity 84. Similarly, CD8+ 
cytotoxic T cells may accidentally destroy uninfected cells that display HIV fragments on 
their surfaces since they either have digested HIV infected cells or since they have engulfed 
HIV particles. We would like to emphasize that the role of CD8+ cytotoxic T cells is 
somewhat controversial: there is circumstantial evidence that the breadth and strength of the 
CD8+ cytotoxic T cells response is associated with HIV long term non progression 85 
indicating that the CD8+ effector cells involved may have a dual role 4. 
Autoimmune mechanisms have also been postulated for the killing of innocent bystanders 86. 
HIV envelope proteins gp120 and gp41 bear some resemblance to MHC II molecules on 
CD4+ T cells. Thus, HIV envelope specific antibodies may cross-react with MHC II and, thus, 
mistakenly damage MHC II+ cells 86.  
Apoptosis occurs to a greater extent in HIV-infected than in non-infected individuals 87.  Of 
note, HIV proteins such as gp120, Tat, Nef, and Vpu have been shown to induce apoptosis in 
CD4+ T-cells, even if not infected by HIV 88. 
The presence of an HIV-encoded superantigen represents another possible mechanism that 
explains bystander killing. Superantigens are polyclonal stimulators of antigen-nonspecific 
CD4+ T lymphocytes. Notably, the Nef protein of HIV is a putative superantigen 89. 
Superantigens serve as potent activators of T cells, rendering them more susceptible to HIV 
infection and ultimately leading to depletion or anergy 89. Anergy denotes an inactivated state 
of CD4+ T cells, which become refractory to further in vitro stimulation through the activation 
of their CD3 molecules when their component CD4 molecules reacted with complexes of 
gp120 antigen and antibody 4. 
It has also been observed that HIV infects precursor CD4+ T cells and damages the 
microenvironment of the bone marrow and the thymus, which probably loose the ability to 
regenerate the CD4+ T-cell pool. 
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1.6.3 Role of immune activation in CD4+ T-cell depletion 
 
It is now widely accepted that chronic immune activation drives both viral replication and 
CD4+ T-cell depletion 78. Several observations implied a crucial role of chronic immune 
activation in HIV pathogenesis: CD4+ T cells expressing the activation markers, CD69, 
CD25, and MHC II as well as CD8+ T cells expressing the activation marker CD38 correlate 
extremely well with HIV disease progression and CD4+ T cell loss in natural infection 90-92. 
Moreover, CD4+ T-cell depletion during the chronic phase is more directly related to the 
overall activation and turnover of T cells than to the viral replication rate 78,93-95. 
Immune activation also facilitates HIV infection of T cells by promoting the upregulation of 
CCR5 and adhesion molecules and by promoting nuclear-factor (NF)-κB activation 96-98. This 
in turn results in increased cytokine production that not only may support HIV replication but 
also have deleterious consequences. Chronic low-level TNF-α expression, for example, 
caused profound disturbances in tissue development, especially a diminution of thymic tissue 
99 and may be at least partly responsible for the severe weight loss and wasting syndrome seen 
in advanced stages of HIV infection 100. The significance of cytokine dysregulation for HIV 
disease progression is also underscored by polymorphisms that reduce IL-10 expression. Low 
IL-10 levels have been associated with slower progression to AIDS 101. Immune activation 
may also destroy the microachitecture of secondary lymphoid organs such as lymph nodes 102 
that will impair the regenerative potential of the immune system 103. 
Immune activation seems to be the primary parameter distinguishing pathogenic from 
nonpathogenic SIV infection in monkeys. SIV-infected rhesus macaques show sustained 
immune activation 104 and progress to AIDS within a short-time. In contrast, immune 
activation is absent in natural SIV infection of Sooty mangabeys and African green monkeys, 
which rarely progress to immunodeficiency despite high levels of viral replication 16. A cross-
sectional study that analyzed more than 100 naturally SIV-infected Sooty mangabeys revealed 
that CD4+ T-cell levels were not related to the level of viral replication or the length of 
infection but rather to the set point level of T-cell activation 105.  
In acute HIV infection, HIV depletes more than half of the total CD4+ CCR5+ T-cell pool 
within a few weeks, mainly in the gut-associated lymphoid tissue 106. This led to the question 
whether chronic immune activation and T-cell proliferation may simply be a homeo-static 
response to massive early CD4+ T-cell depletion and not be causally responsible for 
subsequent CD4+ T-cell depletion and disease progression 103. This is unlikely because T-cell 
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activation declines rapidly during antiviral therapy, despite minimal CD4+ T-cell recovery in 
gut associated lymphoid tissue and long before significant CD4+ T-cell recovery in peripheral 
blood 103,106,107. In contrast, homeostatic mechanism aimed at compensating for virus-induced 
cell loss may be involved in SIV-infected Sooty mangabeys (non-pathogenic infection). Here, 
induction of antiviral therapy is not followed by a rapid decline in T-cell proliferation 105. 
Therapeutic approaches that reduce immune activation may prevent CD4+ T-cell depletion 
and disease progression. This in turn, necessitates a better understanding of the precise 
mechanisms of how HIV induces immune activation.  
The definitive trigger by which HIV causes T-cell activation is still unclear. T-cell activation 
might be partly explained by evolutionary changes in Nef function. Nef from nonpathogenic 
SIV strains mediated downmodulation of the host T-cell receptor and thereby suppressed T-
cell activation, whereas Nef from HIV did not 108. However, this hypothesis remains 
controversial 109.  
Recently, Toll-like Receptors (TLR) have been proposed as potential key players in immune 
activation in HIV infection 110. TLRs belong to the family of pattern recognition receptors, are 
essential in innate immunity in mammals by recognizing conserved patterns of 
microorganisms (PAMP), are selectively expressed on cells of the immune system 111, and are 
classified according to the types of PAMPs they recognize (reviewed in 112). Brenchley et al. 
proposed circulating microbial products (a TLR4 ligand), likely derived from the 
gastrointestinal tract upon breakdown of the mucosal barrier, as a cause of HIV-related 
systemic immune activation 113. Immune activation correlates with HIV viremia and declines 
rapidly after initiation of HAART and long before peripheral CD4+ T-cell recovery 114,115. 
These observations suggest a direct role for viral replication products in immune activation 
116,117. In this context, HIV ssRNA is likely to contribute directly to immune activation: 
human TLR7/8 recognize HIV ssRNA 114,118,119, which encodes for multiple TLR7/8 ligands 
that indeed induced strong immune activation in vitro 114. 
We thus hypothesized that sustained immune activation through TLR7/8 is a main driver for 
chronic immune activation and thereby contributes to the progressive immunodeficiency 
observed in HIV infection. To explore the effects of sustained TLR7 triggering on the 
molecular and cellular components of the lymphoid system of mice, we used the synthetic 
compound R848 which triggers TLR7/8 similarly to HIV ssRNA 114,118,120. Results will be 
shown and discussed in section 3 of this thesis. 
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1.7 Signalling through the HIV receptor complex 
 
HIV infects cells through a receptor complex consisting of the CD4 receptor and one of the 
chemokine receptors CCR5 or CXCR4. Each component of the receptor complex is involved 
in signal transduction pathways, raising the question of whether HIV exploits them to 
optimize conditions for viral replication. HIV may use these particular molecules for more 
than simple attachment to the cell; viral proteins such as gp120 might function as agonist or 
antagonist of cellular receptors, modulating their downstream signalling pahtways 121. An 
understanding of the role of CD4/CCR5 signalling for viral replication might lead to novel 
targets for anti-HIV therapy. 
 
1.7.1 Natural signalling through the HIV receptor complex  
 
CD4 contains four immunoglobulin-like extracellular domains, a membrane-spanning 
segment and a short cytoplasmic tail that noncovalently interacts with the lymphocyte-specific 
protein tyrosine kinase p56lck 122,123. CD4 primarily acts as an accessory molecule of the T-cell 
receptor (TCR)/CD3 complex for binding MHC class II molecules 124. Co-aggregation with 
the TCR/CD3 complex, cross-linking with antibodies or binding of IL-16 results in 
phosphorylation of p56lck  125-127 and a cooperative signalling activity, leading to efficient T-
cell growth and activation 128-130 (Fig. 5). 
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Fig. 5. Scheme of CD4 mediated signalling. Following activation of the TCR/CD3 complex (by binding of e.g., 
MHC II), the CD4 co-receptor-associated SRC-family protein tyrosine kinase p56lck phosphorylates tyrosine 
residues in the cytoplasmic domain of the CD3ζ-chains eventually resulting in 1) phospholipase C (PLC)-
dependent activation of protein kinase C, which leads to an intracellular calcium flux, 2) RAS-mediated 
activation of mitogen-activated protein kinases (MAPKs) and 3) actin-dependent cytoskeletal rearrangements.  
 
The two chemokine receptors CCR5 and CXCR4 belong to the superfamily of seven–
transmembrane domain receptors 131,132 that signal through heterotrimeric G-proteins upon 
ligand binding, and are key regulators of leukocyte trafficking to inflamed tissues 133. 
Chemokine receptors have several conserved structural features, including a DRY motif in the 
second intracellular loop, which is involved in G-protein interaction, and structural motifs in 
the cytoplasmic tail, which are critical for signalling, desensitization, and receptor trafficking 
134. Natural ligands for CCR5 include RANTES, MIP-1α, and MIP-1β. Ligand binding results 
in a chain of events that alters the concentration of one or more small intracellular signalling 
molecules 131,132 (Fig. 6). 
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Fig. 6. Scheme of CCR5/CXCR4 G-protein-coupled-receptor (GPCR) mediated signalling. Activation by 
agonist leads to a conformational change which uncovers G-protein-binding sites. Both the αi subunit and the βγ 
dimers of G proteins can regulate effectors, such as adenylyl cyclase or PLC which result in CCR5-mediated 
intracellular calcium mobilization. Chemokine-induced activation of T cells via CCR5 leads to activation of the 
two related focal adhesion kinases FAK and Pyk2, which also have important roles in cell motility including cell 
spreading and migration. CCR5 ligands activate the three main members of the MAP kinase family (ERK1/2, 
p38, and SAPK/JNK), which are suggested to be critical for T-cell proliferation and the transcriptional activation 
of cytokine genes 134. 
 
1.7.2 HIV interactions with the receptor complex induces signalling  
 
As the name implies, R5-tropic HIV strains are dependent on a HIV receptor complex 
consisting of CD4 and CCR5 135,136. Binding of the HIV envelope protein gp120 to CD4 is the 
initial step in this process 137,138 followed by a subsequent exposure of a cryptic chemokine-
like site in gp120, which then binds to CCR5.  
This binding of HIV gp120 to CD4 or the chemokine co-receptor also initiates signals (Fig. 
7), some of which are specific for HIV, such as activation of non-selective cation channels 139. 
Signalling through CD4 or CCR5 does not appear to affect HIV fusion or entry 140-145. In 
contrast, post-entry steps of the HIV replication cycle such as reverse transcription, DNA 
expression, and protein synthesis are affected by CD4-mediated signalling 146 147-151.  
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After attachment of HIV gp120 to CD4, the CD4 cytoplasmic domain transduces signals 
123,152 resulting in aberrant T-cell activation 153, NF-κB activation 141, priming of CD4+ T cells 
to apoptosis 154, and suppression and deregulation of T-cell responses 153,155. 
Similarly, HIV gp120 also signals through chemokine receptors (Fig. 7) and participates in 
the post-entry stages of the HIV replication cycle 156. Notably, CCR5 activation affected the 
early stages of viral replication which required signal transduction through Gαi proteins 157 
indicating that activation of intracellular signalling pathway by chemokine co-receptor can 
have a direct impact on post-entry events that regulate viral replication 121. Indeed, R5 gp120 
binding to CD4 and CCR5 stimulated extracellular signal-related kinase (ERK), Jun N-
terminal kinase (JNK), and p38 155 which can affect the proliferative capacity and facilitate 
HIV replication through Activator protein 1 (AP1) and NF-κB-mediated pathways that can 
enhance the expression of viral genes or numerous cytokines 121. Moreover, HIV gp120 of 
either CCR5- or CXCR4-tropic strains can induce calcium flux and chemotaxis and activate 
cytoplasmic tyrosine kinase Pyk2 158,159 and the closely related focal adhesion kinase (FAK) 
160. This implies that HIV binding can elicit cytoskeletal rearrangements, which ultimately 
promote cell polarization and motility. This in turn, could facilitate viral translocation to the 
nucleus or enhance the recruitment of T cells to sites of viral production and thereby favor 
viral spreading and dissemination 121.  
 
1.7.3 Limitations of previous studies  
 
Intracellular signals transduced by HIV envelope have been suggested to contribute to the 
immunopathogenesis of HIV infection by priming cells to become optimal targets for 
infection or by recruiting uninfected target cells to areas with high concentrations of virus 
(i.e., lymphoid tissue) 153,158,161. HIV gp120 has also been shown to induce anergy or prime 
cells for apoptosis 153,162.  
However, it remains unclear whether CD4 negatively 163 or positively 140,141,154,164 regulates 
HIV replication. Effects of signalling through the chemokine co-receptor CCR5 also are a 
matter of debate: for example, one study found CCR5-mediated signalling to be dispensable 
for HIV replication 165, whereas another showed that CCR5 signalling facilitates HIV 
replication 166.  
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Fig. 7. Interaction of gp120 with the cellular receptor complex induces various signalling events. CD4 
stimulation by gp120 induces intracellular calcium flux, MAPK activation, actin polymerization, and cross-talk:  
an Lck-dependent signal that results in cross-desensitization of CCR5 167. CCR5 stimulation activates ERK, 
JNK, and p38 which promote cell proliferation and transcriptional activity of NF-κB and AP1. The activation of 
FAK and Pyk2 affects actin polymerization, cell adhesion and migration, and host-cell survival 134. Cross-talk 
occurs in both directions. Collectively, all these signalling events might influence viral transmission and 
replication. However, the role of signalling through CD4 or CCR5 for HIV replication has been a matter of 
debate. 
 
Moreover, these studies focused on signalling by the components individually. The two 
receptor (i.e., CD4 and CCR5), however, are physically 168 and functionally 167,169,170 
associated and there is cross-talk between the receptors 169,170. 
A large body of data has accumulated concerning interactions of the HIV envelope and the 
viral receptor complex. However, no work has yet examined the motifs of CD4 or CCR5 (or 
combinations of motifs) that are critical for HIV replication, cell activation, cell apoptosis, or 
cytokine release. Since HIV entry is a continuous process and cross-talks are known between 
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the transduction pathways of CD4 and CCR5, they can not be dissected into single 
components and signalling can not be attributed to an individual event. Therefore, we 
generated human T-cell lines stably expressing different combinations of either wild-type or 
mutant CD4 and CCR5. These cell lines were used to study both the overall influence of 
signalling through the receptor complex on HIV replication and the contribution of each 
receptor to such effects. Results will be shown and discussed in section 4 of this thesis. 
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1.8 Aims of this thesis 
 
The aims of this thesis were to study host-HIV interactions in vitro and in vivos: 
 
1)  To evaluate RAG-hu mice as a model system for HIV infection.  
Manz et al. recently established a new human-to-small animal xenotransplantation model 
(RAG-hu mice) 49. In brief, transplantation of CD34+ cord blood cells into newborn Rag2-/- 
Il2rg-/- mice led to de novo formation of a human adaptive immune system, (i.e., functional B, 
T, and myeloid and plasmacytoid dendritic cells). Thus, they have several significant 
advantages over other available mouse models: de novo T-cell generation from CD34+ cells 
with a broad T-cell receptor repertoire over at least 6 months, T-cells of naïve and memory 
phenotype, repopulation of lymphoid organs such as lymph nodes and spleen with cells from 
the lymphoid and monocytic lineage, generation of primary immune responses.  Importantly, 
RAG-hu mice represent a very straightforward, easily applicable and ethically less 
problematic model as compared to SCID-hu mice where fetal tissue is transplanted. We 
examined and thoroughly validated RAG-hu mice for its ability to serve as a small animal 
HIV model. Read chapter 2. 
 
2)  To elucidate whether triggering Toll-like receptor (TLR) 7 may be responsible for 
the chronic immune activation and dysfunction seen in HIV infection.  
Chronic immune activation is considered a major contributor to progressive 
immunodeficiency observed in HIV infection. Indeed, chronic immune activation is superior 
as prognostic predictor than serial measurements of CD4+ T-cell counts or of HIV RNA. The 
underlying trigger, however, remains unknown. We hypothesized hat HIV ssRNA itself 
directly contributes to immune activation and dysfunction by continuously triggering TLR7. 
We used the synthetic compound R848 which triggers TLR7/8 similarly to HIV ssRNA to 
explore the effects of sustained TLR7 triggering on the molecular and cellular components of 
the lymphoid system of mice. Read chapter 3. 
Building upon the data generated in this project we may extend our explorations in the RAG-
hu mouse model. This, however, is beyond the scope of this thesis. 
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3)  To investigated the impact of signalling through the HIV receptor complex (i.e., CD4 
and chemokine receptor CCR5) on HIV replication. 
HIV infects cells through a receptor complex consisting of the CD4 receptor and one of the 
chemokine receptors CCR5 or CXCR4. Each component of the receptor complex is involved 
in signal transduction pathways, raising the question whether HIV exploits them to optimize 
conditions for viral replication. The effects of signalling are a matter of debate probably 
because previous studies have focused on signalling by the components individually. 
However, the two receptors are physically associated, which results in reciprocal modulation 
of their signalling responses. We thus analyzed replication of several CCR5-tropic HIV 
molecular clones and patient isolates in a panel of cell lines stably expressing different 
combinations of either wild-type or mutated CD4 and CCR5. Mutations were chosen based on 
motifs known to be involved in signal transductions. Read chapter 4. 
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2.1 Summary: Disseminated and Sustained HIV-Infection in 
CD34+ Cord Blood Cell Transplanted Rag2-/-γc-/- Mice 
 
Stefan Baenziger1, Roxane Tussiwand2, Erika Schlaepfer1, Luca Mazzucchelli3, Mathias 
Heikenwalder1, Michael O Kurrer1, Silvia Behnke1, Joachim Frey4, Annette Oxenius5, Helen 
Joller1, Adriano Aguzzi1, Markus G Manz2 and Roberto F Speck1 
 
Address: 1University Hospital of Zurich, Zurich, Switzerland, 2Institute for Research in Biomedicine, Bellinzona, Switzerland, 3Institute for 
Pathology, Locarno, Switzerland, 4University of Berne, Berne, Switzerland and 5Swiss Federal Institute of Technology, Zurich, Switzerland 
 
Background 
Due to species selectivity, HIV research is largely restricted to in vitro or clinical studies, both 
limited in their ability to rapidly assess new strategies to fight the virus. We evaluated a novel 
mouse model that is based on the transplantation of human cord blood CD34+cells into 
immunodeficient Rag2-/-γc-/- newborn mice for studying HIV. 
 
Results 
Reconstituted mice (CD45+ cell engraftment: 29 ± 18%) were permissive to HIV with up to 2 
× 106 copies/ml 2–6 weeks after infection. Thereafter, viremia stabilized at lower levels for up 
to 4 months. A marked CD4+ cell depletion occurred in all mice infected with X4- strains 
simultaneously with the initial rise of plasma HIV RNA while this was not the case in R5-
infected mice. Spleens and lymph nodes of mice infected with either R5- or X4- strains 
contained p24+ cells. In thymi, however, p24+ cells were detected rather exclusively following 
infection with X4- strain, consistent with the expression of CXCR4 but not CCR5 on human 
CD4+ thymocytes. Similarly as in humans, HIV-infected macrophages were rare. 
 
Conclusion 
Rag2-/-γc-/- mice transplanted with human CD34+ cells develop long-term, high-titer, and 
lymphoid organ disseminated infection irrespective of co-receptor selectivity of HIV strain, 
closely resembling HIV infection in man. In particular, by using HIV strains with distinct co-
receptor selectivity, we clearly illustrate the higher cytopathic potential of X4- strains as 
compared to R5- strains. This straightforward to generate and cost-effective in vivo model 
should be valuable to study virus-induced pathology, and to rapidly evaluate new approaches 
aiming to prevent or treat HIV infection. 
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2.2 Disseminated and Sustained HIV-Infection in CD34+ 
Cord Blood Cell Transplanted Rag2-/-γc-/- Mice 
 
Stefan Baenziger1, Roxane Tussiwand6, Erika Schlaepfer1, Luca Mazzucchelli7, Mathias 
Heikenwalder3, Michael O. Kurrer4, Silvia Behnke4, Joachim Frey8, Annette Oxenius5, Helen 
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of Pathology, University Hospital of Zurich, 8091 Zurich, 5Institute of Microbiology, Swiss Federal Institute of Technology, 8093 Zurich, 
6Institute for Research in Biomedicine, 6500 Bellinzona, 7Institute for Pathology, 6600 Locarno and 8Institute of Veterinary Bacteriology, 
University of Berne, 3001 Berne, Switzerland. 
 
 
Due to species selectivity, human immunodeficiency virus (HIV) research is largely 
restricted to in vitro or clinical studies, both limited in their ability to rapidly assess new 
strategies to fight the virus. To prospectively study some aspects of HIV in vivo, 
immunodeficient mice, transplanted with either human peripheral blood leukocytes or 
with human fetal tissues, have been developed. Although these are susceptible to HIV 
infection, xeno-reactivity and short infection spans, resource and ethical constraints, as 
well as biased HIV co-receptor tropic strain infection, pose substantial problems in their 
use. Rag2-/-γc-/- mice, transplanted as newborns with human CD34+ cells were recently 
shown to develop human B, T, and dendritic cells, constituting lymphoid organs in situ. 
We here tested these mice as a new model system for HIV-1 infection. HIV RNA levels 
peaked to up to 2x106 copies/ml plasma early after infection, and viremia was observed 
for up to 190 days, the longest time followed. A marked relative CD4+ T cell depletion in 
peripheral blood occurred in CXCR4-tropic strain infected mice, while this was less 
pronounced in CCR5-tropic strain infected animals. Thymus infection was almost 
exclusively observed in CXCR4-tropic strain infected mice, while spleen and lymph node 
HIV infection occurred irrespective of co-receptor selectivity, consistent with respective 
co-receptor expression on human CD4+ T cells. Thus, this straight-forward to generate 
and cost-effective novel in vivo model closely resembles HIV infection in man, and 
therefore should be valuable to study virus-induced pathology, and to rapidly evaluate 
new approaches aiming to prevent or treat HIV infection.  
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2.2.1 Introduction 
Since the beginning of the HIV pandemic, research has been hampered due to the lack of 
assessable animal models that mirror infection in man. HIV is a human-specific virus, and 
consequently laboratory rodents as mice or rats are not susceptible to infection 9. Although 
non-human primates as chimpanzees can be infected, they do not develop HIV-associated 
immunodeficiency 12,13, while sooty mangabeys, rhesus macaques, and baboons are only 
susceptible to HIV related simian-immunodeficiency virus 14. Therefore, HIV research in non-
human primates, although of importance, remains restricted by biological as well as by ethical 
and financial constraints 171. Efforts to genetically engineer rodents to become HIV targets 
(e.g., artificial expression of human CD4, CCR5, or CXCR4) have largely failed, because, 
even if infection in vitro was achieved, HIV replication in vivo was limited or absent 9,172,173. 
Thus, substitute xeno-chimeric models have been developed by transplanting 
immunodeficient mice with either human peripheral blood leukocytes (hu-PBL-SCID) 68,174, 
or pieces of human fetal tissues containing hematopoietic cells (SCID-hu) 56,175. Both hu-
PBL-SCID and SCID-hu mice sustain HIV infection and replication in vivo. However, in hu-
PBL-SCID mice xeno-reactivity and successive loss of human leukocytes limit infection to a 
relatively short time frame, and, possibly driven by activation-induced CCR5 expression on 
human cells, infection is skewed towards HIV strains with the respective co-receptor tropism 
72,176. In SCID-hu mice, due to the transfer of human hematopoietic stem cell containing 
tissue, HIV infection can be observed for extended times; however, availability of 
transplantable human fetal organs is restricted for practical and ethical reasons, and HIV 
pathology in these mice is mainly limited to the tissue implants, with naïve T cells being 
preferentially susceptible to CXCR4-tropic strain infection 9,59,177. Given these limitations and 
the fact that no primary immune responses were generated, hu-PBL-SCID and SCID-hu mice 
did not fully match the demand for a small animal model that closely mirrors infection in 
humans.  
Recently, we found that injection of human cord blood CD34+ cells into newborn Rag2-/-γc-/- 
mice leads to development of human T-, B- and dendritic cells, successive formation of 
primary and secondary lymphoid organs, and some in vivo immune responses 49,178. We here 
evaluated these mice as a new model system for both CXCR4- and CCR5-tropic HIV-1 
infection. 
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2.2.2 Results 
CXCR4 and CCR5 expression on de novo generated human thymocytes and CD4+ T 
cells in Rag2-/-γc-/- mice.  
Depending on the use of chemokine receptors in combination with CD4 for cellular entry, 
HIV has been classified into CXCR4- or CCR5- tropic strains 135,136,179. In humans, CD4+ 
thymocytes and CD4+ T cells broadly express CXCR4, while CCR5 expression is restricted to 
a fraction of mainly CD4+ T memory cells 180. Similarly, most of thymic and peripheral CD4+ 
T cells in CD34+ cord blood cell transplanted Rag2-/-γc-/- mice expressed CXCR4, while CCR5 
was found only on a fraction of lymphoid organ CD4+ T cells that almost exclusively 
displayed a memory phenotype as determined by CD45RO expression (Fig. 1 and data not 
shown). Thus, de novo generated human CD4+ thymocytes and T cells in CD34+ cord blood 
cell transplanted Rag2-/-γc-/- mice closely resemble chemokine receptor expression patterns 
observed in humans, and therefore should be valid targets for HIV strains with respective co-
receptor selectivity. 
 
 
Fig. 1. CCR5 and CXCR4 expression on human CD4+ cells in CD34+ transplanted Rag2-/-γc-/- mice resemble 
expression patterns in man. Histograms depict representative receptor expressions (closed histograms) and 
respective isotype controls (open histograms) on CD4+ gated control human PBL and cells isolated from tissue 
of a mouse at 16 weeks after birth and transplantation of CD34+ cells. 
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Long-term and high-titer CCR5- and CXCR4-tropic HIV infection in human CD34+ 
cord blood cell transplanted Rag2-/-γc-/- mice. 
CD34+ cord blood cell transplanted Rag2-/-γc-/- mice with a mean human peripheral blood 
CD45+ and CD4+ cell chimerism of 29.4±18.2% and 2.7±3.0%, respectively (detailed analysis 
of human cell engraftment in representative animals are given in supplementary Table 1), 
were infected i.p. with either CCR5-tropic YU-2 (n=15), or CXCR4-tropic NL4-3 (n=19) 
HIV-strains at 10-28 (mean 16.4±6.7) weeks of age. Plasma levels of viral RNA were 
measured at successive time-points. Independent of viral strains used, HIV RNA levels 
peaked two to six weeks after infection, with up to about 2x106 copies/ml plasma, while 
thereafter viremia mostly stabilized at lower levels, and was maintained for up to 190 (YU-2) 
and 120 (NL4-3) days, the longest time followed (Fig. 2A). No HIV RNA was detectable at 
four weeks post-injection in two YU-2 and five NL4-3 receiving animals. However, upon 
NL4-3 re-infection of four of the latter ones, all four became HIV RNA positive. 
In a subgroup of both CCR5- and CXCR4-tropic strain infected mice (n=4 each), we 
measured HIV RNA as well as relative CD4+ and CD8+ cell counts in peripheral blood over 
time: partial CD4+ T cell depletion occurred in three out of four mice infected with CCR5-
tropic strains beyond 125 days of infection, while all CXCR4-tropic strain infected animals 
showed a more pronounced relative peripheral blood CD4+ T cell depletion already early in 
infection, i.e., beyond day 25, following the initial rise of plasma HIV RNA (Fig. 2B). 
HIV strains recovered from either YU-2 or NL4-3 infected chimeric Rag2-/-γc-/- mice were 
fully functional as co-cultured mouse spleen cells propagated infection in primary human 
peripheral blood leukocytes (PBL) in vitro (Fig. 3). Together these findings indicate that 
CD34+ cord blood cell transplanted Rag2-/-γc-/- mice have an overall high susceptibility to both 
CXCR4- and CCR5-tropic HIV, and develop high and sustained viral titers, comparable to 
titers found in HIV infected individuals. 
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Fig. 2. Long-term and high-titer CCR5- and CXCR4-tropic HIV infection in human CD34+ cord blood cell 
transplanted Rag2-/-γc-/- mice. A) Quantitative HIV RNA plasma levels in animals successfully infected with 
CCR5-tropic (YU-2; n=13) and CXCR4-tropic (NL4-3; n=18) HIV strains. Black triangles and connector lines 
indicate sequential analysis of single mice, brown diamonds indicate single time-point analyzed mice. B) Graphs 
depict quantitative HIV RNA plasma levels (copies/ml plasma; right y-axis) and relative CD4+ and CD8+ T cell 
levels (% of human CD45+ blood cells; left y-axis) in individual mice over time (uninfected n=2, YU-2 and 
NL4-3 infected n=4 each), showing more pronounced CD4+ T cell depletion in CXCR4-tropic infected animals. 
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Fig. 3. CXCR4- and CCR5-tropic HIV infected, chimeric Rag2-/-γc-/- mice passaged HIV propagates infection to 
primary human PBL in vitro. Left graph shows p24 levels in supernatants of HIV-infected mice splenocytes and 
PHA-activated human PBL co-cultures. Right graph shows p24 levels in PHA-activated PBL cultures infected 
with transferred supernatants of primary cultures (left), proving integrity of virions released from infected mouse 
derived splenocytes (representative experiment of 2; blue triangle NL4-3, red daimond YU-2). 
 
HIV spreading in lymphoid organs of human CD34+ cell transplanted Rag2-/-γc-/- mice 
resembles HIV infection in humans. 
To visualize the major cell types productively infected with HIV in lymphoid organs, serial 
sections were taken and stained with anti-HIV p24 capsid antigen and anti-human CD3, 
revealing that, as expected, most of infected cells were human T cells (Fig. 4A). Although 
CD68+ macrophages, CD11c+ dendritic cells, and CD14+ monocytic cells were generated 
from human CD34+ cells in mice (Fig. 4B, C, D and Table 1,) 49, p24 expressing, and thus 
productively HIV infected non-T cells such as CD68+ macrophages were only occasionally 
detected (Fig. 4C, D), suggesting that non-T cells are a minor source of HIV in this model. 
From 18 days post-infection, spleens and lymph nodes of both NL4-3 and YU-2 infected 
animals contained p24+ cells. In thymi, however, p24 expression was detected in NL4-3, but 
only infrequently or not at all in YU-2 infected animals, consistent with the expression of 
CXCR4 but not CCR5 on human CD4+ thymocytes (Fig. 1, Fig. 5).  
In both CXCR4- and CCR5-tropic HIV infected mice, p24+ multinucleated giant cells were 
formed in lymph node and spleen sections (Fig. 4C), a phenomenon previously reported in 
brain and lymphoid tissues of HIV-infected individuals. 
Thus overall, the here observed HIV dissemination in lymphoid organs of human CD34+ cell 
transplanted Rag2-/-γc-/- mice closely resembles HIV infection in humans. 
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Fig. 4. HIV p24+ cells are mostly human CD3+ cells and only occasionally non-T cells such as CD68+ 
macrophages. A) Histologies show consecutive spleen sections (paraffin, 1µm) stained with antibodies against 
human CD3 and p24, and respective merged presentation of both in a YU-2 infected animal 18 days post 
infection. B) Anti human CD68 staining on paraffin embedded material; C) merged anti CD68 (green), HIV-p24 
(red), and DAPI (blue) staining of cryo-embedded spleen (6µm sections), showing that p24+ cells mainly localize 
in white pulp areas (darker area, see also Fig. 4B), whereas CD68+ cells mostly localize at adjacent margins and 
red pulp areas. D) Consecutive spleen cryosection staining and respective merged presentation showing a rare 
CD68 and p24 double positive cell (yellow). Right: 3x enlargement of area with double positive cell. B, C, D) 
representative spleen sections from a YU-2 infected animal 23 days post infection. 
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Table 1: Distribution of human cells in CD34+ cord blood cell transplanted mice 
              
  not infected YU-2 infected NL4-3 infected 
Days post infection   15 15 22 23 15 15 22 23 
Blood                         
● CD45 75.9 37.2 12.4 5.3 18.7 4.8 3.5 29.3 5.3 4.9 5.2 43.1
* CD4 52.2 43.1 12.0 21.1 7.1 5.1 8.6 12.7 14.7 11.7 36.0 38.3
* CD8 31.2 44.2 8.2 8.3 6.5 3.4 2.9 9.5 8.1 5.2 20.9 46.7
* CD19 10.4 8.9 n.a. n.a. n.a. n.a. n.a. 62.6 n.a. n.a. n.a. 4.6
Bone marrow      
● CD45 89.9 45.7 20.2 4.9 52.5 38.3 22.1 22.0 8.4 34.4 1.4 82.0
* CD4  32.2 15.3 2.0 8.2 7.9 5.1 6.4 4.4 3.9 4.6 32.4 47.8
* CD8 34.7 5.6 0.7 1.3 0.2 0.3 3.2 1.7 0.6 0.1 27.0 25.1
* CD19 25.5 52.4 n.a. n.a. n.a. n.a. n.a. 59.1 n.a. n.a. n.a. 9.7
* CD34 n.a. 1.2 7.4 2.9 16.0 12.3 12.4 4.0 2.6 11.1 1.3 10.4
* CD123 n.a. 7.7 1.0 1.1 2.6 1.2 1.4 7.8 1.5 1.4 2.6 1.3
* CD11c n.a. n.a. n.a. 2.9 8.6 4.4 8.1 n.a. 3.2 5.1 27.8 n.a.
Spleen      
● CD45 93.2 55.8 28.0 24.0 27.6 17.1 22.5 26.0 22.2 19.0 6.9 10.1
* CD4  41.3 25.6 4.8 7.1 4.8 1.4 1.7 9.0 5.5 3.5 12.0 33.6
* CD8 18.7 29.9 4.8 5.3 4.0 1.0 1.8 5.5 4.7 2.4 21.5 50.2
* CD19 32.7 36.9 n.a. n.a. n.a. n.a. n.a. 72.7 n.a. n.a. n.a. 9.6
* CD14 0.2 2.5 n.a. n.a. n.a. n.a. n.a. 5.4 n.a. n.a. n.a. 1.0
* CD123 <0.1 <0.1 0.8 0.3 0.5 0.8 0.4 1.0 0.5 0.6 1.6 <0.1
* CD11c 13.4 13.6 1.4 1.6 3.6 0.8 1.1 8.0 1.6 1.1 6.7 11.1
Lymph node      
● CD45 94.8 88.7 81.8 74.8 91.0 60.5 71.7 86.6 86.8 74.4 66.6 89.7
* CD4  75.5 39.5 30.3 31.2 27.7 42.1 36.3 29.3 44.1 38.6 7.3 6.3
* CD8 n.a. n.a. 33.3 32.8 33.7 30.9 14.4 n.a. 24.7 28.8 43.7 n.a.
* CD123 1.5 3.2 n.a. n.a. n.a. n.a. n.a. 0.2 n.a. n.a. n.a. 7.1
Thymus      
● CD45 92.3 82.5 95.7 94.9 94.1 98.2 93.6 98.1 99.0 97.3 94.4 87.4
* CD4 single pos. n.a. n.a. 21.0 44.2 26.0 13.9 42.1 n.a. 33.3 11.5 44.7 n.a.
* CD8 single pos. n.a. n.a. 18.7 14.3 31.4 6.8 13.1 n.a. 4.1 8.4 32.4 n.a.
* double neg. n.a. n.a. 16.1 9.3 19.9 5.5 6.6 n.a. 3.7 10.4 8.8 n.a.
* double pos. n.a. n.a. 44.2 32.2 22.7 73.8 38.2 n.a. 58.9 69.7 14.1 n.a.
Liver                  
● CD45 n.a. n.a. 67.1 36.6 77.6 33.7 26.5 n.a. 48.2 41.5 31.4 n.a.
* CD4  n.a. n.a. 30.2 28.7 35.4 16.9 25.2 n.a. 22.8 27.0 17.9 n.a.
* CD8 n.a. n.a. 9.8 9.3 8.1 3.1 3.1 n.a. 5.9 6.1 30.9 n.a.
* CD123 n.a. n.a. 4.8 3.6 3.5 5.8 8.0 n.a. 2.3 5.3 0.7 n.a.
* CD11c n.a. n.a. 8.6 11.1 38.9 9.3 24.9 n.a. 11.6 15.5 5.0 n.a.
 
● Percentage (%) human CD45 positive cell of all viable mononucleated cells 
* Percentage (%) respective cells of human CD45 positive cells 
 
n.a.: not assessed. Distribution of human cell engraftmen in respresentative mice (mean age 16.6 weeks, range 
14.6-21.9 weeks) as assessed by flowcytometry. 
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Fig. 5. HIV spreading in lymphoid organs of human CD34+ cell transplanted Rag2-/-γc-/- mice resembles HIV 
infection in humans. A) Representative p24 stained thymus and lymph node sections of YU-2 and NL4-3 
infected mice, analyzed at 37 and 23 days post-infection, respectively. No or very rare p24 staining is observed 
in thymi of R5 tropic YU-2 infected animals. B) Representative tissue section of spleen and C) lymph node of a 
YU-2 infected animal at 52 days post infection, showing multinucleated p24+ giant-cells (enlarged inserts in C). 
 
Human CD34+ cell transplanted Rag2-/-γc-/- mice mount no or very limited B cell 
responses to HIV-infection. 
To determine human B cell responses in Rag2-/-γc-/- mice beyond three weeks of infection, 
plasma samples of n=23 were tested for total human IgG levels, and n=25 were analyzed for 
HIV specific IgM and IgG by western blot. As expected from our previous observations 49, 
total IgG levels accounted for a mean of 0.136 g/l (range 0.0295-0.5 g/l), an amount about 80 
times less than found in healthy human adults. Only one animal infected with YU-2 at 23 
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weeks of age (11% human CD45+ cells in peripheral blood), and analyzed at 42 days post-
infection, produced a detectable IgG, but no measurable IgM response against p34, gp41 
(weak), p52, p58, and gp160 (Fig. 6).   
We also performed a limited analysis of T cell responses: spleen cells of each two NL4-3 and 
YU-2 infected animals sacrificed at 52 to 115 days post infection were loaded in vitro with 
HIV specific peptides, covering a broad range of HLA types, followed by flow-cytometric 
measurement of intracellular IFN-γ production. However, no relevant IFN-γ production could 
be detected, suggesting a lack of, or below detection limit T cell response. 
Together these results indicate that HIV infected human CD34+ cell transplanted Rag2-/-γc-/- 
mice mount no substantial or only very occasional B cell, and likewise insufficient T cell 
responses. 
 
 
Fig. 6. Humoral immune response in HIV infected human CD34+ cell transplanted Rag2-/-γc-/- mice. Figure 
depicts western blot analysis of HIV specific IgG and IgM responses. Upper panel: three step dilution of plasma 
from a HIV infected patient (no antiviral therapy) showing full IgG sero-conversion. Lower panel: undiluted 
plasma of  animal showing a measurable IgG response against p34, gp41, p52, p58, and gp160 (A), and 
undiluted plasma of an animal showing no response (B). 
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2.2.3 Discussion  
To investigate infectious agents prospectively, suitable in vivo laboratory models are needed. 
This poses a problem in research involving human specific pathogens as HIV. To this end, 
xeno-chimeric models have been developed by transplanting immunodeficient mice with 
cellular targets of HIV, i.e., either human PBL 68,174, or pieces of human fetal tissues as liver 
and thymus, containing hematopoietic cells (SCID-hu) 175: While suitable to study some 
aspects of HIV in vivo, both models are limited by systematic issues 9. Human PBL 
transplanted into SCID mice (hu-PBL-SCID) are activated within the xenogeneic 
environment, T cells become successively anergic, and, due to lack of both continuing 
hematopoiesis as well as appropriate hu-PBL maintenance, the xeno-graft is non-functional 
within several weeks 9,174. In contrast, mice transplanted with human fetal liver and thymus 
(SCID-hu) de novo generate and maintain human cells, especially T cells, within the human 
thymus graft 56. However, SCID-hu mice are laborious and costly to generate, and availability 
of transplantable human fetal organs is restricted for practical and ethical reasons, limiting 
broader use of these mice in laboratories. Recently, major advances in generating xenogeneic-
mouse models that continuously produce T cells and all other major cell types of the human 
adaptive immune system in respective mouse organs from human hematopoietic stem and 
progenitor cells, were achieved (reviewed in: 40,41,181). We demonstrated that newborn human 
cord blood CD34+ cell transplanted Rag2-/-γc-/- mice develop de novo human T-, B- and 
dendritic cells, form primary and secondary lymphoid organs in situ, and mount some 
immune responses upon tetanus toxoid vaccination or infection with Epstein Barr virus (EBV) 
49. Similar results were obtained by transplanting NOD/SCIDγc-/- mice with either human cord 
blood or mobilized peripheral blood CD34+ cells 48,51,74,182. 
We here establish cord blood CD34+ cell transplanted Rag2-/-γc-/- mice as a new tool to study 
HIV infection and pathogenesis in vivo. In this model system, CXCR4 and CCR5 expression 
on in vivo generated human CD4+ T cells in respective lymphoid organs closely resembles 
HIV co-receptor expression in humans (Fig. 1) 180.  Accordingly, efficient in vivo infection of 
human cells with both CXCR4-tropic (NL4-3) as well as CCR5-tropic (YU-2) HIV stains, 
was reliably achieved (Fig. 3, 4, 5), leading to replication of fully functional HIV (Fig. 2). 
While CXCR4-tropic stains infected all lymphoid organs, CCR5-tropic stain infection was 
largely restricted to extra-thymic tissues (Fig. 5). Both viral strains led to long-term, high-titer 
infection with an initial viremic peak of up to 2x106 HIV RNA copies/ml plasma, followed by 
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a chronic phase with somewhat lower RNA levels for up to 190 days, the longest time 
followed (Fig. 2).  
In both CXCR4- and CCR5-tropic strain infected animals productively HIV-infected cells, 
i.e., p24+ cells, were mostly CD3+, and only occasionally non T cells such as CD68+ 
macrophages (Fig. 4, and data not shown). These findings are reminiscent of data acquired 
from ex vivo isolated lymphoid tissue of HIV-infected individuals, where productive 
macrophage infection by both CXCR4- and CCR5-tropic HIV strains is very infrequently 
observed 80,183,184 and likely only increases in end-stage disease with occurrence of 
opportunistic infections 185.  
Irrespective of co-receptor selectivity, HIV-infected, multinucleated giant cells were formed 
(Figure 5C), a phenomenon previously observed in brain and lymphoid tissues of HIV-
infected individuals, likely associated with high viral replication, spreading infection, and 
CD4+ T cell loss 83,186.  
Together, these findings are clearly distinct from previous observations on HIV infection in 
hu-PBL SCID or SCID-hu mice: although both CXCR4- and CCR5-tropic viruses infect hu-
PBL-SCID mice, CCR5-tropic viruses are more aggressive, likely due to xenogeneic 
activation and CCR5 up-regulation of transferred mature T cells, and, with consecutive graft 
failure, infection is limited to few weeks; in contrast, SCID-hu mice develop few human 
CCR5 carrying cells, and CXCR4-tropic HIV replication is limited rather exclusively to the 
fetal tissue grafts; furthermore, in both SCID models by virtue of their nature, no HIV 
dissemination to respective lymphoid organs occurs. 
In man, CCR5-tropic HIV strains are primarily transmitted and dominate infection over 
extended times. In about half of late stage HIV patients, CXCR4-tropic strains emerge, either 
as cause or consequence of accelerated immunodeficiency, a matter still under debate 187. 
Previously, it was demonstrated that CXCR4-tropic HIV strains lead to pronounced cell 
depletion in human fetal thymus grafts in SCID-hu mice 177, and replicated more efficiently in 
primary human thymocytes in vitro 188. Interestingly, CXCR4-tropic HIV infection in CD34+ 
cell transplanted Rag2-/-γc-/- mice, lead to more rapid blood CD4+ cell loss than CCR5-tropic 
infection (Fig. 2). Thus, these findings rather suggest a causative than secondary role of 
CXCR4 virus in accelerated immunodeficiency, possibly in part by destruction of emerging 
thymocytes 187,189. 
An ultimate goal in the use of substitute xenogeneic small animal models is the generation of 
robust human primary adaptive immune responses in order to rapidly test potential new 
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vaccine candidates, a matter unfortunately not met so far in human hematopoietic stem and 
progenitor cell transplanted animals 9,40,41. However, some limited evidence for primary 
immune responses in the xenogeneic setting were reported: SCID-hu mice were resistant to 
opportunistic infections, suggesting some direct or indirect immune function of the human 
grafts 56; we have demonstrated that human CD34+ cell transplanted Rag2-/-γc-/- mice generate 
some low-level specific IgG responses to tetanus toxoid upon repeated vaccination beyond 12 
weeks of age, and, following EBV infection, some mice showed inverted CD4:CD8 ratios, 
and CD8 T cells proliferated in vitro when stimulated with autologous EBV-transformed 
target cells 49; furthermore, ovalbumin specific human IgM and IgG responses were observed 
in NOD/SCIDγc-/- mice 51. While in the here presented data all tested HIV infected Rag2-/-γc-/- 
mice produced human IgG at levels on average 80 fold lower than healthy human adults, only 
one out of 25 mounted a detectable HIV-specific IgG response (Fig. 6). Similarly, although 
based on limited data, we did not detect HIV-specific T cell responses, as determined by IFN-
γ detection upon in vitro re-stimulation. Low or absent immune responses to HIV might in 
part be due to preferential destruction of virus reactive cells by HIV 190, however, in this 
setting the more likely explanation might be inefficient MHC selection of human T cells in 
the mouse thymus, and possible lack of some cross-reactive cytokines and chemokines in the 
xenogeneic environment 40,41,49,178. Thus, generating primary HIV-specific immune responses 
remains a challenge that might be solved by adding human MHC, cytokines, chemokines, or 
stromal cell compounds to the recipient mouse background, all efforts currently under way. 
In summary, the here presented data establishes newborn human CD34+ cell transplanted 
Rag2-/-γc-/- mice 49 as a new tool to study HIV infection and pathogenesis in vivo. Upon 
CCR5-tropic or CXCR4-tropic HIV challenge these mice develop long-term, high-titer, and 
lymphoid organ disseminated infection, closely resembling HIV infection in humans. This 
straight-forward to generate, cost-effective, ethically unproblematic, and easy to monitor new 
in vivo model should thus be valuable to study virus-induced pathology, as well as 
pharmacologic or genetic approaches aiming to prevent or treat HIV infection. 
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2.2.4 Materials and Methods 
Cord blood samples: Human cord blood was obtained with written parental informed 
consent from healthy full-term newborns with approval of the local ethical board. CD34+ cells 
were enriched using immunomagnetic beads (Miltenyi Biotec) as described 49. Cells were 
either frozen or transplanted immediately. Animals used in this study received 50,000-
600,000 (mean 227,500 ± 140,000) CD34+ selected cells. 
 
Mice: Human CD34+ cell reconstituted mice were generated as described in accordance with 
the guidelines of the Institute for Research in Biomedicine (IRB), Bellinzona, animal facility 
49. Rag2–/–γc–/– mice were originally kindly provided by M. Ito, Kawasaki, Japan. 
 
HIV-1 infection: Viral stocks were obtained by calcium phosphate transfection (Promega) of 
293T cells with pNL4-3 or pYU-2. pYU-2 and pNL4-3 were obtained from B. H. Hahn, 
University of Alabama, Birmingham, AL, and M. A. Martin, Laboratory of Molecular 
Microbiology, National Institute of Allergy and Infectious Diseases, Bethesda, MD, 
respectively, through the NIH AIDS Research and Reference Reagent Program. 48 hours after 
transfection, virus was harvested, filtered (0.22 µm), and frozen at –80°C until use. Mice were 
injected i.p. with 0.2 ml PBS containing either YU-2 or NL4-3 at a tissue culture-infecting 
dose 50 of 2x106. Infection was performed in a BL3 laboratory in accordance with IRB and 
the Institute of Veterinary Bacteriology (University of Bern) animal facility guidelines.  
 
Analysis: Plasma HIV RNA concentrations were determined by Cobas Amplicor RT-PCR 
assay (Roche Diagnostics). p24 antigen levels in cell-culture supernatants were quantified by 
ELISA as described 191. Human cell engraftment in mice was measured by flow cytometry as 
described 49. Anti CXCR4 (12G5) and CCR5 (2D7) antibodies were from BD Pharmingen. 
Immunohistochemical stainings were performed in an automated Ventana Discovery Module 
(Ventana, Strasbourg, France). Paraffine sections were incubated in a 1:5 dilution of mouse 
monoclonal antibody to HIV-1 p24 (clone Kal-1; Dako). Staining for CD3 (SP7, Labvision) 
was performed according to Ventana protocols. Immunofluorescent stainings and microscopy 
were done as described 192. Briefly, slides were sequentially incubated with: 1) mouse anti-
HIV-1 p24 diluted 1:10 (DAKO Diagnostics AG, Zug, Switzerland), 2) 5 µg/ml of Cy3-
conjugated goat anti-mouse immunoglobulin (Ig) (Amersham, Little Chalfont, GB); 3) 5 
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µg/ml of mouse IgG (Sigma, Buchs, Switzerland); 4) FITC-conjugated mouse anti-human 
CD68 (1:20; DAKO), 5) rabbit anti-FITC (1:2000; DAKO), and 6) 5 µg/ml Alexa 488-
conjugated goat anti-rabbit Ig (Molecular Probes Europe BV, Leiden, The Netherlands) and 
0.5 µmol/L of 4',6-diamidino-2-phenylindole (DAPI; Sigma). To assess non-specific binding, 
tissue from untransplanted and/or uninfected transplanted mice was stained as controls. 
 
Immune responses: Human IgG levels in serum were measured on LC-Partigen plates 
(Behring, Marburg, Germany). HIV specific Western blot analysis was done using a 
commercially available kit (New Lav BlotI, BIO RAD). HIV-specific T cell responses were 
evaluated as previously described 193: briefly, 106 splenocytes from HIV-infected and 
uninfected mice were pulsed with pools of overlapping peptides covering the HIV gag (NIH 
HIV-1 Consensus B Gag (15-mer) Peptides Set; pool I: Cat Nr. 7872 – 7933, pool II: Cat Nr. 
7934 – 7994) or HIV nef (NIH HIV-1 Consensus B Nef (15-mer) Peptides Complete Set, Cat 
Nr. 5189) or with a 17-peptide pool (NIH Cat Nr. 7891, 7920, 7926, 7945, 7976, 7980, 7983 
(gag), 5507, 5527, 5544, 5576 (pol), 6287, 6412, 6420 (env), 5172, 5183 (nef), 6078 (vpr)) at 
a concentration of 2x10-6M/peptide. One hour later, brefeldin was added for 5 hours. 
Splenocytes were stained with mAb against CD4, CD8, and intracellularly against IFN-γ 
using BD Cytofix/Cytoperm permeabilization/fixation kit (BD Pharmingen).  
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Advances in generation of mice that upon human hematopoietic stem and progenitor 
cell transplantation develop and maintain human hemato-lymphoid cells fueled an 
already thriving field of research. We here focus on human T cell development and HIV 
infection in Rag2-/-γc-/- mice transplanted as newborns with human CD34 positive cord 
blood hematopoietic stem and progenitor cells.  
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2.3.1 Introduction  
For good reasons knowledge on human physiology and pathology is largely gained by 
observation, cautious, informed consent, and safety-oriented in vivo experimentation, and in 
vitro surrogate assays. Using these approaches, rigorous scientific proof is often impossible. 
Thus, progress in clinical research is mostly slow. Most societies agree on animal research 
using worms, flies, and small vertebrates given appropriate ethical consideration. Because of 
their high similarity with human beings, easy access and experimental feasibility, laboratory 
mice have become the main model for in vivo biomedical research reported in the vast 
majority of published work in high-ranking scientific journals. And for sure, the capturing 
slogan "They (laboratory animals) save more lives than 911 (the emergency call number)" is 
not an over-statement. However, although genome similarities are higher than naïvely 
expected, 65 million years of diverge in human and mouse evolution have shaped two species 
that differ substantially in size, lifespan, reproductive activity, and exposure to environmental 
challenges, as e.g., co-evolving species-specific infectious agents. Thus, also regarding 
hematology and immunology, mice are not men, accounting for one of the reasons that great 
achievements in mice are quite often lost in translational research 194,195.  
Experimentation with human hemato-lymphoid system mice took off almost 20 years ago, 
paralleling increasing application of clinical hematopoietic stem cell transplantation for 
malignant disease and immunodeficiencies, as well as the rising HIV pandemic. Some basic 
requirements need to be met for hematopoietic cell engraftment, differentiation and function: 
cells need to find appropriate locations, must be supported by respective nurturing factors 
from the host environment, and must not be rejected. In cross-species transplantation, this 
requires immune-deficiency of the recipient, as well as cross-reactivity of homing molecules, 
and differentiation and survival factors, if not produced in sufficient amounts by transplanted 
cells themselve.  
As the detailed history and state of the art in this field were recently reviewed 39-42and major 
scientific contributions to the field are discussed in other chapters of this meeting book, we 
here briefly set the main focus on our work on T cell development and HIV infection using 
immunodeficient Rag2-/-γc-/- mice (generated by M. Ito at the Central Institute for 
Experimental Animals, Japan), transplanted as newborns with human CD34+ hematopoietic 
stem and progenitor cells.  
 
 
55 
2.3.2 Human T cell development and HIV infection in immunodeficient mice 
transplanted as newborns with human CD34 positive hematopoietic stem and 
progenitor cells. 
One of the major improvements achieved by using newborn NOD/SCIDγc-/- and Rag2-/-γc-/-
mice as recipients for human hematopoietic stem and progenitor cell grafts is efficient intra-
thymic de novo development of human T cells 49,51,54,178. In contrast to newborn 
transplantation, T cell development in adult NOD/SCIDγc-/- recipients is less efficient but can 
be enhanced by exogenously adding human IL-7 48,182. Human T cells generated in the mouse 
thymus include in fairly physiologic ratios CD4+ and CD8+ T cells with a broad Vβ 
distribution, Foxp3+ CD25+ regulatory T cells, and γδ T cells. Mature T cells exit the thymus 
and home to secondary lymphoid organs. What is the MHC restriction and functionality of 
human T cells educated on a mouse thymic background? Data generated mostly in mice 
demonstrates that under normal developmental conditions positive selection preferentially 
occurs on cortical thymic epithelial cells, while both medullary epithelial cells and 
hematopoietic derived dendritic cells are involved in negative selection (e.g., reviewed in 196). 
We did not observe human thymic epithelial cells in CD34+ cell transplanted mice in line with 
expectations of epithelial cell germ-layer derivation, while dendritic cells of both mouse and 
human origin constitute the thymus. Thus, human developing thymocytes should in theory be 
positively selected on mouse epithelial cells, while negative selection might occur on both 
mouse and human MHC. If so, it would be reasonable to expect that T cells positively 
selected on mouse MHC would continue to preferentially interact in negative selection also 
with mouse MHC. However, under certain conditions hematopoietic offspring cells are likely 
involved in positive selection, as pointed out by several mouse to mouse transplantation 
studies 197,198. Moreover, species-specific differences in thymic selection might exist, and 
human thymocyte-thymocyte MHC class II interaction, and thus at least some CD4 T cell 
selection, might occur on human MHC 199,200. Upon T cell exit from the thymus, they depend 
on homeostatic factors, both MHC and cytokines for survival (e.g., reviewed in 201). As in 
human hematopoietic stem and progenitor cell transplanted mice human MHC is only present 
on hematopoietic but no other tissues, presentation of both “self” and “non-self” peptides in 
the context of both MHC class I and II will depend on cellular tropism of these. 
Given all considerations mentioned above, what experimental data on reactivity of mouse 
background generated human T cells has been reported? 1) human T cells isolated from 
mouse lymph nodes and spleen proliferated vigorously in mixed lymphocyte reactions 
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(MLRs) when stimulated with human allogeneic DCs, but weakly or not at all when 
stimulated with human autologous DCs. Proliferative response to mouse DCs was low, 
however, there was a small difference with stronger proliferation of T cells when stimulated 
with fully mismatched versus host mouse type dendritic cells 49. 2) cytotoxic activity against 
human allogeneic target cells could be blocked using human MHC class I or II antibodies, 
respectively 51. 3) some responses of human T cells in mice to in vivo infection of human B 
cells with Epstein-Barr virus are observed, however, in some cases human T cells were not 
capable to control EBV driven B cell proliferation 49. 4) human T cells specific for viral 
epitopes were only observed in the context of mouse MHC upon infection of mice with 
influenza virus 40; 5) when mature, mouse derived human T cells were transferred to non-
transplanted Rag2-/-γc-/- mice, we observed no relevant homeostatic cell expansion; similarly, 
high peripheral T cell turn-over rates and lack of long-term T cell maintenance was observed 
by other groups 40, suggesting that peripheral homeostatic T cell maintenance might not 
function appropriately, an issue that still needs to be resolved by more experimentation.  
In summary, thus far no firm conclusion on the biology of T cell selection in this setting 
where the T cells are of human and the thymic stroma is of mouse origin can be drawn. It can 
only be suggested that T cell tolerance, i.e., possibly negative selection, for both autologous 
human and mouse MHC is achieved. Beyond, insufficient T cell responses due to no or 
weakly cross-species reactive co-stimulation and cytokine responses might account for 
additional difficulties in any human T cell response observed in this setting. In terms of 
appropriate T cell selection, the obvious solution is to replace mouse by human MHC 
components, creating at least for thymic selection, a similar situation as in mice co-
transplanted with same donor fetal thymic tissue 57,202. It will be of high interest to see if 
human T cell development will pursue in the absence of any tissue MHC, a model situation of 
allogeneic hematopoietic cell transplantation in human MHC deficiencies 57.  
As in our human cord blood CD34+ cell transplanted mice human T cells developed and 
seeded secondary lymphoid organs, we and concomitantly others, tested these mice, and mice 
co-transplanted with human thymus, as models for HIV infection 82,203-206. We infected human 
hemato-lymphoid system mice i.p. with either CCR5 tropic or CXCR4 tropic HIV-1 strains. 
Irrespective of co-receptor selectivity, HIV RNA plasma copies peaked at 2-4 weeks after 
infection, comparable to HIV infection in man. Thereafter, viremia mostly stabilized at lower 
levels and was maintained for up to 190 days, the longest time followed. HIV generated in 
mice was functional, since supernatants of infected mouse-derived cell cultures propagated 
infection in primary human leucocytes. As in man, developing human CD4+ thymocytes in 
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mice are mostly CXCR4-positive, but lack CCR5 expression, while peripheral CD4+ T-cells 
express CXCR4 and/or CCR5. Thymic HIV infection was detected upon CXCR4 tropic 
infection, while secondary lymphoid organ infection occurred in both CXCR4- and CCR5-
tropic virus infected animals (Fig. 1).  
 
 
Fig. 1 Rag2−/−γc−/− mice, transplanted as newborns with human CD34+ cord blood cells and subsequently infected 
with HIV, develop lymphoid organ-disseminated, productive HIV infection. Histology shows HIV p24 staining 
preferentially localized in the white pulp area in the spleen of an HIV-infected mouse (18 days after infection 
with CCR5-tropic YU-2; Magnification 20x) 
 
 
In both CXCR4- and CCR5-tropic strain infected animals productively HIV-infected cells, 
i.e., HIV-p24+ cells, were mostly CD3+ and only occasionally non T cells such as CD68+ 
macrophages. In some mice with high numbers of productively infected cells, syncytium 
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formation occurred in both spleen and lymph nodes, a process observed in brains and 
lymphoid tissue of HIV infected individuals, likely associated with high viral replication, 
spreading, and CD4 cell loss. Overall, CXCR4-tropic HIV infection lead to more rapid blood 
CD4+ cell loss than CCR5-tropic infection, reminiscent of CXCR4-tropic emergence of HIV 
strains in late-stage human HIV disease. One out of 25 infected mice mounted a HIV-specific 
IgG response detectable by standard clinical assays 82. Furthermore, although based on limited 
data, we did not detect robust HIV-specific T cell responses, as determined by IFN-γ 
detection upon in vitro re-stimulation, in line with other concomitant reports 204. Thus, 
although specific immune responses are observed, they thus far lack robustness, i.e., are not 
predictable in frequency and levels, prohibiting e.g., at this stage efficient pre-clinical vaccine 
testing. However, as is, this model will be valuable to study virus-induced pathology and to 
evaluate new non-adaptive immunity dependant approaches aiming to fight HIV.   
 
 
2.3.3 Conclusions  
It can be anticipated that basic and preclinical in vivo human immunology and infectious 
disease research will greatly benefit from improved, easy-to generate and broadly available 
human hemato-lymphoid system mice over the coming years.  
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2.4 Work in progress 
2.4.1 RAG-hu mice as a screen for antiretroviral compounds that block sexual 
transmission. 
Mucosal HIV transmission, i.e., vaginal and rectal transmission, is the primary mode of 
transmission worldwide, and understanding its biology is pivotal for ending the HIV 
pandemic. HIV research, in general, has long been hampered by the lack of an effective small 
animal model that replicates HIV infection in man. As a further “proof of concept,” we 
propose to use RAG-hu mice to study mechanism(s) of vaginal HIV transmission, a 
particularly critical route of HIV infection, and to efficiently test compounds / vaccines for 
blocking mucosal HIV transmission in a preclinical model.  
 
Progesterone treatment thins the mulitlayer, stratified squamous epithelium. 
Vaginal transmission studies in monkey models with SIV have frequently pretreated the 
challenged animals with progesterone, with the purpose of altering the cellular architecture of 
the vaginal epithelium to facilitate viral transmission. In addition, this treatment synchronizes 
the oestrous cycle among experimental animals. Experiments with hu-PBL-SCID mice 
revealed that vaginal HIV transmission is only successful with prior administration of 
progestin 207,208. Therefore, we investigated the influence of progesterone treatment on the 
vaginal epithelium of Rag2-/- γc-/- mice as related to their histological appearance (Fig 1). 
 
 
Fig. 1: Progesterone treatment of Rag2-/-γc-/-  results in a thinning of the multilayer, stratified, squamous 
epithelium (B) as compared to the vagina of untreated mice (A) Mice were treated subcutaneously with 2.5 mg 
progestin (Depo-Provera, Pfizer). 
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RAG-hu mice have human cells in the epidermal layer of the vagina. 
In macaques HIV is first detected in specialized cells of the lymphoid system, namely 
dendritic cells, in the vagina soon after inoculation with SIV. The conventionally used mouse 
models (i.e., hu-PBL-SCID, SCID-hu) lack human target cells in the vagina that free virus 
could infect. In contrast, it might be highly likely that RAG-hu mice have human cells in the 
epidermal layer of the vagina. We therefore tested whether RAG-hu mice have human cells in 
the epidermal layer of the vagina (Fig 2). Indeed, we detected the presence of some human 
cells by immunohistochemical staining.   
 
 
Fig. 2: RAG-hu mice have human cells in the epidermal layer of the vagina (arrows). Vaginal tissue of RAG-hu 
mice was stained for the panhuman leukocyte marker CD45 or the macrophage marker CD68.  
 
 
Cell-associated viral transmission by vagina irrespective of co-receptor usage. 
Vaginal transmission of cell-associated virus is more efficient than that of cell-free virus. 
Moreover, it has been reported that HIV strains using the chemokine receptor CCR5 is much 
more efficiently transmitted than HIV strains using the chemokine receptor CXCR4 for 
cellular entry.  
We, thus, tested in a first step vaginal HIV transmission with cell-associated HIV. RAG-hu 
mice allow for cell-associated HIV transmission by vagina irrespective of co-receptor usage 
(Fig 3). We are currently investigating the transmission of cell-free HIV. 
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Fig. 3: RAG-hu mice allow for cell-associated viral transmission by vagina irrespective of co-receptor usage. 
Seven days after progestin treatment, mice were anaesthetized and 2x106 HIV infected human peripheral 
leukocytes (huPBL) per mouse were inoculated by the vaginal route. Three weeks later, HIV RNA load in 
peripheral blood was determined by Cobas Amplicor assay. Five mice were inoculated vaginally with human 
PBL infected with a CCR5-tropic strain (Yu-2; black bars) and three mice were inoculated with human PBL 
infected with a CXCR4-tropic strain (NL4-3; gray bars).  
 
 
Perspective 
A mouse model of vaginal transmission of cell-associated and cell-free virus would provide a 
simple and inexpensive tool to identify antiretroviral compounds that block sexual 
transmission. Blocking heterosexual transmission of HIV would be a milestone in the fight 
against the HIV pandemic. The long-term goal would be to make this model available to the 
research community for wider testing of various compounds for inhibiting HIV vaginal 
transmission.  
We would like to emphasize that this humanized mouse model is susceptible to the vaginal 
transmission of HIV strains using either CCR5 or CXCR4. Consequently, our model may 
help to elucidate whether the preferential transmission of CCR5-tropic viruses in the clinical 
setting reflects preferential movement of CCR5-utilizing virus-infected cells across the 
mucosal barrier or an enhanced ability of these cells for the spread of HIV.  
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2.4.2 APOBEC3: its role as restriction factor in HIV infection. 
Although antiretroviral therapy has dramatically ameliorated the situation of people living 
with HIV, the pandemic continues resulting in more than 40 million people infected, almost 5 
million people newly infected and 3 million deaths in 2005. Thus, new therapeutic strategies 
are urgently needed 1. 
A powerful mechanism of innate immunity has recently been discovered, in which APOBEC 
proteins pose powerful barriers to the replication of HIV and other retroviruses 209,210. 
APOBEC are a family of cytidine deaminases. They hinder HIV replication mainly by 
hyperdeamination of the nascent HIV DNA strand in newly infected cells 211,212. HIV on its 
part has evolved Vif (viral infectivity factor), which mediates APOBEC degradation 213. The 
balance between APOBECs and Vif is highly likely to be a crucial determinant for the 
outcome of HIV infection; targeting APOBEC/Vif interaction might represent a promising 
therapeutic approach 214, which in turn necessitates a detailed understanding of its molecular 
mechanisms. Little is known, however, about the signalling pathways involved in induction of 
APOBEC expression. Moreover, APOBECs have been examined exclusively in vitro by using 
predominantly cell lines; the importance of APOBECs in an in vivo system has yet to be 
explored. 
 
Working Hypothesis: We hypothesize, that APOBEC3 proteins are key players in the innate 
immune response against HIV and are anti-viral active throughout the course of HIV disease.  
The main goal of this study is i) to investigate APOBEC3’s anti-viral effects against various 
HIV strains in vitro and in particular in vivo, and ii) to what extent APOBEC3’s anti-viral 
activity may be enhanced by cytokines and ligands triggering pattern recognition receptors, in 
particular ligands triggering Toll-like receptors. RAG-hu mice have significant advantages 
over existing xeno-chimeric models and represent an excellent tool to approach APOBEC 
biology in an in vivo setting. 
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Chronic immune activation is a major cause for progressive immunodeficiency in 
infection by human immunodeficiency virus-1 (HIV). The underlying trigger, however, 
remains largely unknown. HIV single-stranded RNA serves as a potent immune 
activator by triggering Toll-like receptor (TLR) 7/8. We hypothesized that sustained 
TLR activation induces immune activation and thereby may contribute to progressive 
immunodeficiency. The synthetic compound R848 was used to explore the effects of 
sustained TLR7 triggering on the murine lymphoid system. Sustained TLR7 activation 
induced an immunopathology reminiscent of progressive lymphoid destruction in HIV 
disease. We show profound lymphopenia, elevated proinflammatory cytokines, 
splenomegaly, contracted lymphoid subsets, and altered lymphoid microarchitecture 
with enlarged B- and T-cell zones and reduced marginal zone B lymphocytes. Upon 
exposure to inactivated vesiculo-stomatitis virus, antibody production was abolished, 
although splenic lymphocytes were activated and total IgG was elevated. These TLR7-
specific effects were partly mediated by interferon regulator factor 7 and type I 
interferon receptor signalling. Our data imply that HIV itself may directly contribute to 
immune activation and dysfunction by stimulating TLR7. Notably, HIV virions and 
single-stranded RNA reach high copy numbers in plasma, although only a minor 
fraction of these particles is infectious. Manipulation of TLR7 signalling may thus be a 
potential antiviral strategy. 
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3.1 Introduction 
Progressive CD4+ T-cell depletion and chronic immune activation are hallmarks of human 
immunodeficiency virus-1 (HIV) infection. Chronic immune activation includes aberrant 
cytokine production, redistribution of lymphocyte subpopulations, polyclonal B-cell 
activation, increased T-cell turnover, and increased numbers of activated T cells.  
Several observations suggest a crucial role of chronic immune activation in HIV pathogenesis. 
i) Increased numbers of activated CD4+ T cells expressing the activation markers CD69, 
CD25, and MHC class II as well as activated CD8+ T cells expressing the activation marker 
CD38 correlate with HIV disease progression and CD4+ T-cell loss in untreated infection 90-92. 
Notably, CD38 expression on CD8+ T cells is considered to be a better prognostic marker 
than CD4+ T-cell counts or peripheral HIV RNA load 104. ii) Immune activation is absent in 
non-pathogenic simian immunodeficiency virus (SIV) infection. In particular, the natural 
hosts of SIV, sooty mangabeys and African green monkeys, show only minimal increases in 
immune activation and rarely progress to immunodeficiency despite high levels of viral 
replication 16,215. iii) Immune activation facilitates HIV infection of T cells by promoting co-
receptor, adhesion molecule, and nuclear factor (NF)-κB expression 96-98. iv) Persistent 
immune activation in mice that constitutively express CD70, can induce lethal T-cell 
immunodeficiency 216.  
The precise mechanism and underlying trigger by which HIV causes immune activation 
remain poorly understood. Immune activation in pathogenic SIV and HIV infections might be 
partly explained by evolutionary changes in Nef function. Schindler and colleagues 108 noted 
that the Nef from nonpathogenic SIV strains mediates downmodulation of the host T-cell 
receptor and thereby suppressed T-cell activation, whereas Nef from HIV did not. However, 
this hypothesis remains controversial 109. Alternatively, T-cell recognition of HIV antigens, 
gp120- and Nef-mediated signalling 217,218, and regulatory CD4+ T-cell depletion 219 have also 
been proposed as major contributors to immune activation. Regulatory T cells are important 
for suppression of T-cell activation. 
Toll-like receptor (TLR) activation may not only enhance antiviral immunity by activating the 
immune system (reviewed in 220), but also play a pivotal role in aberrant immune activation in 
HIV infection 110. TLRs belong to the family of pattern recognition receptors, are essential in 
innate immunity in mammals by recognizing conserved patterns of microorganisms (PAMP), 
are selectively expressed on cells of the immune system 111, and are classified according to the 
types of PAMPs they recognize (reviewed in 112). TLR3, 7, 8 and 9, are localized 
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intracellularly and detect nucleic acids derived from viruses or bacteria. In particular, TLR7/8 
sense viral single-stranded (ss) RNA 221.  
Brenchley et al. proposed circulating microbial products (TLR4 ligands), likely derived from 
the gastrointestinal tract upon breakdown of the mucosal barrier, as a cause of HIV-related 
systemic immune activation 113. Immune activation correlates with HIV viremia and declines 
rapidly after initiation of HAART and long before peripheral CD4+ T-cell recovery 114,115. 
These observations suggest a direct role for viral replication products in immune activation 
116,117. In this context, HIV ssRNA is likely to contribute directly to immune activation: 
human TLR7/8 and murine TLR7 recognize HIV ssRNA and synthetic imidazoquinoline-like 
molecules 114,118,119. Importantly, HIV ssRNA has been shown to encode for multiple TLR7/8 
ligands that indeed induce strong immune activation in vitro 114. 
In natural HIV infection, the immune system fails to eliminate the virus, resulting in persistent 
ssRNA and virion production, although only a minor fraction of these virions (i.e., 1/60,000) 
is infectious 222. Nonetheless, these non-functional viral particles may have a biological 
significance because they constantly induce TLR signalling. We recently showed that 
constant triggering of TLRs is harmful to the immune system. Repetitive triggering of TLR9 
dramatically altered the morphology and functionality of mouse lymphoid organs 223.  
Here we hypothesized that sustained immune activation through TLR7/8 is a main driver for 
chronic immune activation and thereby contributes to the progressive immunodeficiency 
observed in HIV infection. To explore the effects of sustained TLR7 triggering on the 
molecular and cellular components of the lymphoid system of mice, we used the synthetic 
compound R848, which triggers TLR7/8 in a manner similar to HIV ssRNA 114,118,120. Unlike 
in humans, TLR8 is nonfunctional in mice 224. We demonstrate that chronic triggering of 
TLR7 in mice results in immune activation, functional impairment and disruption of the 
lymphoid system reminiscent of HIV-associated pathology.  
 
3.2 Results 
Continuous stimulation of TLR7 induced sustained lymphopenia and increased 
neutrophil and monocyte numbers.  
To assess the effects of sustained TLR7 triggering in vivo, C57BL/6 mice were treated with 
the R848 daily for up to 42 days. We hereby aimed to replicate the persistent nature of HIV 
infection with sustained exposure of lymphoid tissue to HIV ssRNA burden.  
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Fig. 1. Sustained stimulation of TLR7 dramatically induced sustained lymphopenia and increased neutrophil and 
monocyte numbers. (A–D) Mice were treated with the TLR7 ligand R848 in a daily fashion. After 7 days of 
treatment, blood was analyzed for the presence of leukocytes, lymphocytes, monocytes, neutrophils, and 
thrombocytes 1 h after the last injection. (A) R848 treatment did not affect absolute numbers of circulating 
leukocytes. Left: 1 mg R848/kg/day; analysis by flow cytometry before and after treatment. Numbers signify 
percentage of viable leukocytes as determined by FSC/SSC characteristics. Arrowhead indicates monocytes and 
neutrophils (i.e., large granular cells with high FSC/SSC properties). Right: analysis by hemocounter. (B) Total 
lymphocytes and all major lymphocytic cellular subsets (i.e., B220+ B cells, CD4+, and CD8+ T cells) were 
massively decreased, whereas (C) monocyte and neutrophil numbers increased. Effects are dose- and TLR7-
dependent. Lymphocyte, monocytes and neutrophils numbers were determined mechanically; absolute numbers 
of lymphocyte subpopulations were determined using BD truCOUNT technology. (D) Thrombocyte numbers 
were determined with hemocounter. (E) Similar analysis after 21 days of TLR7 stimulation. Error bars indicate 
standard error. Data of at least three individually measured animals are shown. pIC = polyI:C. 
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Mice treated with R848 showed no loss of body weight or signs of overt toxicity: liver 
enzymes and markers of renal, hepatic, cardiac, and pancreatic functions remained the same 
as those in PBS-treated control mice (data not shown). In general, no or only minor blood-
parameter changes were observed at the lowest dose of 0.01 mg/kg/d R848, whereas 
pronounced effects were observed at 0.1 and 1 mg/kg/d R848. TLR7 triggering at neither dose 
did not alter absolute numbers of circulating leukocytes as determined by flow cytometry 
(Fig. 1A, left) and by an automatic hemocounter (Fig. 1A, right). Similar data were observed 
when mice were given a single dose and analyzed after 30, 90, and 180 min (data not shown), 
in contrast to recently reported data 225.  
In contrast, total lymphocytes and all major lymphocytic cellular subsets (i.e., B220+, CD4+, 
and CD8+ cells) were significantly decreased after 7 days of TLR7 triggering in a dose-
dependent fashion (Fig. 1B), consistent with reported data 114,226. In contrast, absolute and 
relative monocytes and neutrophils numbers dramatically increased (Fig. 1A, C and data not 
shown). Blood from R848-treated mice also showed a tendency towards reduced thrombocyte 
counts (Fig. 1D), which is frequently associated with HIV infection 227. The detected changes 
in blood are TLR7 specific and not a universal phenomenon in response to triggering TLRs, 
since equivalent triggering of TLR3 by its ligand polyI:C did not lead to changes in any of the 
above described parameters in C57BL/6 mice when compared to untreated controls. 
Moreover, the observed effects were nearly completely abolished in TLR7-/- mice. In contrast, 
type I interferon (IFN)-mediated signalling via the IFN receptor (IFNAR) and interferon 
regulatory factor (IRF) 7 signalling seemed not to be critically involved, since white blood 
cell counts were similar in R848-treated IFNAR-/- or IRF7-/- mice, when compared to 
C57BL/6 mice (Fig. 2).  
We next addressed whether chronic TLR7 triggering over an expanded time period with low 
doses would have the same effect as the 7-day high-dose regimen. Treatment with R848 for 
21 and 42 days induced similar effects. No or only minor effects were detected at the lowest 
dose of 0.01 mg/kg/d, while profound lymphopenia and increased neutrophil and monocyte 
numbers were seen at the 10-fold dose (Fig. 1E and not shown). In conclusion, sustained 
triggering of TLR7 dramatically alters white blood cell counts, including profound 
lymphopenia and increased neutrophil and monocyte levels.  
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Fig. 2. R848-induced lymphopenia and increased neutrophil and monocyte numbers are TLR7 dependent. Mice 
were treated with 1 mg/kg/d R848 for 7 days. Blood lymphocytes, monocytes, neutrophils, and thrombocytes 
numbers were determined with a hemocounter one hour after the last injection. Effects are TLR7 dependent but 
IFNAR and IRF 7 signalling seems not to be critically involved because effects in R848-treated mice lacking 
IFNAR or IRF7 were similar as in wildtype mice. Data of at least 3 individually measured animals are shown but 
IFNAR-/- thrombocyte counts (#) where only 2 animals are shown. 
 
 
Sustained triggering of TLR7 causes reduced antigen-specific humoral immune 
response and immune activation.  
Defective humoral immunity is a hallmark of HIV infection 228,229. Gunzer et al. suggested 
that the R848-induced lymphopenia and the concurrent transient decrease of immune cells 
might lead to a transient immunodeficiency with a corresponding increase in susceptibility to 
infections 225. On the other hand, TLR agonists represent promising candidates to efficiently 
induce specific antibody responses.  
We sought to determine the effect of chronic TLR7 activation on humoral immune responses. 
After 7 days of R848 treatment (1 mg/kg/d) mice were immunized intravenously with 1x106 
plaque forming units (PFU) of ultraviolet-inactivated vesicular stomatitis virus (UV-VSV). 
Antigen exposure is a major determinant for a subsequent VSV-specific humoral immune 
response. Since the milieu generated by sustained triggering of TLR7 may affect the strength 
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of VSV replication and thus the antigen exposure, we used inactivated VSV that guaranteed 
the same antigen-load in the mock- and R848-treated mice. All mice showed an IgM-IgG 
class switch between days 3 and 7 after immunization (Fig. 3A). However, triggering TLR7 
caused reduced IgM titers at day 3 after UV-VSV challenge and a striking reduction in 
immunoglobulin class switch with very low IgG titers 7 and 10 days after UV-VSV challenge. 
Thereafter, IgG titers slowly recovered, perhaps because stopping R848 treatment upon 
immunization led to gradual reversion of TLR7-mediated effects and because antigen was 
gradually released from its local depot. Nonetheless, VSV-specific IgG titers were still 
slightly reduced 20 days after immunization. 
B-cell activation, with the consequent hypergammaglobulinaemia, is one of the most 
characteristic features of the intricate immune impairment observed in HIV infection 228. This 
phenomenon involves all immunoglobulin subclasses and results in the augmented production 
of HIV-specific and, mostly, HIV-unrelated antibodies 230. By contrast, chronic hyper-
activation of B lymphocytes could lead to B-cell exhaustion or anergy and to concomitant low 
levels of immunoglobulin. We tested whether sustained triggering of TLR7 negatively 
affected total IgG levels, which in turn could explain the attenuation of VSV-specific IgG 
levels. UV-VSV inoculation and subsequent antibody response resulted in a twofold increase 
of total IgG on day 20 after immunization in both mock- and R848-treated mice (Fig. 3B). 
Strikingly, total IgG levels were increased by approximately 50% in R848-treated mice as 
compared to mock-treated mice after 7 days of R848 treatment. Thus, immunosuppression 
was not due to a general incapability of B cells to produce IgG. 
Splenic lymphoid subpopulations from R848-treated C57BL/6 mice displayed an activated 
phenotype as determined by an increased mean fluorescence intensity of the early activation 
marker CD69 and an increased percentage of CD69-expressing cells (Fig. 3C and D). The 
extent of activation was dose-dependent (Fig. 3C). In particular, more than threefold increase 
in the percentage of CD69+ B220+ B lymphocytes and CD69+ CD8+ T cells was detected in 
C57BL/6 mice treated with 1 mg/kg/d R848 for 7 days. CD69+ CD4+ T cells were increased 
twofold (Fig. 3D). CD69 upregulation was not observed in TLR7-/- mice and less pronounced 
in IFNAR-/- or IRF7-/- mice. Analysis of mesenteric lymph nodes revealed similar results (not 
shown). Surprisingly, lymphoid subsets from the blood showed no signs of CD69 
upregulation (not shown), indicating a particular activation pattern that occurred locally in 
secondary lymphoid organs. Moreover, splenic T cells did not upregulate activation marker 
CD44 or downregulate cell-adhesion molecule CD62L.  
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Fig. 3. Chronic TLR7 triggering results in a weakened antigen-specific humoral immune response despite 
immune activation. (A) Attenuation of humoral immune response after treatment with UV-VSV. Mice were 
treated with PBS or 1 mg/kg/day R848 for 7 days and subsequently immunized with UV-VSV. Neutralizing IgM 
and IgG titers were monitored for the following 20 days. N = 5 (B) Immunosuppression is not due to a general 
incapability of B cells to produce IgG. Total IgG levels were measured at day 0, after treatment with 1 
mg/kg/day R848 for 7 and 20 days after UV-VSV inoculation. Means were compared using paired t test. ns = not 
significant. N ≥ 5 (C–D) Splenic lymphoid subpopulations from R848-treated animals displayed an activated 
phenotype after 7 days of treatment. Receptor expression was analyzed by flow cytometry. (C) Dose-dependent 
increase of CD69 mean fluorescence intensity on B220+ B cells. Red and blue lines indicate cells stained with 
isotype or specific mAb, respectively. One representative mouse from each group is shown. (D) TLR7-
dependent increase in the percentage of lymphoid subsets expressing CD69. Error bars indicate standard error. N 
≥ 5. 
 
Effects were not cumulative, because the degree of CD69 upregulation was similar after 7, 21, 
or 42 days. When mice were treated with 0.1 mg/kg/d R848 for 21 and 42 days, we observed 
a consistent two- to threefold increase of splenic CD69 expression. Long-term treatment with 
0.01 mg/kg/d R848 for 42 days had only minor effects (not shown). 
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In conclusion, our data suggest that sustained triggering of TLR7 induces a particular 
lymphocyte activation in secondary lymphopid organs, but prevents an adequate antibody 
response against UV-VSV. 
 
 
Sustained TLR7 triggering disrupts the lymphoid structure.  
We further elucidated the reasons for the observed TLR7-stimulation dependent 
immunosuppression. Since efficient immune responses rely on intact lymphoid organs, we 
investigated splenic follicular and germinal centre microarchitecture upon sustained TLR7 
stimulation. Treatment with 0.1 or 1 mg/kg/d R848 led to malformed and severely enlarged 
white-pulp follicles (Fig. 4). Moreover, sustained TLR7 triggering resulted in a dose-
dependent hypertrophy of B-cell follicles as well as CD8+ and CD4+ T-cell zones in the 
splenic white pulp (Fig. 4A). Conversely, marginal zone B lymphocytes were strongly 
reduced (B220 and CD21/35; arrowhead). Macrophages, in particular marginal zone 
metallophilic MOMA-1+, which appear to play a role in the initial response to systemic 
infection 231, and F4/80+ red pulp macrophages, which are extensively involved in the 
clearance of senescent erythrocytes 231, did not seem to be affected (Fig. 4B). Repetitive 
treatment with PBS, polyI:C or 0.01 mg/kg/d R848 did not induce any derangement of 
lymphoid micro-architecture (Fig. 4).  
Again, the effects detected were likely to be persistent rather than cumulative or mitigated. 
When mice were treated for a longer period, splenic microarchitecture was not further 
compromised. After 21 and 42 days of 0.01 mg/kg/d R848 treatment, spleen microarchitecture 
was only slightly disturbed, and B- and T-cell areas were nearly unaltered, in contrast to a 
massive enlargement in 0.1 mg/kg R848-treated mice (Figs. 5A/B and 6A/B) which was 
already seen after 7 days. 
Disruption of the lymphoid structure was TLR7 dependent since TLR7-/- mice showed neither 
disrupted white pulp follicles with enlarged B- and T-cell zones nor diminished marginal zone 
B lymphocytes after 7 days of treatment with 1 mg/kg/d R848 (Fig. 7A/B). IRF7-/- mice 
displayed no obvious symptoms of lymphoid follicle malformation. In contrast, IFNAR-/- 
mice showed some degree of inflated follicles with loosened rings of marginal zone B cells 
(Fig. 7A/B), indicating that IFNAR and IRF7 signalling partly contributed to R848-mediated 
pathology. 
73 
 
 
Fig. 4. Disruption of the lymphoid structure after 7 days of chronic TLR7 stimulation. Spleen cryosections of 
C57BL/6 mice treated for 7 days with R848. (A) Applied dose correlated with malformation of splenic lymphoid 
follicles with enlarged T- (CD4 and CD8) and B- (B220) cell zones, and reduced marginal zone B lymphocytes 
(B220 and CD21/35; arrowhead). (B) MOMA-1+ and F4/80+ macrophages were not affected. (C) PNA+ germinal 
centres (arrowheads) and FDC-M1+ networks were reduced at day 7 but not at day 21 or 42 of treatment. R848 
concentrations (mg/kg/day) as indicated. N ≥ 3. 
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Fig. 5. Disruption of the lymphoid structure is not further compromised after 21 days of chronic TLR7 
stimulation. (A) Spleen cryosections of C57BL/6 mice showing a dose dependent malformation of lymphoid 
follicles with enlarged T and B cell zones, and reduced marginal zone B-lymphocytes. Lymphoid disruption was 
not further compromised after 21 days of treatment as compared to the 7 day-treatment (see also Figure 4). (B) 
MOMA-1+ and F4/80+ macrophages were not affected. (C). N ≥ 3. 
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Fig. 6. Disruption of the Lymphoid Structure is not further compromised even after 42 days of chronic TLR7 
stimulation. (A-B) See legend figure 5 for details.  
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Fig. 7. Disruption of the Lymphoid Structure is TLR7 dependent. (A) Spleen cryosections of C57BL/6, TLR7-/-, 
IFNAR-/- and IRF7-/- mice after 7 days of treatment with 1 mg/kg/d R848, showing a TLR7 dependent 
malformation of splenic lymphoid follicles since TLR7-/- mice showed normal T- and B-cell zones as well as 
unaltered marginal zone B-lymphocyte rings. IRF7 knockout mice showed no obvious symptoms of lymphoid 
follicle malformation. In contrast, IFNAR-/- mice showed somewhat inflated follicles with loosened rings of 
marginal zone B cells. (B) MOMA-1+ and F4/80+ macrophages as well as FDC-M1 networks and PNA+ 
germinal centres (data not shown) were not affected. N ≥ 3. 
 
PNA+ germinal center B-cell clusters and FDC-M1+ follicular dendritic cell-networks were 
reduced upon treatment for 7 days with 1 mg/kg/d R848 (Fig. 4C). PNA+ clusters were 
increased after 21 and, even more pronounced, after 42 days of treatment with 0.1 mg/kg/d 
R848, whereas FDC-M1+ cell-networks seemed not to be affected. Flow cytometric and RT-
PCR analysis confirmed these histological findings: relative frequencies of B220/PNA+ and 
B220/(germinal center B-cell antibody GL7)+ splenocytes were reduced after 7 days of TLR7 
triggering at 0.1 and 1 mg/kg/d R848, and were increased after 21 and 42 days of treatment at 
0.1 mg/kg/d R848 (Fig. 8A). Milk fat globule EGF 8 (MFG-E8) mRNA, a marker for 
follicular dendritic cells (FDC; Kranich et al., under resubmission), was reduced after 7 days 
of TLR7 triggering at 1 mg/kg/d, and was unchanged after 21 or 42 days of treatment at 0.1 
mg/kg/d (Fig. 8B). 
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Fig. 8. Germinal center B cells and MFG-E8 mRNA are decreased at day 7 and increased or unaffected at day 
21/42 of repetitive TLR7 triggering. (A) C57BL/6 mice were treated as indicated. Splenic germinal center B-cell 
frequencies were evaluated by flow cytometry by staining for B220 in conjunction with FITC-labeled PNA 
(upper panel) or GL7 antibody (lower panel). Percentage of double positive cells was normalized to that of  
corresponding mock treated animals. Error bars indicate 95% confidence intervals. N ≥ 3. (B) RNA was 
extracted from spleen (n = 3), pooled for reverse transcription and analyzed for MFG-E8 transcripts. Mean 
normalized MFG-E8 expression was calibrated to the matching mock control. Error bars indicate SEM of mean 
normalized expression relative to calibrator.  
 
Sustained triggering of TLR7 resulted in an expansion of relative frequencies of myeloid 
cells and a relative contraction of lymphoid subsets. 
An efficient immune response also requires spatially and temporally orchestrated interactions 
of proper cell types, and this requires organized frequencies and proportions of respective 
immune cells. We sought to assess splenic immune cell distribution upon triggering TLR7. 
After 7 days, spleen weight was 3.3-fold greater in R848-treated than in PBS-treated wild-
type mice (Fig. 9A). Notably, although splenomegaly is found in almost 70% of 
asymptomatic HIV-infected adults 232, it was absent in TLR7-/- mice and less pronounced in 
IFNAR-/- or IRF7-/- mice after R848 treatment.  
Hyperplasia was probably due to myeloid and possibly due to erythroid expansion in the red 
pulp. Levels of CD11b+ macrophages, CD11c+ dendritic cells and CD11b+/Gr-1+ neutrophils 
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were increased by about 50% (Fig. 9B upper panel), whereas that of lymphoid subpopulations 
was decreased. Numbers of B220+ B lymphocytes were reduced by about half as were levels 
of CD4+ and CD8+ T cells (Fig. 9B, lower panel). Again, reductions were absent in TLR7-/- 
mice and less pronounced in IFNAR-/- or IRF7-/- mice, indicating that the observed effects 
depend only in part on IFNAR and IRF7 signalling. We also found a 50% relative reduction 
of B220+ B lymphocytes in mesenteric lymph nodes, but levels of CD4+ and CD8+ T cells 
were slightly increased rather than reduced (not shown). 
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Fig. 9. Splenomegaly is associated with an expansion of relative frequencies of myeloid cells and a relative 
contraction of lymphoid subsets. (A) Splenomegaly is dose- and TLR7-dependent. Splenomegaly was less 
pronounced in INFAR-/- or IRF7-/- mice and absent in TLR7-/- mice upon 1 mg/kg/day of R848 treatment. Spleen 
weight was first normalized to total body weight of each individual mouse and, second, normalized to the spleen 
weight of mock-treated animals. Error bars indicate 95% confidence intervals. (B) The prevalence of CD11b+ 
macrophages, CD11c+ dendritic cells and CD11b+/Gr-1+ neutrophils was increased, whereas that of lymphoid 
subpopulations was decreased as compared to mock-treated animals (C). Mice were treated with PBS or 1 
mg/kg/day R848 for 7 days. Splenocytes were stained with indicated antibodies and relative numbers were 
assessed by flow cytometry. Error bars indicate standard error. N ≥ 3. 
80 
Sustained triggering of TLR7 results in rapid and long-lasting cytokine deregulation. 
TLR7 activation induces an array of cytokines, including IFNs and proinflammatory 
cytokines such as TNF-α, IL-6, and IL-12p40. Aberrant cytokine production is a hallmark of 
HIV infection and may represent a mode by which HIV induces immunodeficiency. Notably, 
TNF-α, IL-6, and IL-10 levels increase in plasma with kinetics paralleling the raise in plasma 
viraemia in acute HIV infection and are elevated in chronic infection 233. Mice treated with 1 
mg/kg/d R848 for 7 days were analyzed for plasma cytokine levels in a mouse 23-BioPlex 
cytokine assay. IL-10, IL-6, TNF-α, and IL-12p40 were the cytokines that were altered to 
greatest degree (not shown) and therefore investigated in more detail. 
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Fig. 10. Rapid and long-lasting cytokine deregulation upon triggering TLR7. Mice were bled from the tail vein, 
and cytokine levels were measured using a multiplexed particle-based flow cytometric cytokine assay. (A) Rapid 
cytokine deregulation. Cytokine levels were measured before (BL), 90 min after the first injection, and on day 3 
of repetitive treatment. IL-12p40 levels were measured 6 h after a single dose and on day 7 of repetitive 
treatment. (B) Long-lasting cytokine deregulation. Mice were treated daily at indicated concentrations, and 
cytokine levels were monitored over time (i.e., on day 7, 21, and 42 of treatment). (C) Cytokine deregulation is 
TLR7 dependent. C57BL/6 and knockout mice were treated with 1 mg/kg/day of R848 for 7 days. Cytokine 
levels at day 0 (left bars) and at day 7 (right bars) are shown. Error bars indicate standard error. N ≥ 3. 
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Injection of polyI:C or 0.1 and 1 mg/kg/d R848 resulted in an immediate increase of IL-10, 
IL-6, and TNF-α plasma levels within 90 min, whereas injection of PBS and 0.01 mg/kg/d 
R848 had no effect (Fig. 10A). Moreover, 1 mg/kg/d R848 resulted in a rapid increase of IL-
12p40 as measured 6 h after injection (Fig. 10A). IL-10 and IL-12p40 levels remained high 
after 3 and 7 daily injections, respectively. IL-6 and TNF-α levels were lower at day 3 than at 
90 min, but levels were still higher than in mock-treated mice. 
Results obtained after triggering TLR7 over an expanded time period (i.e., up to 42 days; Fig. 
10B) with low doses of R848 (i.e., 0.01 and 0.1 mg/kg) were similar to those obtained after 
triggering TLR7 for 7days (Fig. 10A). Long-term treatment with PBS or 0.01 mg/kg/d R848, 
again, had no effect. IL-10 and TNF-α were permanently elevated with levels being very 
stable over time, although TNF-α showed a profound initial burst. IL-6 slowly decreased to 
almost normal values (Baseline: 0.68 pg/ml, 90 min: 881 pg/ml, 3 d: 114 pg/ml, 7 d: 13.47 
pg/ml, 21 d: 3.48 pg/ml, 42 d: 1.62 pg/ml). IL-12p40 consistently was >1300 pg/ml.  
R848 treatment (7 days, 1 mg/kg/day) of IRF7-/- or IFNAR-/- mice induced IL-10 and IL-
12p40, but to a lesser degree than in C57BL/6 mice (Fig. 10C). In contrast, TLR7-/- mice had 
normal cytokine levels. In conclusion, the immediate and persistent cytokine deregulation by 
the action of R848 is TLR7 dependent and reminiscent of HIV infection in humans. 
 
 
Sustained triggering of TLR7 induces thymic hypocellularity with decreased absolute 
numbers of CD4 single-positive, CD4/CD8 double-positive, and double-negative 
thymocytes. 
The thymus is the primary lymphoid organ supplying new T lymphocytes to the periphery and 
might compensate for the loss of T cells caused by HIV. HIV infection, however, results in 
thymic dysfunction and thymic involution that may recover with potent antiretroviral therapy 
234,235. To investigate whether long-term TLR7 triggering also affects thymic function, we 
examined thymus cellularity and the percentage of cells in each thymocyte subset by 
measuring the surface expression of CD4 and CD8 antigens in mice treated with 1 mg/kg/day 
R848 for 7 days. Total thymocytes were reduced 1.9-fold in R848-treated C57BL/6 mice as 
compared to mock-treated animals (Fig. 11A). No thymic hypocellularity was detected in 
IFNAR-/-, IRF7-/-, or TLR7-/- mice.  
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Flow cytometric analysis of thymocytes from R848-treated mice revealed an increase in the 
prevalence of mature CD4+ and CD8+ single-positive (SP) thymocytes from 6.9 to 9.7% and 
1.9 to 4.5%, respectively, together with a reciprocal reduction in cells that expressed both CD4 
and CD8 (DP) from 79.8 to 72.4% (Fig. 11B). Prevalence of double-negative thymocytes was 
slightly increased, although not significantly (p=0.11). However, in regard to the 1.9-fold 
reduction of total thymocytes upon TLR7 activation (Fig. 11A), a different pattern was 
observed: absolute numbers of all thymocyte subsets were decreased with the exception of 
CD8+ SP cells. Absolute reduction of DP thymocytes was most prominent because thymuses 
from R848-treated mice contained less then 50% of DP cells as compared to thymuses from 
PBS-treated mice.  
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Fig. 11 Thymic hypocellularity upon triggering TLR7. Mice were treated with PBS or 1 mg/kg/day of R848 for 
7 days. (A) Thymus was hypocellular in C57BL/6 mice but not in knockout mice upon treatment with R848. 
Thymocytes were counted manually and normalized to total thymocyte counts of the corresponding mock-
treated animals. Error bars indicate 95% confidence intervals. (B) Relative cell numbers in each thymocyte 
subset were measured in C57BL/6 mice by staining for CD4 and CD8, followed by flow cytometric analysis. 
Error bars indicate standard error. For C57BL/6 animals data from three independent experiments, each with n = 
3, were pooled; n = 3 for knockout mice. 
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3.3 Discussion  
Chronic immune activation is a major cause for progressive immunodeficiency in HIV 
infection. TLR stimulation is a possible underlying trigger. We used a murine model to assess 
whether sustained TLR7 stimulation contributes to immune activation by studying the effects 
on the lymphoid system. Sustained triggering of TLR7 led to i) altered white blood cell 
counts, including profound lymphopenia and increased neutrophil and monocyte levels ii) 
immune activation and attenuated humoral immune responses, iii) disruption of the lymphoid 
structure, including splenomegaly, enlarged T and B cell zones, reduced marginal zone B-
lymphocytes and a relative contraction of lymphoid subsets, iv) cytokine deregulation, v) 
thymic hypocellularity. We also showed that the observed effects were TLR7- and dose 
dependent, and that IRF-7 and IFNAR mediated signalling only partly contributed to R848 
mediated pathology. 
Sustained TLR7 triggering led to altered white blood cell counts. We first monitored blood 
parameters, because hematological abnormalities are common in HIV-infected patients. 
Repetitive TLR7 triggering resulted in a depletion of lymphocytes from the blood together 
with a reciprocal increase of neutrophils and monocytes. This effect was dose dependent and, 
more importantly, stable as long as R848 treatment was maintained. In fact, TLR7 stimulation 
did not lead to steadily increasing amounts of damage or to an attenuated response over time, 
pointing to the possibility that the level of TLR7 signalling over time is a major determinant 
of the observed effects. Of note, individuals with higher HIV RNA levels 6 months after 
seroconversion had faster progression to AIDS 236. Blood from R848-treated mice also 
showed a tendency towards lower thrombocyte counts. In HIV infection, the number of 
platelets can be low 237 due to trapping of platelets in the enlarged spleen or abnormally high 
levels of TNF-α 238, which is released upon TLR7 engagement. Two recent studies 
investigated lymphopenia in acute viral infection and in treatment with a single systemic dose 
of immunomodulatory agents, such as TLR ligands 225,226. Our results revealed two net 
differences: i) lymphocytes but not granulocytes or monocytes were depleted from the blood 
by R848, and ii) lymphopenia was rather specific to TLR7 activation than an universal 
phenomenon of TLR triggering, since triggering TLR3 had no effect. The latter may be 
explained by different doses that were applied in the different studies. The facts that TLR3 
and TLR7 activation both induced similar cytokine patterns, but only TLR7 activation 
induced lymphopenia, also indicate that chronic activation of distinct TLRs over time results 
in characteristic lesions. 
84 
Sustained TLR7 triggering led to immune activation and attenuated humoral immune 
responses. R848-induced lymphopenia with its concurrent reduction of immune effector cells 
might lead to immune insufficiency and increased susceptibility to infections 225. On the other 
hand, R848 is currently discussed as an effective vaccine adjuvant to stimulate humoral 
immune responses 239,240 since TLR7 ligands directly stimulate B cells 241. Our observation 
that sustained TLR7 triggering led to immunosuppression with weakened antigen-specific 
immune responses suggests that sustained TLR7 stimulation may be harmful while temporary 
and time-limited triggering may result in antiviral and protective effects. This is in line with a 
previous report, where guinea pigs infected with Herpes simplex virus showed impaired 
antibody responses upon repetitive TLR7 triggering 242.  
The findings that R848 treatment stimulated B cells to express an activated phenotype and 
secrete unspecific antibodies indicated that immunosuppression was not due to a general 
incapability of B cells to produce IgG. B-cell activation and hypergammaglobulinaemia are 
characteristic for HIV infection 228,230.  
Sustained TLR7 triggering led to disruption of the lymphoid structure. Secondary lymphoid 
organs are the critical place of HIV replication in vivo, even shortly after infection, when HIV 
expression is active throughout the period of asymptomatic HIV infection 161. Hence the 
ssRNA burden in lymphoid tissue may perpetually trigger TLR7 from the early time point of 
infection. We thus tested whether TLR7-mediated changes in spleen morphology and 
composition accounted for the weakened antigen-specific humoral immune response. Indeed, 
the prevalence and density of splenic lymphoid subsets (i.e., CD4+, CD8+, and B220+ cells) 
decreased upon R848 treatment, probably due to disproportionate myeloid expansion reducing 
the efficiency of immune cells to exert cell-cell contact mediated functions and very likely 
underlies the observed effect of immunosuppression. We also show that sustained TLR7 
triggering caused splenomegaly, follicular hyperplasia, T- and B-cell zones enlargement, and 
a loss of marginal zone B lymphocytes, further emphasizing that sustained TLR7 triggering 
may contribute to disease progression in HIV infection. Notably, splenomegaly is often found 
in HIV-infected individuals 232 and follicular hyperplasia has been reported in early-stage 
disease 161.  
As HIV disease progresses, there is a shift from follicular hyperplasia to follicular involution 
with disruption of the FDC network being characteristic during this transition 243. Upon R848 
treatment for 7 days, FDC networks were reduced. At day 21 or 42, however, FDC networks 
seemed not to be affected. Involution might occur after much longer periods of TLR 
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triggering or if higher doses of R848 would be applied. Nevertheless, the R848-induced 
hyperplasia and the loss of intact lymphoid tissue architecture may give way to follicular 
involution, fibrosis, and even lymphocyte depletion. Remarkably, our data also fit with data 
from a study in transgenic mice with the systemic lupus erythmatosus susceptibility 1 (Sle1) 
locus and a translocated copy of TLR7, which results in a twofold TLR7 expression. These 
mice develop pronounced splenomegaly, increased numbers of activated T cells, and aberrant 
expansion of most immune cell lineages, especially monocytes and neutrophils 244,245. 
Sustained TLR7 triggering led to cytokine deregulation. TLR7 triggering induced 
permanently elevated IL-10, IL-6 , and TNF-α levels, which also are elevated in chronic HIV 
infection 233. IL-10 may have a crucial role in immuoregulation by balancing pathogen-
specific immunity and immune-mediated tissue damage. Remarkably, in lupus-prone mice, 
abnormal TLR9-mediated IL-10 cytokine production could account for a number of immune 
abnormalities, such as increased B-cell survival, chronic activation, and 
hypergammaglobulinaemia 246. Observations from LCMV models have also suggested that 
IL-10 blocking strategy may positively affect chronic viral infections, such as HIV or 
hepatitis C virus (HCV) in humans 247-249. Similarly, polymorphisms that reduce IL-10 
expression have been associated with slower progression to AIDS 101. Finally, IFN-α and 
ribavirin, the current therapy for HCV, downmodulate IL-10 secretion 250. Because IL-6 plays 
an essential role in the differentiation of activated B cells, IL-6 overproduction may contribute 
to polyclonal B-cell activation and to the pathogenesis of AIDS by inducing HIV replication 
251. 
Chronic, low-level TNF expression causes profound disturbances in tissue development, 
especially a diminution of thymic tissue 99. In line with these data, R848-treated mice showed 
thymic hypocellularity, indicating that TLR7 stimulation may damage thymic function and 
thereby impair the thymus’ capacity to compensate for the loss of T cells caused by HIV. 
Taken together, these data imply that TLR7-mediated immunoregulatory cytokine 
deregulation can influence the outcome of chronic infections. Their modulation could be used 
as a therapeutic strategy to improve the outcome for the host. 
IRF-7 and IFNAR mediated signalling only partly contributed to R848 mediated pathology. 
Using mice deficient for TLR7-/-, we clearly show that R848-mediated effects were TLR7 
dependent. Upon ligand recognition, TLR7 triggers innate immune responses and IFNs 
through NF-κB- and IRF7-dependent signalling pathways, respectively 252. Recent reports 
demonstrated that IRF7 is essential for the induction of IFN-α/β genes via the TLR-activated 
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MyD88-dependent pathway 253, and that IFN-α/β directly regulate lymphocyte recirculation 
and cause transient blood lymphopenia 226, pointing to a potential role of IFNAR signalling in 
R848-induced pathology. Although effects upon TLR7 triggering in IFNAR-/- or IRF-/- mice 
were generally less pronounced, they were still quite impressive (e.g., lymphopenia). This was 
unexpected since lymphopenia is critically dependent on IFNAR signalling 226. Also 
counterintuitively, IFN-α levels were not elevated upon repetitive R848 treatment (not 
shown). However, in the above-mentioned study mice were given a single dose of R848, 
while in our study, mice were treated for several days. Daily dosing with high doses of TLR7 
ligands for 5 consecutive days led to tachyphylaxis: IFNs were almost completely down-
regulated 254, which is normally not seen when doses are separated by more than 2 days. 
Taken together, these data imply that short- and long-term TLR7 activation may have 
different mechanisms of action. IFNAR and IRF7 signalling only partly contributed to R848-
mediated pathology, but other pathways may also be involved, possibly through NF-κB (e.g., 
IL-6, IL-10, TNF induction).  
In conclusion, our data demonstrate that sustained TLR7 triggering in mice results in immune 
activation and disruption of the lymphoid system reminiscent of HIV-associated pathology. 
This underlines that HIV ssRNA itself probably contributes to persistent immune activation 
and pathology by signalling through TLR7 and explains in part the chronic immune 
dysfunction in HIV infection. Hence, manipulating TLR7 triggering or down-stream 
signalling may be therapeutically valuable to reduce chronic hyper-immune activation and 
immune dysfunction. 
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3.4 Material and Methods 
Mice and Treatment 
C57BL/6 mice were purchased from Harlan (The Netherlands). IFNAR-/- and TLR7-/- mice 
were kindly provided by Karl S. Lang (Institute of Experimental Immunology, University 
Hospital of Zurich, Zurich, Switzerland). IRF7-/- mice were provided by Kenya Honda 
(University of Tokyo, Tokyo, Japan). Knockout status of all animals was verified by PCR 
analysis with DNA isolated from the tail. C57BL/6, IFNAR-/-, and IRF7-/- mice were housed 
under specific pathogen-free conditions. TLR7-/- animals were housed in filter cages under 
conventional conditions. All procedures were approved by the veterinarian authorities from 
the Canton of Zurich, Switzerland. 
Age- and sex-matched mice (6–8 weeks) were injected intraperitoneally (i.p.) on a daily basis 
for 7 days with 0.01, 0.1, or 1 mg/kg/day R848 and for 21 or 42 days with 0.01 or 0.1 
mg/kg/day R848. Control mice were treated with polyI:C (50 µg/mouse/day) or with PBS. 
R848 was kindly provided by 3M Pharmaceuticals. 1 mg/kg/day R848 amounts to a dose of 
20 µg per injection. Polyinosinic-polycytidylic acid (polyI:C) was from Sigma. Substances 
were dissolved in PBS and administered i.p. at 200 µl/dose. Mice were analyzed 1 h after the 
last injection unless otherwise stated.  
 
Quantification of Peripheral Blood Leukocytes 
Blood samples were collected in heparinized microtainers (BD Biosciences) by terminal 
bleeding from the heart 1–2 h after the last R848 injection. Absolute and relative numbers of 
leukocytes, lymphocytes, monocytes, neutrophils, and thrombocytes were quantified on an 
Abbott Zelldyn 3500 or counted manually after staining on Hematec (Bayer) at the 
veterinarian-medical hospital, Zurich, Switzerland.  
 
Flow Cytometry 
Absolute counts of lymphocyte subpopulations were determined by BD truCOUNT 
technology and by staining the samples for CD4 (clone L3T4), CD8 (Ly-2), and B220 (RA3-
6B2), according to the manufacturer’s protocol. The activation status of the splenocytes was 
analyzed by four-color flow cytometry with monoclonal antibodies (mAbs) against CD4, 
CD8, B220, and CD69 (H1.2F3) after lysis of erythrocytes with ACK lysis buffer. Similarly, 
frequencies of myeloid cells in spleen were determined by staining for CD11b (M1/70), 
CD11c (HL3), and/or Gr-1 (RB6-8C5). Splenic germinal center B-cell frequencies were 
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evaluated by staining for B220 in conjunction with FITC-labeled peanut agglutinin (PNA; 
Vector Laboratories) or GL7 antibody. All antibodies were from BD PharMingen. Cells were 
acquired on a FACS Calibur (BD Biosciences). Data were analyzed with FlowJo 7.1 software. 
 
VSV-specific Serum Neutralization Test and Determination of Total IgG 
The Indiana strain of VSV (VSV-IND; Mudd-Summers isolate) was originally obtained from 
D. Kolakofsky (University of Geneva, Geneva, Switzerland), propagated on BHK-21 cells, 
and allowed to form plaques on Vero cells. Before injection in mice, VSV-IND was 
ultraviolet-inactivated (UV Stratalinker 1800 with 5 UV light bulbs of each 8W (254 nm); 
Stratagene) for 5 min in an open 60-mm Petri dish. 
To measure neutralizing antibody titers, sera were prediluted 16-fold in supplemented 
Dulbecco's Modified Eagle Medium (DMEM) and heat-inactivated for 30 min at 56 °C. Serial 
twofold dilutions were mixed with equal volumes of virus diluted to contain 500 PFU/ml. The 
mixture was incubated at 37 °C and 5% CO2 for 90 min. The serum-virus mixture (100 µl) 
was transferred onto Vero cell monolayers in 96-well plates and incubated at 37 °C for 1 h. 
Monolayers were overlaid with 100 µl DMEM containing 1% methylcellulose. After 
incubation at 37 °C for 24 h, the overlay was removed, and the monolayer was fixed and 
stained with 0.5% crystal violet. The highest dilution of serum that reduced the number of 
plaques by 50% was taken as the neutralizing titer 50. To determine IgG titers, undiluted 
serum was pretreated with an equal volume of 100 mM β-mercaptoethanol in saline. Total 
IgG was quantified with mouse IgG ELISA quantification kit (Bethyl Laboratories), 
according to the manufacturer’s instructions. 
 
Histology and Immunohistochemistry 
Spleens were stored in Hank's Buffered Salt Solution (HBSS) and flash frozen in liquid 
nitrogen for immunohistological analysis. Frozen sections of the spleen (6 µm) were stained 
with H&E. Antibodies FDC-M1 (4C11; 1:50, Becton Dickinson) and CD21/35 (8C12; 1:100; 
PharMingen) and antibodies to CD45RO/B220 (RA3-6B2; 1:400; PharMingen), MOMA-1 
(1:50; BMA; Augst), F4/80 (1:50; Serotec), PNA (1:100; Vector Laboratories), CD4 (YTS 
191; 1:200), and CD8 (YTS 169; 1:50) were used as primary reagents for 
immunohistochemistry and lectin histochemistry, as described 255. Antibodies against CD4 
and CD8 were kindly provided by R. Zinkernagel (University Hospital of Zurich, Zurich, 
Switzerland). Image acquisition was performed on a Axiophot-microscope (Zeiss) equipped 
with a JVC digital camera (KY-F70; 3CCD) and analyzed with their software. 
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Measurement of Serum Cytokines 
Mouse blood was collected into serum separator microtubes (BD Biosciences) by tail-vain 
bleeding or cardiac punctuation and centrifuged for 10 min at 5,400 g to obtain serum. 
Cytokine protein levels in serum were measured using a multiplexed particle-based flow 
cytometric cytokine assay. Bioplex mouse kits for IL-6, IL-10, IL-12 (p40), and TNF-α were 
purchased from BioRad. The procedures closely followed the manufacturer’s instructions. 
The analysis was conducted using FC 500 flow cytometer (BeckmanCoulter). 
 
PCR Array Profiling and MFG-E8 RT-PCR 
Splenic samples were immediately subjected to RNAlater (Qiagen) and stored at -20 °C until 
use. RNA was extracted from 20 mg of samples with the RNeasy mini-kit (Qiagen) according 
to the manufacturer’s instructions. For tissue homogenates, blocks were disrupted with a 
mortar and pestle in lysis buffer containing 2-ME. After extraction, RNA was pooled from 
replicates (n = 3). To remove residual DNA, RNA preparations were treated with DNAfree 
(Ambion) according to the manufacturer’s instructions. RNA quality, as judged by gel 
electrophoresis and spectrophotometry, was comparable in all samples. Reverse transcription 
was performed with 5 µg  of total RNA in a total volume of 50 µl. RNA was incubated with 
1250 ng of oligo(dT) primer (Life Technologies) and 500 µM dNTPs (Roche) at 65°C for 5 
min, followed by incubation on ice for 5 min. Samples were then incubated with 3 mM MgCl2 
(Promega) and 60 U of RNase inhibitor (Roche) in 1x ImProm-II RT reaction buffer 
(Promega) at 42°C for 2 min. ImProm-II RT (500 U; Promega) was added, and reactions were 
performed at 42°C for 50 min, followed by inactivation at 65°C for 15 min. Residual RNA 
was digested with 1250 ng of RNase (Roche) at 37°C for 20 min.  
RT-PCR was performed using an ABI Prism 7700 sequence detection system (Applied 
Biosystems) with conditions as mentioned above. MFG-E8 mRNA, representative of 
follicular dendritic cell marker FDC-M1, and GAPDH housekeeping gene were detected 
using ready-to-use primer/probe kits (Applied Biosystems; Mm00500549_m1 and 
Mm99999915_g1). All reactions were performed in triplicate. Data  were analyzed in two 
steps. First, the mean normalized gene expression (MNE) for every sample was determined 
using the software application Q-Gene (calculation procedure for MNE 2) 256. Second, 
normalized MFG-E8 expression, relative to that of  respective Mock treated mice was 
assessed. 
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Statistical Analyses 
Data are depicted as means and SEM. Means were compared using the unpaired t test, unless 
otherwise stated in the figure legends (e.g., * p<0.05, ** p<0.01, *** p<0.001). 95% 
confidence intervals of normalized data were computed using graph pad software, according 
to EC Fieller 257. 
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HIV infects cells through a receptor complex consisting of the CD4 receptor and one of 
the chemokine receptors CCR5 or CXCR4. Each component of the receptor complex is 
involved in signal transductions, raising the question of whether HIV exploits them to 
optimize conditions for viral replication. Here we analyzed several steps of the HIV 
replication cycle of two CCR5-tropic (R5) HIV molecular clones and three R5 patient 
isolates in a panel of cell lines stably expressing different combinations of either wildtype 
(wt) or mutant CD4 (wt or 398) and CCR5 (wt, R126N, 320, or double mutant). 
Phenotypical and functional analyses of the cells demonstrated intact and deficient 
signalling in the wt and mutant cell lines, respectively. Quantities of early reverse 
transcripts in 398/wt and 398/320 cells were enhanced relative to those in wt/wt cells, 
suggesting that disruption of signalling through CD4 increased the efficiency of early 
reverse transcription. There was no statistically significant difference in the amount of 
early reverse transcripts between 398/wt and 398/320 cells, indicating that signalling 
through CCR5 does not have a major effect on early HIV replication. In contrast to 
early reverse transcription, levels of productive infection and virus production did not 
appear to be directly affected by disruption of CD4 and/or CCR5 signalling. In 
conclusion, our data suggest that i) signalling through CD4 has an inhibitory effect on 
early reverse transcription, whereas CCR5 signalling does not play a major role, and  ii) 
later steps of the HIV replication cycle are not modulated by CD4/CCR5 signalling.    
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4.1 Introduction 
Entry of HIV-1 into cells requires interactions between the HIV envelope glycoprotein 
(gp)120 and a cellular receptor complex consisting of the CD4 receptor and one of the 
chemokine receptors CCR5 or CXCR4 258. HIV isolates are classified based on their 
chemokine co-receptor use into CCR5-tropic (R5) and CXCR4-tropic strains 135. R5 isolates 
are considered more relevant in HIV pathogenesis because they are responsible for viral 
transmission, predominate during the early stages of the disease, and are present throughout 
the whole infection period 259. Individuals homozygous for a 32–base pair deletion in the 
coding region of CCR5 are almost completely resistant to HIV infection 260,261.  
Each component of the receptor complex is also involved in signal transduction networks. 
CD4 serves as an accessory molecule of the TCR/CD3 complex for binding peptide-MHC 
complexes 262. Its cytoplasmic tail noncovalently associates with the lymphocyte-specific 
protein tyrosine kinase p56lck (Lck) 122,263-267. Cross-linking of CD4 with antibodies or the 
binding of peptide-MHC complexes or IL-16 to CD4 results in phosphorylation of Lck 268-270 
and subsequent CD4+ T-cell activation 270-272.  
The two chemokine receptors and their ligands are key regulators of leukocyte trafficking to 
inflamed tissues 273. Natural ligands for CCR5 include RANTES, MIP-1α, and MIP-1β. 
CCR5 belongs to the family of seven-transmembrane domain receptors that signal through 
heterotrimeric G-proteins upon ligand binding. Chemokine receptors have several conserved 
structural features, including a DRY motif in the second intracellular loop, which is involved 
in G-protein interaction, and structural motifs in the cytoplasmic tail, which are critical for 
signalling, desensitization, and receptor trafficking 274.  
The binding of HIV-1 gp120 to CD4 or the chemokine co-receptor also initiates signals, some 
of which are specific for HIV, such as the activation of non-selective cation channels 275. 
Signalling through CD4 or CCR5 does not appear to affect HIV-1 entry 147,149,276-279. In 
contrast, post-entry steps of the HIV replication cycle are modulated by CD4-mediated 
signalling, but it is unclear whether CD4 negatively 146 or positively 147-151 regulates HIV 
replication. Similarly, the effects of signalling through the chemokine co-receptor are a matter 
of debate: for example, one study found CCR5-mediated signalling to be dispensable for HIV 
replication 280, whereas another showed that CCR5 signalling facilitates HIV replication 281.  
Previous studies focused on signalling by the components individually. However, the two 
receptors are physically 282 and functionally 283-285 associated. Here, we generated human T-
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cell lines stably expressing different combinations of either wild-type (wt) or mutant CD4 and 
CCR5. These cell lines were used to study both the overall influence of signalling through the 
receptor complex on HIV replication and the contribution of each receptor to such effects. 
The mutations in CD4 and CCR5 were chosen based on motifs known to be involved in signal 
transductions. The cells lines were inoculated with two R5 molecular clones and three R5 
patient isolates and the efficiency of different stages of HIV replication in the mutant cell 
lines was compared to that in the wt CD4/CCR5 cell line.   
 
 
4.2 Results 
Receptor expression and proliferation of T-cell lines stably expressing wt or mutant CD4 
and CCR5.  
To assess the effects of signalling through CD4 and/or CCR5 on HIV replication, we 
generated T-cell lines stably expressing different combinations of wt or mutant CD4 and 
CCR5 (Fig. 1) by means of lentiviral transduction. The mutations introduced into CD4 and/or 
CCR5 (i.e., deletion of the cytoplasmic tail of CD4; single mutation of the DRY motif in 
CCR5, partial deletion of the cytoplasmic tail of CCR5, or both) were chosen based on motifs 
known to be involved in signal transductions. For example, signalling through CD4 is 
mediated by the interaction of p56lck with the cytoplasmic tail of CD4 263; the DRY motif of 
CCR5 is involved in G-protein interaction, and structural motifs in the cytoplasmic tail are 
critical for signalling, desensitization and receptor trafficking 274. These cell lines were 
derived from A2.01 cells, a CD4- CCR5- derivative of the human T-cell leukemic line, A3.01 
286. The cell lines will be referred to by abbreviations that indicate the variant of CD4/CCR5 
expressed. 
Cell surface expression of CD4 and CCR5 was analyzed after several weeks of selection. 
CD4.398 was expressed at lower levels than those of CD4.wt (Fig. 2A). For each CCR5 
variant, expression was similar in cells co-expressing either CD4.wt or CD4.398 (Fig. 2B). 
CCR5.wt and CCR5.R126N were expressed at fairly high levels, whereas CCR5.320 and 
especially CCR5.dm showed lower expression levels. Notably, receptor expression levels 
were reproducible in different transduction experiments and stable over time (data not 
shown).  
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Cell proliferation was similar in all cell lines as assessed by flow cytometry of cells stained 
with CFSE, showing that the mutations introduced into CD4 and/or CCR5 had no adverse 
effect on cell proliferation (Fig. 3).   
 
  
Fig. 1. Schematic representation of A2.01 T-cell lines expressing different combinations of wt or mutant CD4 
and CCR5. A2.01 cells were first genetically complemented with wild-type CD4 (CD4.wt) or CD4 with a 
deletion of the cytoplasmic tail after residue 398 (CD4.398).  Subsequently, these cell lines were additionally 
complemented with wild-type CCR5 (CCR5.wt) or CCR5 with a point mutation in the DRY motif 
(CCR5.R126N), a deletion of the cytoplasmic tail after residue 320 (CCR5.320), or both mutations (double 
mutant; CCR5.dm). The cell lines will be abbreviated as follows: wt/wt,  wt/R126N, wt/320, wt/dm, and 398/wt, 
398/R126N, 398/320, 398/dm.  
 
 
Disruption of signal transduction pathways through CD4 and/or CCR5 mutations. 
Stimulation of CD4+ T cells with antigen results in phosphorylation and internalization of 
CD4, and this response can be mimicked by treatment with phorbol esters 287. CD4 down-
modulation in response to phorbol esters is abrogated if the cytoplasmic tail of CD4 is 
removed 147. Indeed, CD4.wt but not CD4.398, was down-modulated upon stimulation of the 
cells with PMA, irrespective of which CCR5 variant was co-expressed (Fig. 4), showing that 
CD4.wt, but not CD4.398 was responsive to stimuli.  
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Fig. 2. Cell surface expression of CD4 and CCR5 in CD4/CCR5-expressing A2.01 T-cell lines. After several 
weeks of selection, cells were stained with a mAb against either CD4 (A) or CCR5 (B). Receptor expression was 
analyzed by flow cytometry. Dashed and solid lines indicate cells stained with isotype or specific mAb, 
respectively; MFI = mean fluorescence intensity.  
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Fig. 3. Cell proliferation of A2.01 T-cells expressing different combinations of wt or mutant CD4 and CCR5. 
Cells were stained with CFSE, and aliquots of cells were analyzed by flow cytometry immediately (broken 
lines), one day (dashed lines) or four days (solid lines) after staining. Results are representative of three 
experiments. 
 
 
Fig. 4. Effect of CD4 mutation on signalling. Cells were stimulated with PMA (0.05 µg/ml; solid lines) or not 
(dashed lines). After 4 h, cells were analyzed for CD4 cell surface expression by flow cytometry. Results are 
representative of four experiments. 
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CCR5 variants were functionally characterized by analyzing ligand-stimulated receptor 
endocytosis/recycling and signalling. As reported 288,289, CCR5.wt, CCR5.R126N, and 
CCR5.320 were internalized with similar efficiencies in response to MIP-1β (Fig. 5A, left 
panel). In contrast, much less CCR5.dm than wt receptor was internalized. When the ligand 
was withdrawn, all CCR5 variants completely recovered (Fig. 5A, right panel). These results 
were independent of expression of CD4.wt or CD4.398. To corroborate these data, we also 
analyzed MIP-1β-induced CCR5 internalization with acid washes 289 to remove residual 
surface-bound chemokine. This protocol gave similar results (data not shown). 
Stimulation of cells with MIP-1β consistently resulted in actin polymerization in cells 
expressing CCR5.wt or CCR5.320 as assessed by flow cytometric detection of phalloidin-
FITC+ cells (Fig. 5B). Phalloidin binds to polymerized actin. The response was higher in cells 
co-expressing CD4.398 than in those co-expressing CD4.wt. Actin polymerization was 
slightly lower in wt/320 and 398/320 cells than in wt/wt and 398/wt cells. Wt/R126N and 
398/R126N cells showed no actin polymerization, whereas the response in wt/dm and 398/dm 
cells was variable. Similar results were obtained when MIP-1β-induced chemotaxis was 
analyzed (data not shown). 
As reported 276,277,280,281,288, mobilization of intracellular calcium in response to MIP-1β was 
abrogated in cells expressing CCR5.R126N or CCR5.dm and slightly reduced and prolonged 
in cells expressing CCR5.320 (Fig. 5C). As observed with actin polymerization, cells co-
expressing CD4.398 showed a stronger MIP-1β-induced increase of intracellular calcium 
concentrations than those co-expressing CD4.wt. This finding is consistent with data showing 
a reciprocal cross-desensitization between the two receptors 284, indicating CD4/CCR5 cross-
talk.  
These results reinforce our concept of investigating CD4/CCR5 receptors as an entity. To 
summarize, functional characterization of our cell lines confirmed disruption of signal 
transduction pathways through CD4 and CCR5 in the mutant cell lines, validating our 
experimental system to investigate the role of CD4/CCR5-mediated signalling on HIV 
replication. 
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Fig. 5. Effect of CCR5 mutations on signalling. (A) Internalization and recovery of CCR5 in response to MIP1-
β. Cells were stimulated with MIP-1β (1 µg/ml; solid lines) or not (dashed lines). After 2 h of stimulation, half of 
the cells were analyzed for CCR5 internalization by flow cytometry (left panel). The other half of the cells were 
thoroughly washed, incubated for another 4 h, and then analyzed for CCR5 recovery (right panel). Results are 
representative of four experiments. (B) CCR5-mediated actin polymerization upon MIP1-β stimulation. Actin 
polymerization was assessed after stimulation with MIP1-β (1 µg/ml) for 15 s by flow cytometric analysis of 
phalloidin-FITC binding. Left panel shows results for cells expressing CD4.398 and CCR5.wt for a 
representative experiment; unstimulated cells were used to determine background activity. Right panel shows 
results after subtraction of background activity of three experiments. (C) Intracellular calcium mobilization upon 
MIP1-β stimulation. Cells were loaded with Indo-1 AM and acquired on a LSR II flow cytometer. After 
obtaining a baseline for 30 s, MIP1-β (500 ng/ml) was injected (arrow), and cells were acquired for another 2 
min. Data are presented as mean Indo-405/Indo-530 fluorescence emission versus time (in s). An increase in 
calcium is detected as an increase in Indo-1 fluorescence at 405 nm and as a decrease at 530 nm. Results are 
representative of two experiments. In (B) and (C), no response was observed in cells lacking CCR5 expression 
(data not shown). 
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CD4 signalling has an inhibitory effect on early reverse transcription.  
To examine the effect of disrupting signalling through CD4 and/or CCR5 on the efficiency of 
early, post-entry events in the HIV infection process, we quantified early reverse transcripts 6 
h p.i. by real-time PCR after inoculation of the cell lines with two R5 HIV molecular clones 
(49.5 290 and YU.2 291) and three R5 HIV plasma-derived patient isolates 292.  
 
 
Fig. 6. Increased efficiency of early reverse transcription by disruption of CD4 signalling. Cells were inoculated 
with the R5 molecular clones YU-2 and 49.5 and three different R5 patient isolates. Quantities of early reverse 
transcripts were determined 6 h p.i. by real-time PCR. Expression of early reverse transcripts was normalized to 
that of the housekeeping gene beta-actin (MNE). Data show logarithmised MNE and represent mean ± SEM of 
(n = 4–6). Levels of early reverse transcripts in cognate and parental cells lacking either CCR5 or both CD4 and 
CCR5, respectively, were ≥ 10-fold lower than those in cells expressing both CD4 and CCR5 (data not shown). 
P-values are shown for significantly different levels of early reverse transcripts compared to those in the wt/wt 
cell line using Dunnett post-hoc test.  
 
Two main observations were made: First, for all HIV strains tested but isolate 8, quantities of 
early reverse transcripts in wt/dm cells were lower than those in wt/wt cells; this difference 
was statistically significant for YU-2 (Fig. 6). A similar difference was observed between 
398/dm and 398/wt cells, at least for YU-2, 49.5, and isolate 5, albeit non-significantly. This 
pattern was reminiscent of the considerably reduced cell surface expression of CCR5.dm 
relative to that of CCR5.wt (Fig. 2). Of note, low levels of receptor expression may limit HIV 
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entry into cells 293-300. Thus, we quantified cell entry of YU-2 with a recently described 
enzymatic fluorescence-based assay 301. Indeed, the extent of viral entry into wt/dm cells was 
considerably smaller than that into wt/wt cells (Fig. 7). Thus, the decreased quantities of early 
reverse transcripts in cells expressing CCR5.dm likely reflect a lower level of HIV cell entry 
due to a low number of CCR5 molecules and, therefore, receptor complexes available on the 
cell surface. 
Second, and more importantly, levels of early reverse transcription in 398/wt cells (all viruses 
but isolate 5) and 398/320 cells (all viruses) were higher compared to that in wt/wt cells; for 
isolate 8, these differences reached statistical significance (Fig. 6). HIV entry into 398/wt and 
398/320 cells is expected to be decreased or similar relative to that into wt/wt cells because 
basal cell surface expression of CD4.398 was lower than that of CD4.wt (Fig. 2), and CD4 
cell surface expresion was not altered 6 h p.i. (data not shown). Furthermore, disruption of 
CD4/CCR5 signalling appears not to affect viral cell entry 147,149,276-279. Thus, our data suggest 
that disruption of signalling through CD4 increases the efficiency of early reverse 
transcription.  
 
 
 
  
Fig. 7. Decreased entry of YU-2 into wt/dm cells. Cells were challenged or not with YU-2 virions containing 
BlaM-Vpr, loaded with CCF2/AM dye, and analyzed for viral cell entry by flow cytometry. Left panel shows 
representative results for CD4.wt/CCR5.wt cells; a gate was set based on the fluorescence of uninfected cells to 
determine background fluorescence. Right panel shows percentage of cells displaying increased blue 
fluorescence (447 nm) indicating viral cell entry after subtraction of background fluorescence. Data are given as 
mean ± SEM of two experiments. 
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Quantities of early reverse transcripts were higher in 398/320 cells than in 398/wt cells (this 
difference was also observed in cells co-expressing CD4.wt and seen with all strains used), 
suggesting that the effect of CD4 signalling is modulated by signalling through the C-terminal 
part of CCR5. However, there was no statistically significant difference (after Bonferroni 
correction) in the amount of early reverse transcripts between the cognate cell lines, indicating 
that disruption of signalling through CCR5 does not have a major effect on early reverse 
transcription.  
Taken together, early HIV replication seems to be negatively regulated by CD4 signalling, but 
appears not to be substantially affected by CCR5 signalling.  
 
 
CD4 and/or CCR5 signalling does not affect early–late steps of HIV replication.  
To examine the effect of CD4 and/or CCR5 signalling on steps of the HIV replication cycle 
after early reverse transcription, we first determined the percentage of cells positive for the 
HIV core protein p24 by flow cytometry two days after inoculation with the molecular clones 
YU-2 and 49.5 and the patient isolates 2, 5 and 8. The percentage of p24+ cells is a marker of 
productive infection and reflects the efficiency of several replication steps, including reverse 
transcription, integration, transcription and/or translation. In these experiments, cells were 
treated with Enfuvirtide, a fusion inhibitor, to ensure only one round of HIV replication.  
For all HIV strains tested but 49.5, significant differences in the percentage of productively 
infected cells between one or several mutant cell lines and wt/wt cells were found: productive 
infection of 398/wt cells was significantly increased with YU-2, isolate 2, and isolate 8, and 
that of 398/320 cells was significantly higher with YU-2, isolates 2, 5, and 8 (Fig. 8). This 
pattern was reminiscent of the higher levels of early reverse transcripts in these cells 
compared to those in wt/wt cells (Fig. 6). Indeed, statistical analysis (unpaired t-test 
Bonferroni correction) revealed no difference between the patterns of early reverse 
transcription and productive infection. Thus, the significantly higher levels of productive 
infection of 398/wt and 398/320 cells relative to those of wt/wt cells likely reflect the greater 
amounts of early reverse transcripts in these cells. In other words, CD4 and/or CCR5 
signalling does not seem to modulate late reverse transcription, integration, transcription 
and/or translation.  
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Fig. 8. Effect of CD4/CCR5 mutations on productive HIV infection. Cells were inoculated with the molecular 
clones YU-2 and 49.5 or patient isolates 2, 5, or 8 and analyzed for intracellular expression of the HIV p24 core 
protein on day 2 p.i. by flow cytometry. Background staining was determined with mock-infected cells and 
subtracted. Cognate and parental cells lacking either CCR5 or both CD4 and CCR5, respectively, were not 
productively infected (data not shown). After inoculation with virus, cells were treated with Enfuvirtide. Data 
show the logarithmised percentage of p24+ cells (background subtracted) and represent mean ± SEM (n = 5–6). 
P-values are shown for significantly different levels of productively infected cells compared to those in the wt/wt 
cell line using Dunnett post-hoc test. 
 
 
Second, we assessed the effect of the CD4/CCR5 mutations on the amount of virus produced 
by the infected cells by measuring the p24 concentration in the culture supernatant of cells on 
days 2 and 6 p.i. by ELISA. Cells were treated throughout the experiments with Enfuvirtide. 
For all five HIV strains, virus production in 398/wt and 398/320 cells was lower than that in 
wt/wt cells; a statistically significant difference was found for 49.5 between 398/320 cells and 
wt/wt cells (Fig. 9). This is directly opposite to the higher relative levels of early reverse 
transcription (Fig. 6) and productive infection (Fig. 8) in these cells. To explain this result, it 
has to be considered that the presence of CD4 on the cell surface poses several problems for 
post-entry steps of the HIV replication cycle, including retention of budding virions 302. 
Importantly, in contrast to CD4.wt, CD4.398 is not down-modulated upon stimulation with 
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PMA (Fig. 4) or several days after infection with HIV (data not shown). Thus, the lower 
amount of virus produced in cells expressing CD4.398 is likely explainable by an impaired 
release of virions due to the permanent presence of this CD4 variant rather than by the 
disruption of signalling through CD4. 
 
 
 
 
Fig. 9. Reduced virus production in cells expressing CD4.398. Cells were infected and treated as described in the 
legend to Fig. 8, and p24 concentrations in the cell culture supernatants were analysed by ELISA on day 2 and 6 
p.i.. Data show the logarithmised area under the curve (AUC) and represent mean ± SEM (n = 5–6). P24 
concentrations in cell culture supernatants from HIV-inoculated cells expressing only CD4 but not CCR5 HIV 
were negligible (data not shown). P-values are shown for significantly different levels of virus production 
compared to those in the wt/wt cell line using Dunnett post-hoc test. 
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4.3 Discussion 
Each of the components of the HIV receptor complex is involved in signalling, raising the 
question of whether HIV exploits these signalling pathways to facilitate its own replication. In 
this work, we established an experimental system consisting of a panel of cell lines stably 
expressing different combinations of wt and mutant CD4 and CCR5, which were infected 
with two R5 HIV molecular clones and three R5 HIV plasma-derived patient isolates. The 
influence of signalling through the receptor complex on HIV replication was assessed by 
comparing the efficiency of different steps of the HIV life cycle in the mutant cell lines 
relative to that in the CD4.wt/CCR5.wt cell line. Our data suggest that early reverse 
transcription is negatively regulated by signalling through CD4, but not substantially 
modulated by CCR5 signalling, and that later steps of the HIV replication cycle are not 
directly affected by CD4/CCR5 signalling.    
Our experimental system was designed to take into account that CD4 and CCR5 are 
physically associated 282, and that there is a functional cross-talk between the receptors: the 
activation of CD4 by IL-16 results in enhanced signalling through CCR5 285; conversely, 
CCR5 increases a migratory response induced by IL-16 through CD4 in Th1 cells 283; 
furthermore, a reciprocal cross-desensitization between the two receptors has been reported 
284.  
We first characterized our cell lines phenotypically and functionally. Cell surface expression 
of CD4.398 was lower than that of CD4.wt. As reported, CCR5.R126N and CCR5.wt were 
expressed similarly 277,280,281. The lower levels of CCR5.320 expression seen by us and others 
276,303 are likely explained by disruption of two motifs within the C-terminal tail of CCR5, 
which are critical for its cell surface expression (i.e., a membrane-proximal basic domain at 
residues 314–322 303 and a cysteine cluster (Cys-321, -323, and -324) 279,303. Cell surface 
expression of an as yet uncharacterized CCR5 variant, CCR5.dm (i.e., R126N in the DRY 
motif and a deletion after residue 320), was even lower than that of CCR.320. The DRY motif 
and the C-terminal cysteine cluster constitute a bipartite motif that is required for binding of 
β-arrestins 304. Thus, β-arrestins may also be important for optimal cell surface expression of 
CCR5, independent of their role in agonist-promoted internalization and trafficking of 7TM G 
protein-coupled receptors 305. We also generated cell lines co-expressing CD4 and a truncated 
CCR5 variant which was made by introducing a premature stop codon after Leu-308. 
However, this CCR5 variant was barely expressed at the cell surface (data not shown) and 
was not investigated further. 
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Wt and mutant CD4 were signalling-intact and -defective, respectively: stimulation with PMA 
resulted in down-modulation of CD4.wt, but not CD4.398, as reported 147; likewise, CD4.wt, 
but not CD4.398 was down-modulated upon infection with HIV (data not shown). In line with 
previous reports 288,289, CCR5.wt, CCR5.R126N, and CCR5.320 showed efficient 
internalization upon incubation with MIP-1β and recovery upon chemokine withdrawal. In 
contrast, the weak endocytosis of CCR5.dm is most likely explained by its inability to bind β-
arrestins. CCR5.wt and CCR5.320 consistently mediated actin polymerization when 
stimulated with MIP1-β, whereas CCR5.R126N-mediated polymerization was negligible, and 
CCR5.dm mediated a variable response. Actin cytoskeletal rearrangements are induced upon 
coupling of 7TM receptors to G proteins, which depends on the DRY motif. Similarly, 
CCR5.wt and CCR5.320 mediated effective chemotaxis upon MIP-1β stimulation 280,288,289, 
whereas CCR5.R126N and CCR5.dm did not (data not shown). In accord with published 
reports 276,277,280,281,288, CCR5.R126N and CCR5.dm failed to mobilize calcium; CCR5.320 
displayed a smaller but longer response than wt CCR5. In all three assays (i.e., actin 
polymerization, calcium mobilization, and chemotaxis), responses mediated by CCR5.wt 
were more pronounced in cells co-expressing CD4.398 than in those with CD4.wt. This 
finding is compatible with data showing that CD4 induces a Lck-dependent signal that results 
in cross-desensitization of CCR5 284. Thus, phenotypic and functional characterization of the 
cell lines indicated CD4/CCR5 cross-talk and validated our experimental system to 
investigate the role of CD4/CCR5-mediated signalling on HIV. 
We analysed several parameters of HIV replication in our cell lines: 1) the amount of early 
reverse transcripts by real-time PCR as a marker of early HIV replication; 2) the percentage of 
p24+ cells by immunostaining/flow cytometry two days p.i. as a marker for productive 
infection, reflecting the efficiency of reverse transcription, integration, transcription, and 
translation; and 3) the concentration of p24 in the cell culture supernatants over time by 
ELISA as a marker for virus production, reflecting the efficiency of all steps of the replication 
cycle, including virus assembly and budding. Furthermore, unlike most of the previous studies 
examining the effect of signalling on HIV replication, we used several HIV strains, i.e., two 
R5 molecular clones and three R5 plasma-derived patient isolates, in our infection 
experiments.  
 Analysis of early reverse transcription revealed two different patterns: First, quantities of 
early reverse transcripts were lower in cell lines expressing CCR5.dm than in cell lines 
expressing CCR5.wt. Importantly, CCR5.dm had a strongly reduced cell surface expression 
relative to that of CCR5.wt and low levels of receptor expression are a limiting factor for HIV 
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entry into cells 293-300. Indeed, analysis of YU-2 cell entry showed considerably lower levels in 
wt/dm than in wt/wt cells. Therefore, the low level of early reverse transcripts in cells 
expressing CCR5.dm is likely explainable by a low level of HIV cell entry due to the low cell 
surface expression of this CCR5 variant rather than by disruption of signalling through CCR5.  
Second, levels of early reverse transcription were generally higher in cells expressing 
CD4.398 than in cells with CD4.wt. This difference was most pronounced for isolate 8. 
Unfortunately, the enzymatic fluorescence-based assay used to measure cell entry of YU-2 is 
not readily applicable to primary HIV isolates since the production of viral particles 
containing BlaM-Vpr involves proviral DNA, which is available for several molecular clones, 
but generally not for primary isolates. Furthermore, for unknown reasons, uninfected cells 
expressing CD4.398 displayed a high background fluorescence when loaded with CCF2/AM 
dye, preventing us from accurately quantifying HIV entry into these cells. Thus the 
significantly higher levels of early reverse transcription in cells expressing CD4.398 could in 
fact reflect a higher level of viral cell entry. However, basal cell surface expression of 
CD4.398 was lower compared to that of CD4.wt, and this expression pattern was not altered 6 
h p.i., i.e., at the time point when cells were analysed for early reverse transcription (data not 
shown). Moreover, disruption of CD4/CCR5 signalling seems not to affect viral cell entry 
147,149,276-279. Therefore, HIV entry into cells expressing CD4.398 is expected to be rather 
decreased as compared to cells expressing CD4.wt. Thus, disruption of signalling through 
CD4 appears to increase the efficiency of early reverse transcription, suggesting that 
signalling through CD4 inhibits HIV replication at this early, post-entry step.  
To assess whether the negative effect of CD4 signalling on early HIV replication was  
modulated by signalling through CCR5, we compared the levels of early reverse transcripts in 
398/R126N, 398/320, and 398/dm cells to those in 398/wt cells. There was a tendency 
towards higher levels in 398/320 cells than in 398/wt cells. This suggests that signalling 
through the C-terminal part of CCR5 may moderately modulate the effect of CD4 signalling.  
Flow cytometric analysis of the percentage of p24+ cells on day 2 p.i. revealed a higher level 
of productive infection of cells expressing CD4.398 as compared to cells expressing CD4.wt. 
This pattern was similar to that of early reverse transcription, and indeed, statistical analysis 
showed no difference betweeen these two parameters. Therefore, the higher level of 
productive infection likely reflects the greater amount of early reverse transcripts in these 
cells. In other words, CD4 signalling does not seem to directly affect late reverse 
transcription, integration, transcription, and translation. 
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Finally, measurement of p24 in the cell cultures over time revealed a lower level of virus 
production by 398/wt and 398/320 cells relative to that by wt/wt cells (significant for 49.5). 
This pattern was directly opposite to that of early reverse transcription and productive 
infection, the levels of which were higher in these cells. A possible explanation for this 
phenomenon is an increased retention of budding virions in these cells. CD4 is normally 
down-regulated by HIV to ensure efficient replication, since its presence prevents among 
others efficient release of viral particles 302. However, down-modulation of CD4.398 upon 
stimulation with PMA or several days after infection with HIV (data not shown) is impaired.   
The role of signalling through CD4 or CCR5 for HIV replication has been a matter of debate. 
Several investigators reported enhanced HIV replication by CD4 signalling 147-151, whereas 
one study demonstrated a negative effect 146. Likewise, CCR5-mediated signalling had a 
positive effect on HIV replication in one study 281, but not in another 280. Our data are partly in 
line with the study demonstrating a negative effect of CD4 signalling on HIV replication 146. 
However, in this study, viral replication was modulated on the level of productive infection 
and virus production, whereas viral entry and reverse transcription were not altered. In 
contrast, we observed modulation of early reverse transcription by CD4 signalling, but no 
direct effect on steps thereafter. As for CCR5, our data suggest a minor, if any role of 
signalling through this receptor for early reverse transcription.  
In conclusion, our data suggest that CD4 signalling has an inhibitory effect on early HIV 
replication, whereas CCR5 signalling does not play a major role for this modulation, and that 
later steps of the HIV replication cycle are not directly affected by CD4/CCR5 signalling.    
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4.2 Materials and methods 
DNA constructs. pIRESpuro-CD4.wt and pIRESpuro-CD4.398 were generated by cloning 
the sequences encoding CD4.wt and CD4.398, respectively, into pIRESpuro (Clontech 
Laboratories). CD4.398 was obtained as described 306 by site-directed mutagenesis (Quick 
Change Site-Directed Mutagenesis kit, Stratagene). For constructs encoding CCR5 variants, 
CCR5 sequences were cloned into the retroviral vector pEneo (from B.C. Schaefer 307). 
CCR5.320 was made by introducing a premature stop codon after Phe-320 in CCR5.wt. 
CCR5.R126N and CCR5.dm were generated by changing Arg-126 to Asn in CCR5.wt and 
CCR5.320, respectively, by site-directed mutagenesis. All plasmids were confirmed by 
sequencing. 
 
A2.01-CD4/CCR5 cell lines. A2.01 cells (NIH AIDS Research and Reference Reagent 
Program) were genetically complemented with CD4 by electroporation with a Bio-Rad Gene 
Pulser (Bio-Rad) and subsequently with wt or mutated CCR5 by lentiviral transduction 
through spinoculation at 1,200 × g for 2 h at 25°C. Cells were grown in culture medium 
(RPMI1640, 10% FCS, 100 U/ml penicillin, 100 mg/ml streptomycin (Gibco, via Invitrogen 
AG), 0.5 µg/ml puromycin (Sigma), and 800 µg/ml neomycin (Gibco).  
 
Virus production. Lentiviruses encoding wt or mutant CCR5 were produced by transfecting 
293T cells with pMoMLV, pMD2.G (from D. Trono, University of Geneva), and the 
respective pEneo-CCR5 construct. For virions containing BlaM-Vpr, 293T cells were 
transfected with pYU-2, pCMV-BlaM-Vpr (from M. Cavrois, 301), and pAdVAntage 
(Promega). Culture supernatants were concentrated by Amicon Ultra centrifugal filters 
(Millipore). 49.5 and YU-2 stocks were produced with p49.5 290 and pYU-2 291, respectively. 
p24-Gag levels of virus stocks were determined as described 308. Plasmids were obtained 
through the NIH AIDS Research and Reference Reagent Program unless otherwise noted. 
293T cells were transfected by the calcium phosphate method (Promega, via Catalys AG). 
Patient isolates (from A. Trkola, 292) were expanded on PBMC and titrated on A2.01 cells 
expressing CD4.wt and CCR5.wt. The 50% tissue culture infectious dose of the virus stocks 
was determined -as described 292. 
 
Receptor expression. Cells were stained with a monoclonal (mAb) against CD4 (clone RPA-
T4), CCR5 (2D7), or isotype immunoglobulins (BD Biosciences-Pharmingen) and analyzed 
by flow cytometry.  
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Cell proliferation. Cells were stained with 0.05 µM carboxy fluoroscein succinimidyl ester 
(CFSE) (Molecular Probes, via Invitrogen) and analyzed 1 and 4 days later by flow cytometry 
immediately after staining. 
 
CD4 down-modulation. Cells were starved in selective medium with 0.1% FCS for 24 h, 
incubated in culture medium with or without 0.05 µg/ml phorbol myristic acetate (PMA) 
(Sigma) for 4 h at 37°C in humidified air with 5% CO2, and analyzed for CD4 cell surface 
expression. 
 
CCR5 internalization. Cells starved for 24 h were analyzed for CCR5 cell surface 
expression after stimulation with 1 µg/ml MIP1-β (PeproTech EC) for 2 or 4 h after 
chemokine withdrawal.  
 
Actin polymerization. Cells starved for 24 h and prewarmed for 10 min at 37°C were 
stimulated in 400 µl of RPMI 1640 with 1 µg/ml MIP1-β for 15 s at 37°C. The reaction was 
stopped with 100 µl of a perm/stain/fix solution (PBS, 0.1% saponin, 0.5 µg/ml phalloidin-
FITC (Sigma), and 20% paraformaldehyde). Cells were incubated on ice for 10 min, washed, 
and analyzed by flow cytometry. 
 
Flow cytometry. Cells were acquired on a FACSCalibur (BD Biosciences), unless otherwise 
stated and data analyzed with FlowJo software (Tree Star). 
 
Calcium mobilization. Cells were resuspended in HBSS (Cambrex Bioscience, via 
BioConcept) with 1 mM Ca+2, 1 mM Mg+2, 4 mM Probenicid (Sigma), and 1% FCS at 1 × 106 
cells/ml, loaded with 2 µg/ml Indo-1 penta-acetoxymethyl ester (Indo-1 AM; Molecular 
Probes), and incubated at 37°C for 30 min. Cells were acquired on a LSR II (BD Biosciences; 
violet bandpass filter centered at 395 nm and blue bandpass filter centered at 500 nm) at 200–
300 cells/s for 30 s, MIP1-β (500 ng/ml) was injected, and acquisition continued for another 2 
min. 
 
Viral cell entry. HIV cell entry was examined with an enzymatic fluorescence-based method 
essentially as described 301. Briefly, 2 × 106 cells were incubated with virions containing 
BlaM-Vpr (400−500 ng p24-Gag) at 37°C for 2 h, washed once in CO2-independent medium 
(Gibco), and then loaded with CCF2/AM dye (Panvera, via Invitrogen) for 1 h at room 
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temperature (r.t.). After one wash with CO2-independent medium, the BlaM reaction was 
allowed to develop for 16 h at r.t. Cells were then washed once in PBS and fixed in 1.2% 
paraformaldehyde for 24 h at 4°C. Finally, cells were washed twice and resuspended in PBS, 
and analyzed on a FACS Aria (BD Biosciences). 
 
Quantitation of early reverse transcription. Quantitative, real-time PCR was performed 
using an ABI Prism 7700 sequence detection system (Applied Biosystems). The R-U5 region, 
representative of minus-strand strong-stop vDNA, was detected using primers HIV-SS-F4, 
HIV-SS-R4 (1 µM each), probe P-HUS-SS1 (100 nM) 309 and qPCR Master mix 
(Eurogentec). A2.01 cells were infected with HIV isolates as described below. Total DNA 
was isolated with QIAmp DNA blood Mini kit as per the manufacturer’s recommendations 
(Qiagen). In each PCR reaction, 200 ng of total DNA was amplified in a final volume of 15 
µl: 50°C for 2 min, 95°C for 10 min, followed by 60 cycles of two-step amplification 
regimens (95°C for 15 s and 60°C for 1 min). The beta-actin housekeeping gene was 
amplified in separate reactions with a purchased ready-to-use primer/probe kit (Eurogentec). 
All reactions were performed in duplicate. Specific amplification efficiencies were 
determined by measuring serial dilutions and included in the data analysis.  
Data from real-time quantitative PCR were analyzed in two steps. First, the mean normalized 
gene expression (MNE) (i.e., normalized to the housekeeping gene) for every sample was 
determined using the software application Q-Gene (calculation procedure for MNE 2) 310.  
 
HIV infections. Cells (2 × 105/well in 96-well U-bottom plates) were spinoculated in 
duplicate with virus (0.5 (49.5) or 5.0 ng (YU-2) of p24-Gag; patient viral isolates were used 
at an MOI of 0.001) at 1,200 x g for 2 h at 25°C, cultured for 4 h, and extensively washed. For 
quantitation of early reverse transcripts (Fig. 6), DNA was extracted from the cells 6 h post-
infection (p.i.) and analysed by real-time PCR as described above. For analysis of productive 
infection (Fig. 8), cells were cultured for 2 days, permeabilized/fixed with Cytofix/Cytoperm 
(BD Bioscience), and stained for intracellular p24 with a p24-specific mAb (KC57, Beckman 
Coulter). To control for background staining, the percentage of p24+ cells in mock-infected 
cells was substracted from that in HIV-infected cells. Virus production (Fig. 9) was analysed 
by measuring the p24 concentrations in the cell-culture supernatants on days 2 and 6 p.i. by 
ELISA 308. In all experiments, cells were treated with Enfuvirtide (Fuzeon, 50 µg/ml; Roche) 
after inoculation with virus; Enfuvirtide was maintained thereafter in the cell cultures 
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throughout the experiments. Cognate and parental cell lines (i.e., lacking either CCR5 or both 
CD4 and CCR5) were used as controls in all infection experiments. 
 
Statistics. Values of early reverse transcription (MNE), productive infection (percentage of 
p24+ cells), and virus production (area under the curve (AUC) of p24 concentrations in the 
cell culture supernatants analysed by ELISA on day 2 and 6 p.i.) were analyzed separately for 
each virus (molecular clones YU-2, 49.5, patient isolates 2, 5, 8). Mixed two-way analysis of 
variance with random factor experiment and fixed factor cell line was applied to 
logarithmized data. Post-hoc comparisons were performed using Dunnett- and Bonferroni-
tests where appropiate. Differences between cell lines were compared between early reverse 
transcription and infection using unpaired t-test with Bonferroni correction. The program 
SPSS 13 (SPSS Inc. Chicago, IL) was used for all analyses. P-values p < 0.05 were 
considered statistically significant.  
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Conclusions and Outlook 
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5.1 Current HIV mouse models 
 
HIV is responsible for the progressive immunodeficiency which culminates in AIDS and 
which has resulted in an ongoing pandemic. The available anti-retroviral drugs efficiently 
suppress HIV but reveal major limitations such as side effects, emergence of resistant strains, 
psychic distress and high costs.  
Since the start of the HIV pandemics, HIV research has been hampered by the lack of a small 
animal model. A small versatile HIV animal model would be of utmost value for examining 
HIV pathogenesis and testing novel treatment approaches. Notably, HIV is a human specific 
pathogen and does not infect and replicate in rodents such as mice or rats. To overcome this 
limitation mouse models such as hu-PBL-SCID 68,174 and SCID-hu mice 56,175 have been 
developed in which human hematopoietic cells and tissues are transplanted into mice that are 
compromised in their capacity to reject xenogenic grafts. Both models sustain HIV infection 
and replication in vivo. However, in hu-PBL-SCID mice xeno-reactivity and successive loss 
of human leukocytes limit infection to a relatively short time frame, and infection is skewed 
towards R5- tropic HIV strains 72,176. In SCID-hu mice HIV infection can be observed for 
extended times; however, availability of transplantable human fetal organs is restricted for 
practical and ethical reasons, and HIV pathology in these mice is mainly limited to the tissue 
implants, with naïve T cells being preferentially susceptible to CXCR4-tropic strain infection 
9,59,177. One of the major improvements was achieved by using NOD/SCID Il2rg-/- (NOG) and 
newborn Rag2-/- Il2rg-/- (RAG-hu) mice as recipients for human hematopoietic stem and 
progenitor cell grafts because this approach allows tremendously high engraftment levels and 
efficient intra-thymic de novo development of human T cells 49,51,54,178, which are the targets 
for HIV. 
We established the humanized Rag2-/- Il2rg-/- mice based on the transplantation of human 
CD34+ at newborn age (RAG-hu mice 49) as a new tool to study HIV infection and 
pathogenesis in vivo. RAG-hu mice have several significant advantages over other available 
mouse models: they sustain de novo T cell generation from CD34+ cells with a broad 
repertoire over at least 6 months, T cells are not activated by xenogeneic tissue and populate 
secondary lymphoid organs as lymph nodes and spleen where they encounter newly formed 
human B cells and antigen presenting cells, human cells in concert built up secondary 
lymphoid organ structures, and some human primary immune responses were detectable49,178. 
Finally, compared to SCID-hu mice where multiple fetal organs are transplanted, RAG-hu 
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mice represent a very straight-forward, easily applicable and ethically less problematic model. 
We show that RAG-hu mice are indeed an ideal model supporting long-term, high-titer, and 
lymphoid organ disseminated HIV replication closely resembling HIV infection in humans, 
thus allowing to study HIV pathogenesis with respect to effects on the thymic function, bone 
marrow and secondary lymphoid organs 82  (chapter2).  
Shortly after we have pubished our work, there were a number of reports which have 
corroborated our data showing that hNOG, RAG-hu, and RAG-hu mice co-transplanted with 
human thymus/liver are valuable as models for HIV infection 82,203-206 (Table 2).  
 
The comparison of all these humanized mouse models indicate that 1) hNOG mice seem to 
allow higher and more stable levels of chimerism and, thus, better immune responses than 
RAG-hu mice but long-term studies are limited in hNOG mice. Notably, in hNOG, HIV 
infection could only be monitored for 43 days due to wasting and due to their short lifespan 
204. The same group thereafter reported that myeloablation procedures were not required for 
human cell engraftment and that hNOG mice without myeloablation stably survived beyond 
300 days after transplantation permitting long-term studies on HIV pathogenesis 311. 
However, a direct comparison between RAG-hu and hNOG mice is lacking; that 2) the bone 
marrow/liver/thymus (BLT) model is the only model that currently allows to reproducibly 
study intrarectal transmission or gastrointestinal tract associated infection 206. The BLT model 
is a combination of the SCID-hu and the human CD34+ cell-transplanted NOD/SCID model: 
the bone marrow is reconstituted with HSC, which generate e.g., T-cell progenitors that 
repopulate the implanted human thy/liv organoid 202. The BLT model, incorporates the best 
aspect of each model and develops a significantly more complete human immune system 
including reconstitution of the gut associated lymphoid tissue 202. However, this model is 
extremely complex, labor intensive and costly; that 3) many different mouse strains, 
reconstitution procedures, infection protocols and combinations thereof are currently used. 
The optimal host strain, age and route of infection are not yet known. A thorough direct 
comparative analysis of the various model systems would need to be done. 
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5.1.2 Expected value of these models.  
 
The hNOG and RAG-hu models have distinct attributes which make them highly valuable for 
testing novel compounds and pharmacologic approaches aiming to prevent or treat HIV 
infection. Attributes are: high-titer viremia over months, easy monitoring of HIV RNA copy 
numbers in the blood and susceptibility to HIV strains with distinct co-receptor selectivity. 
This should allow to investigate the emergence of resistant strains upon long-term treatment 
and to investigate the effect of anti-retroviral treatment on established HIV infection. Notably, 
in rather all previous publications using the SCID mouse model, investigational drugs have 
been either applied prior or within days after HIV exposure which represents  rather “pre-“ or 
“post-exposure prophylaxis”. We also believe that the human lymphoid like system permits to 
study immunomodulation (e.g., with cytokines) for enhancing the body’s own immune 
defence. 
Many laboratories including ours are aiming to establish the above mentioned models to study 
mucosal HIV transmission: vaginal and rectal transmissions are the primary mode of 
transmission worldwide, and blocking mucosal transmission would be a very critical step to halt 
the HIV pandemic. A small HIV mouse model which permits to study mucosal transmission is 
anxiously awaited from the HIV research community, especially for testing compounds (i.e., 
microbicides) that, when applied vaginally or rectally, will prevent HIV transmission. Our 
preliminary data on vaginal (chapter 2) and the data from Sun et al.206 on intrarectal transmission 
are promising.   
 
5.1.3 Future directions 
 
The genetic manipulation of fetal CD34+ cells prior to transplantation may open a new avenue 
to study the effects of individual gene products on HIV in vivo and therefore host-HIV 
pathogen interactions. In chapter 2 we propose to investigate the in vivo significance of 
APOBEC cytidine deaminases, which pose a powerful mechanism of innate immunity. These 
models may also be used to investigate the role of chronic immune activation in disease 
progression which could extend our findings from chapter 3. There, we propose that 
sustained TLR7 stimulation by HIV ssRNA may directly contribute to immune activation, 
which is considered a major cause for progressive immunodeficiency in HIV infection. RAG-
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hu mice may help to test the ability of specific TLR antagonists to reduce immune activation 
and thereby disease progression in HIV-infected mice. 
One of the major limitations is the lack of human MHC expression in non-hematopoietic 
tissue and in the mouse thymus, which is required to support the selection and survival of T 
cells following human stem-cell engraftment 41. Human thymocytes in humanized mice 
possibly are positively selected on mouse and negatively selected on both mouse and human 
MHC (chapter 2). Human T cells positively selected on mouse MHC (H2) will not be able to 
recognize antigens presented by HLA-expressing human antigen-presenting cells in the 
periphery 39. Moreover, emigrating T cells depend on homeostatic factors such as cytokines, 
which may not provide the adequate stimuli because of defects in cross-species interactions. 
These limitations hinder the generation of robust human T-cell responses and adequate T-cell 
help, which in turn hinders the generation of human B-cell responses against T-cell dependent 
antigens such as HIV. Nevertheless, the observation that B-cell maturation to IgG producing 
cells only occurred in mice with T-cell development 42 and the detection of specific, although 
inconsistent and low, B-cell responses 51,82, suggest some T-cell help at least. The lack of 
human follicular dendritic cells (FDC) may further hamper B-cell responses 49.  
The expression of transgenic human MHC, the addition of human stroma cells with FDC 
differentiation capacity as well as the addition of human cytokines, growth factors, and 
chemokines might therefore improve the models value for vaccine testing. HLA-transgenic 
mice are currently being generated in the NOG strain 39. Finally, in vitro expansion of 
haematopoietic precursor cells prior to transplantation may help to increase the cohort-size 
and to decrease the engraftment variability. This is important, because less than 10 animals 
can usually be transplanted from one graft, and inter- and intra-litter engraftment variability is 
high, probably due to donor-cell variability, pre-transplant cell handling, and the 
transplantation procedure itself. If these problems can be solved the possible use of these 
models will be enormous, and will impact on both basic and preclinical research, although it 
may rather reduce than replace the number of studies that are required in large animals and 
humans. Notably, humanized mice might be instrumental in vaccine and drug development 
against human pathogens such as HIV, Epstein-barr-, Dengue- or influenza virus, as they not 
only develop all types of human cells that are needed for viral infection and growth but also 
the major types of human cells that orchestrate adaptive immune responses 41. 
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5.2 The role of TLR signalling in immune activation  
 
Chronic immune activation is a major cause for progressive immunodeficiency in HIV 
infection. The precise mechanism and the underlying trigger by which HIV causes immune 
activation remain poorly understood. There is growing notion that TLR activation may not 
only enhance antiviral immunity by activating the immune system (reviewed in 220), but also 
play a pivotal role in aberrant immune activation seen in HIV infection 110. In natural HIV 
infection, the immune system fails to eliminate the virus resulting in persistent ssRNA 
production, which can constantly induce TLR7/8 signalling. Thus, we hypothesized that 
TLR7/8 signalling is a main driver for chronic immune activation and thereby contributes to 
the progressive immunodeficiency observed in HIV infection (chapter 3). To explore the 
effects of sustained TLR7 triggering on the molecular and cellular components of the 
lymphoid system of mice, we used the synthetic compound R848 which triggers TLR7/8 
similarly to HIV ssRNA 114,118,120. In conclusion, our data demonstrated that sustained TLR7 
triggering in mice results in immune activation and disruption of the lymphoid system 
reminiscent of HIV associated pathology; Sustained triggering of TLR7 led to i) altered white 
blood cell counts, including profound lymphopenia and increased neutrophil and monocyte 
levels ii) immune activation and attenuated humoral immune responses, iii) disruption of the 
lymphoid structure, including splenomegaly, enlarged T and B cell zones, reduced marginal 
zone B-lymphocytes and a relative contraction of lymphoid subsets, iv) cytokine deregulation, 
v) thymic hypocellularity. We also showed that the observed effects were TLR7- and dose 
dependent, and that IRF-7 and IFNAR mediated signalling only partly contributed to R848 
mediated pathology. 
Our findings underline that HIV ssRNA itself probably contributes to persistent immune 
activation and pathology by signalling through TLR7, and explains in part the chronic 
immune dysfunction in HIV infection. Manipulating TLR7 triggering or down-stream 
signalling may be therapeutically valuable to reduce chronic hyper-immune activation and 
immune dysfunction. Proof of concept studies are now needed to test, whether blocking of 
TLR7/8 signalling can block immune activation and dysfunction in SIV-infected macaques 
and in HIV-infected humanized mice. 
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5.2.1 Immune-based therapies to decrease T-cell activation  
 
Rizzardi et al. recently suggested that directly interfering with immune activation might 
positively affect immunologic outcomes in HIV acute infection. Treatment of patients with 
primary HIV infection with the immunosuppressive drug cyclosporine A coupled with 
antiretroviral therapy resulted in significantly greater CD4+ T-cell recovery through at least 64 
weeks of follow-up 314. These findings further corroborate a causal role of T-cell activation in 
HIV pathogenesis. Nevertheless, treatment of patients with chronic HIV infection with 
immunosuppressive drugs either showed no or negative clinical benefit 315,316 probably due to 
side effects and unspecific and generalized suppressive effect on protective, antigen-specific 
immune responses. The ideal therapy would preserve protective immune responses while 
preventing generalized immune activation. Elucidation of the mechanisms by which HIV 
causes immune activation will help to develop such targeted immune-based therapies 103. 
 
5.2.2 Immune activation and T-cell depletion  
 
Several studies, including ours (chapter 3), identified potential underlying triggers of immune 
activation. Little is known, however, about how immune activation eventually causes T-cell 
depletion and progressive immunodeficiency.  
For many years CD4+ T-cell loss has been explained by the “tap and drain” hypothesis 79 in 
which CD4+ cells are constantly eliminated by HIV (drain) and constantly replaced by 
homeostatic compensation (tap). A small imbalance between death and replenishment results 
in a gradual decrease of CD4+ T cells over time. The “runaway hypothesis” is a candidate 
mechanism explaining this imbalance; immune activation and homeostatic proliferation drive 
infection, higher viral loads, more recruitment of cells into an activated state, further infection 
events, and slow runaway depletion of CD4+ T cells 317. Yates et al, however, rejected this 
runaway hypothesis, because their mathematical model predicted a rapid attainment of a 
stable CD4+ T-cell set point which fails to explain the slow decline 317. They proposed the 
model of virus adaptation, in which progression is driven by slow adaptation of the virus 
resulting in increased infectivity (e.g., co-receptor switch or changes in receptor expression on 
chronically stimulated target cells, viral fitness, immune escape), as a major force driving 
depletion 318.  
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5.3 HIV receptor complex signalling – impact on HIV replication  
 
 
Although the introduction of highly active antiretroviral treatment has been a major 
breakthrough in the care of HIV-infected patients, it is not able to cure patients and is 
accompanied by poorly tolerable side effects and potential long-term toxicity. To develop new 
treatment strategies, more complete knowledge of the HIV replication cycle and its 
interactions with cell components and a detailed understanding of HIV immunopathogenesis 
are mandatory. In chapter 4 we aimed to delineate motifs within the cellular receptor 
complex, CD4 and CCR5, that are critical for HIV replication and investigated the impact of 
cellular receptor complex-mediated signalling on several parameters of HIV replication (e.g., 
early reverse transcripts, productive infection, and virus production). In conclusion, our data 
suggest that CD4 signalling has an inhibitory effect on early HIV replication, whereas CCR5 
signalling does not play a major role for this modulation, and that later steps of the HIV 
replication cycle are not directly affected by CD4/CCR5 signalling.    
We also noted that, in some cases, mutation or deletion of signalling motifs in CD4 and/or 
CCR5 affected HIV replication in an isolate-dependent manner. This observation may have 
major negative implications for drug development: it will be highly unlikely that targeting a 
single host signalling molecule will have an impact on HIV infection since each HIV isolate 
will differently exploit this signalling pathway, some isolates will be inhibited while other 
isolates will show enhanced replication. This behaviour of HIV is reminiscent of the extreme 
viral versatility and ability of HIV to develop resistance to reverse transcriptase inhibitors.  
We will pursue this line of research looking at the receptor function relationship of the 
receptor complex consisting of CD4 and CXCR4 and HIV replication. We would like to 
emphasize that CCR5-tropic strains are the strains sexually transmitted and which persist till 
late stage of HIV disease. The emergence of CXCR4-tropic strains is associated with a 
progressive decline of the HIV target cells, the CD4+ T cells. We are convinced that the 
engagement of the HIV receptor complex by CXCR4-tropic strains is different from the one 
by CCR5-tropic strains and thus its molecular elucidation is critical for a detailed 
understanding of late stage HIV disease.  
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Triggering TLR7 in mice tesults in immune activation anddDisruption of the 
lymphoid system, resembling HIV-associated pathology. (submitted) 
 
2008 Baenziger S,  Ziegler P, Mazzucchelli L, Bronz L, Speck RF, Manz MG  
Human T cell development and HIV infection in Human Hemato-Lymphoid System 
Mice.  Current Topics in Microbiology and Immunology 2008, Vol.324.  In press. 
 
 
Talks and Abstracts: 
 
03/2005 Speaker at the 4th day of clinical research, University Hospital Zurich. 
Mice with a human adaptive immune system (huAIS-RG mice) as a potential novel 
animal model for studying HIV infection.  
03/2005 Speaker at the 3rd Swiss Molecular Microbiology Workshop, ETHZ.  
Mice with a human adaptive immune system (huAIS-RG mice) as a potential novel 
animal model for studying HIV infection.   
11/2005 Talk at the Institute of Veterinary Bacteriology University of Berne. 
Disseminated HIV-infection in cord-blood cell transplanted Rag2-/γc-/- mice 
03/2006 Speaker at the Annual Congress of the Swiss Society of Allergology and 
Immunology, ETH Zurich. 
 Disseminated HIV-infection in cord-blood cell transplanted Rag2-/γc-/- mice 
03/2006 Poster at the 5th day of clinical research, University Hospital Zurich. 
Disseminated HIV-infection in cord-blood cell transplanted Rag2-/γc-/- mice 
05/2006 Speaker at the 2nd Swiss Workshop on Basic HIV research, Murten. 
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Sustained HIV replication and infection of lymphoid organs in cord-blood cell 
transplanted mice. 
Poster at the 2nd Swiss Workshop on Basic HIV research, Murten. 
CD4/CCR5 signalling affects HIV replication in an isolate-dependent manner. 
05/2006 Poster at RETROVIRUSES, Cold Spring Harbour, NY, USA. 
Sustained HIV replication and infection of lymphoid organs in cord-blood cell 
transplanted mice. 
 
03/2007 Poster at KEYSTONE SYMPOSIA, Whistler, Canada. 
Triggering of toll-like receptor 7 (TLR7) in mice results in immune activation and 
disruption of the lymphoid system reminiscent of HIV associated-pathology. 
 
 
Grants and Prices 
 
05/2006 Travelling Grant to the congress RETROVIRUSES by the ZNZ. 
05/2006  The Bristol-Myers Squibb HIV/AIDS AWARD 2006, to reward a young 
investigator in an experimental research project in the field of HIV.  
12/2006 Fellowship from the Roche Research Foundation for the 3rd year of my Ph.D. 
thesis work.  
12/2006 OPO Foundation: Does triggering of TLR7 contribute to HIV pathology?  
04/2007 Empiris Foundation: APOBEC3: It’s role as restriction factor in HIV 
infection?  
04/2007 Jahrespreis der Mathematisch-Naturwissenschaftlichen Fakultät (MNF) der 
Universität ZH.  
 
 
Authorisations for animal experiments 
 
02/2005  Infection of mice with Human Immunodeficiency Virus (HIV) 
12/2005 Does triggering of TLR7 contribute to CD4+ T-cell loss in human 
immunodeficiency virus (HIV) type-1 infection? 
 
 
Courses 
 
11/2004 LTK Modul 1 – Laboratory Animal Course, University of Zurich. 
05/2005 Introduction to Flow Cytometry Course, University of Berne. 
2005 - 2006 ZNZ Introductory Course in Neuroscience, Zurich. 
05/2006 Writing research papers for publication. 
06/2006 Flow Cytometry Forum – Technical Training, Beckman Coulter. 
10/2006 LTK Modul 14E – Actual Topics in Laboratory Animal Science. 
11/2006 LTK Modul 2 – Training as Animal Experiment Coordinator. 
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